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 1
 Summary 
 
A multi-cellular organism has many different types of cell and each is characterised 
by a particular morphology and metabolism to perform a specialised function. 
Variation occurs between the cell types despite the fact that every cell in an organsism 
has the same genetic material. The physiology of each individual cell type is due to 
differences in the expression of proteins, the molecular workers of the cellular 
factory. Proteins are coded for by genes and one of the major levels of regulation of 
gene expression is through transcription. Transcription of genes is the molecular 
process where RNA polymerase II (RNAPII) transfers the DNA code into an RNA 
code. This process is regulated at multiple steps by transcription factors and their 
cofactors. The chromatin structure also has a role in transcription regulation since the 
DNA must be accessible to transcriptional regulators for RNAPII activity.  
Nuclear Factor kappa B (NF-κB) is a family of inducible transcription factors 
responsible for transcription of a wide variety of genes upon cellular stimulation with 
a huge array of factors. RelA (also called p65) is a major member of this family and is 
expressed in all cell types. The transcription of NF-κB regulated genes may be 
regulated according to the cell type due to a cell type specific chromatin status and 
cell type enriched cofactors. The aim of this thesis was to identify novel cell type 
enriched cofactors of RelA(p65) dependent transcription. A proteomics approach was 
used to isolate and identify proteins that interact with the transcription activation 
domain (TAD) of RelA(p65). Known and novel cofactors of RelA(p65)-TAD were 
identified. Among others, a novel RelA(p65)-TAD interaction partner, called MYB 
binding protein 1a (MYBBP1a), was found as a cell type enriched factor. MYBBP1a 
was detected to repress NF-κB regulated transcription in vivo and in vitro and to 
compete with a co-activator for interaction with the TAD of RelA(p65). The work 
presented in this thesis shows the identification of cell type enriched cofactors of NF-
κB and indicates that the cofactor occupancy of RelA(p65) could be important in the 
regulation of cell type specific gene expression.  
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 Zusammenfassung 
 
Ein vielzelliger Organismus besteht aus vielen verschiedenen Zelltypen, die aufgrund 
verschiedener Morphologien und Metabolismen spezialisierte Funktionen 
übernehmen können. Obwohl jede Zelle in einem Organismus das gleiche genetische 
Material aufweist, treten Unterschiede zwischen den verschiedenen Zelltypen auf. Die 
Physiologie jedes Zelltyps beruht auf der unterschiedlichen Expression von Proteinen, 
den molekularen Regulatoren der zellulären Maschinerie. Proteine wiederum werden 
von Genen kodiert; diese werden zum grossen Teil auf Ebene der Transkription 
reguliert. Gentranskription ist der molekulare Prozess, bei welchem die RNS 
Polymerase II (RNAPII) die Information der DNS in RNS überschreibt. Dieser 
Prozess wird auf verschiedenen Ebenen durch Transkriptionsfaktoren und ihre 
Kofaktoren reguliert. Auch die Chromatinstruktur spielt eine Rolle, da die DNS für 
die Regulatoren der RNAPII-Aktivität zugänglich sein muss. 
 Nukleärer Faktor kappa B (NF-κB) ist eine Familie von induzierbaren 
Transkriptionsfaktoren. Nach zellulärer Stimulation durch eine Vielzahl von Faktoren 
sind sie verantwortlich für die Transkription einer breiten Anzahl von Genen. Das 
wichtigste Mitglied dieser Familie ist RelA (auch p65 genannt), welches in allen 
Zelltypen exprimiert wird. Für die Transkription von Genen, welche von NF-κB 
reguliert werden, sind auch der zelltyp-spezifische Chromatinstatus und Kofaktoren, 
welche in diesem Zelltyp angereichert sind, wichtig. Das Ziel dieser Doktorarbeit war 
es, neue zelltyp-spezifische Kofaktoren der RelA(p65)- abhängigen Transkription zu 
identifizieren. Dafür wurde eine spezielle Proteomics-Methode angewendet um 
Proteine zu isolieren und identifizieren, welche mit der Transkriptions-Aktivierungs-
Domäne (TAD) von p65 interagieren. So wurden bekannte und auch neue Kofaktoren 
von p65-TAD identifiziert. Einer dieser neuen Interaktionspartner, MYB Bindendes 
Protein 1a (MYBBP1a), stellte sich als zelltyp-spezifisch angereicherter Faktor 
heraus. MYBBP1a reprimierte NF-κB regulierte Transkription in vivo und in vitro 
und konkurrierte mit einem bekannten Ko-Aktivator um die Bindung an die TAD von 
p65. Die in dieser Doktorarbeit präsentierten Ergebnisse bestätigen die Identifikation 
von zelltyp-spezifischen Kofaktoren für NF-κB und weisen darauf hin, dass die 
Komplexbildung von RelA(p65) mit Kofaktoren eine wichtige Rolle in der 
Regulation der Genexpression spielt. 
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 Abbreviations 
 
AhR Aromatic hydrocarbon receptor 
ACF ATP-utilizing chromatin assembly and remodelling factor 
AML1 Acute myeloid leukaemia protein 1 
ATM Ataxia telangiectasia mutated 
ATP Adenosine 5'-triphosphate 
ATR ATM and Rad3 related protein 
BAF Brg or Brm associated factors 
BRG Brahma-related gene 1  
BRM  Brahma  
BUR Base unpairing region 
CBP cAMP-response element binding (CREB) binding protein 
ChIP  Chromatin immunoprecipitation 
CHRAC Chromatin-accessibility complex  
CIITA Class II transactivator 
CoA Coenzyme A 
co-REST Co-repressor of RE1 silencing transcription factor 
CT Carboxyl-terminal 
CTD  Carboxyl terminal domain 
DBD DNA binding domain 
DNA Deoxyribonucleic acid 
DNA-PKcs DNA dependent protein kinase, catalytic subunit 
ER Estrogen receptor 
GTF General transcription factor 
H Histone 
HAT Histone acetyl transferase 
HBO1 HAT bound to ORC1 
HDAC Histone de-acetylase 
HIV1-LTR Human immunodeficiency virus 1 long terminal repeat 
IFN Interferon 
Ig Immunoglobulin 
IKK IκB kinase 
IL Interleukin 
IR Ionising radiation 
IRF Interferon regulator factor 
kbp Kilo base pairs  
LPS Lipopolysaccharide 
MAPK Mitogen activated protein kinase 
MAR Matrix attachment region 
MORF MOZ (monocytic leukemia zinc finger) -related factor 
mRNA Messenger ribonucleic acid 
MYBBP1a Myb binding protein 1a 
N-CoA-1,2,3 Nuclear receptor co-activator 1,2,3 
N-CoR Nuclear receptor co-repressor 
NELF  Negative elongation factor 
NES Nuclear export signal 
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 NF-κB Nuclear Factor kappa B 
NHEJ Non-homologous end joining 
NHR Nuclear hormone receptor 
NLS Nuclear localisation signal 
NoRC Nucleolar remodeling complex 
NRD Negative regulatory domain 
NT Amino-terminal 
NuRD Nucleosome remodeling and deacetylation 
OPT  Oct-1/PTF/transcription 
ORF  Open reading frames 
PARP1 Poly ADP-ribosylpolymerase 1 
PCAF P300/CBP associated factor 
PGC-1α PPARγ co-activator 1α 
PIC Pre-initiation complex 
PKA Protein kinase A 
PMA Phorbal 12-myristate 13-acetate 
PML   Promyelocytic leukemia 
PPARγ Peroxisome proliferation activated receptor γ 
PRMT Protein arginine methyltransferase 
P-TEFb  Positive transcription elongation factor b 
RHD  Rel Homology Domain 
RNA Ribonucleic acid 
RNAPII RNA Polymerase II 
RSF Remodeling and spacing factor 
SAGA Spt-Ada-Gcn5-acetyltransferase 
SAP Sin associated protein 
SATB1  Special AT-rich binding protein 1 
SET Su(var), E(z) and trithorax 
SIR  Silence information regulator 
SMRT Silencing mediator for retinoic acid and thyroid hormone receptor 
SRC-1,2,3 Steroid receptor co-activator 1, 2, 3 
SREBP1a Sterol regulatory element binding protein 1a 
SSU72 Suppressor of sua7 protein 72 
STAGA Spt3-TAF31-GCN5L acetylase 
STAT2 Signal transducer and activator of transcription 2 
TAD Transcription activation domain 
TBP  TATA box binding protein 
TF  Transcription factor 
TFII  Transcription factor of RNAPII 
TFIIIC Transcription factor of polIII C 
TFTC TBP free TAF complex 
tip60 HIV Tat-interacting protein 60 kDa 
TNFα Tumour necrosis factor alpha 
TRRAP Transactivating/transformation domain associated protein 
TSA  Trichostatin A 
WCRF Williams syndrome transcription factor related 
WICH WSTF-ISWI chromatin remodeling complex 
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Introduction 
 
1 The mechanism of RNA Polymerase II Transcription  
Within the cell the transcription of particular genes is regulated by external and 
internal molecular signals (reviewed in [1]). External signals such as cytokines, 
hormones and stress signals, together with internal signals such as nutrient and 
Adenosine 5'-triphosphate (ATP) levels activate many different signal transduction 
pathways. These pathways lead to the activation of appropriate cellular responses, 
which is often dependent on the regulation of gene expression through modulation of 
transcription. Both the intensity and duration of transcription of a particular gene can 
be regulated. The intensity of transcription can be regulated by variation of the 
number of polymerases transcribing at once. Since transcription of genes often occurs 
in waves the duration of transcription can be increased by increasing the number of 
transcription waves or by elongating each wave.  
RNA polymerase II (RNAPII) transcription involves a cycle of events 
(reviewed in [2]). It starts with the building of a large protein complex, containing the 
factors required for transcription initiation (pre-initiation complex formation) and 
finishes with termination of RNA synthesis and the recycling of the protein factors 
involved, ready for the next round of transcription (transcription termination and re-
initiation).  
Regulation of transcription is tightly linked to regulation of chromatin 
structure (reviewed in [3]). In order for transcription to occur the transcription 
machinery must have access to the DNA substrate. This often requires adjustment of 
the chromatin structure at gene regulatory elements. After transcription some of the 
chromatin adjustments are retained to maintain the potential of the gene to be actively 
transcribed once again. Transcription factors (TFs) and transcription cofactors are the 
proteins that regulate transcription both positively and negatively by altering the 
accessibility of the DNA substrate as well as influencing protein complex formation 
during the different steps of transcription. 
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1.1 The General Transcription Initiation Machinery 
1.1.1 RNA Polymerase II 
In eukaryotic cells there are three RNA polymerases, RNA polymerase I, II and III. 
RNAPII is the polymerase that synthesises the protein coding messenger RNA 
(mRNA) in the cell. The structure of the 12 subunit elongating RNAPII complexed 
with DNA substrate has been shown at least three times at high resolution [4-6]. The 
structures give insight into the mode of action of RNAPII and the model for catalysis. 
DNA enters a groove in the enzyme and is unwound by the effect of positive and 
negative charged residues of RNAPII pushing and pulling about 12-14 nucleotides of 
the template strand away from the non-template strand of DNA. The rNTPs are 
positioned in a pocket of the enzyme, directly opposite the template strand at position 
+1 (the transcription start site). RNA and DNA hybrids are formed and survive for 
around 7 nucleotides. The RNA/DNA hybrids are unravelled, the DNA strands re-
dimerise, and the nascent RNA and duplex DNA leave the enzyme at right angles to 
each other (reviewed in [7] and [8]). The largest subunit of RNAPII is Rpb1, and it 
has a carboxyl terminal domain (CTD) essential for the regulation of transcription as 
well as other RNA processing events. The CTD contains phosphorylatable repeats of 
YSPTSPS (52 in humans and 26 in yeast) and seems to be unstructured [9]. 
1.1.2 The transcription cycle 
Transcription by RNAPII occurs in cycles, consisting of pre-initiation 
complex (PIC) assembly, open complex formation, catalysis of the first diester bond, 
promoter escape, elongation, termination and re-initiation. The control of the 
transcription cycle is tightly linked with the phosphorylation and dephosphorylation 
of the serines and threonines in the CTD of RNAPII. The recruitment of various 
factors involved in transcription and mRNA processing is dependent on the 
phosphorylation state of the CTD (Figure 1) (reviewed in [2]). In the first step of the 
transcription cycle, PIC formation, the CTD of RNAPII is not phosphorylated [10, 
11].  
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Figure 1. The transcription cycle and CTD phosphorylation events. RNAPII CTD is 
phosphorylated at serine 5 by TFIIH CAK upon transcription initiation. The transcription elongating 
complex is stalled to promote mRNA capping and is released by Bur1/2, Ctk1 (yeast) and P-TEFb 
(human). Upon elongation RNAPII CTD is phosphorylated at serine 2 by P-TEFb. Dephosphorylation 
by phosphatases (PTase), such as SSU72 and FCP1, occurs at termination/re-initiation allowing 
recycling of RNAPII and 3’ processing of the nascent RNA. Picture taken from [12]. 
 
 
PIC formation requires several general transcription factors (GTFs), which are 
assembled at the promoter in order. RNAPII, transcription factor of RNAPII F and B 
(TFIIF and TFIIB) and TATA box binding protein (TBP) are the minimal protein 
components required to accurately initiate transcription in vitro from various 
supercoiled promoters [13-15].  Transcription from non-supercoiled DNA in vitro 
requires further GTFs including TFIIE and TFIIH [13-15]. Mediator is a large protein 
complex, often associated with RNAPII to form a holoenzyme and is also important 
for transcription of many genes. Chromatin immunoprecipitation (ChIPs) show that in 
vivo all the GTFs and Mediator are recruited to many different promoters but not open 
reading frames (ORFs) in yeast implying that the proteins are generally required for 
transcription initiation [16]. The structure of a RNAPII, Mediator, TBP, TFIIB and 
TFIIF complex has been modelled by comparison of electron micrographs, crystal 
structures and structural predictions of the components [8]. However, no Med-
RNAPII-TFIIF complexes were found in S. cerevisiae although 20% of cellular 
RNAPII is associated with Mediator and 50% of RNAPII is associated with TFIIF, 
implying that these factors may not interact with RNAPII at once [17]. For PIC 
formation at TATA box containing promoters the order of GTF recruitment is TBP 
(or TFIID), TFIIB plus TFIIA, TFIIF plus RNAPII, TFIIE plus TFIIH (reviewed in 
[18]). In some cases it has been shown that RNAPII joins the PIC as a holoenzyme 
with Mediator, while in other cases Mediator precedes or follows RNAPII recruitment 
to the promoter.  
 10
Introduction 
During open complex formation the DNA strands are separated by RNAPII as 
described in Section  1.1.1. This is an ATP dependent reaction and is enhanced by 
TFIIE and TFIIH [19]. Transcription is initiated by formation of the first 
phosphodiester bond, and phosphorylation at serine 5 of the CTD by the Cdk 
activating kinase (CAK) subdomain of the multi-protein TFIIH. Promoter 
escape/clearance refers to the stage of transcription between initiation and elongation. 
Small RNAs are formed and the RNAPII has a tendency to spontaneously dissociate 
from the DNA. RNAPII instability is reduced when the transcript is longer than 9 bp, 
and is completely stable when the transcript is longer than 23 nucleotides [20]. 
RNAPII CTD is phosphorylated at serine 5 during promoter clearance and during 
stalling. DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole) sensitivity 
inducing factor (DSIF) and negative elongation factor (NELF) interact with the 
phosphoserine and recruit the mRNA capping machinery (Figure 1).  
Transcription elongation is the process whereby full-length mRNA transcripts 
are produced. The elongating RNAPII is present in a large multi-protein complex, the 
RNAPII transcription elongation complex (TEC). TEC is distinct from the PIC as 
GTFs (except TFIIF) have dissociated from RNAPII and remained at the promoter. 
RNAPII must overcome transcriptional pausing, transcription arrest and transcription 
termination. RNAPII may naturally pause during transcription due to physical barriers 
present such as histones and mRNA processing factors. Many protein factors affect 
the pausing and also the rate of elongation e.g. TFIIF, TFIIS, FCP-1 (TFIIF 
associating RNAPII CTD phosphatase), P-TEFb (positive transcription elongation 
factor b), elongins, TREX (transcription/export complex), proteosome components, 
and ELLs (eleven nineteen lysine rich leukaemia gene proteins) (reviewed in [2, 12]). 
Other elongation factors are involved in the displacement of repressive chromatin 
proteins. The structure of the elongating RNAPII indicates how the long transcript 
cleavage factor, TFIIS, could stretch from the outside of RNAPII to the inside, to 
approach the active site with a hairpin like structure to stimulate the nuclease activity 
of RNAPII [6]. In this way stalled RNAPII would be released from the RNA substrate 
to re-initiate transcription. The structure of the elongating RNAPII complex also 
indicates that once the transcript is more than 18 nucleotides long it is accessible to 
the solvent and therefore mRNA processing enzymes [6]. During transcriptional 
elongation RNAPII CTD is heavily phosphorylated at serine 2 by various kinases 
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such as P-TEFb (CyclinT and Cdk9) [21]. Co-transcriptional splicing factors and 
elongation factors are recruited to the RNAPII (Figure 1). 
Transcription initiation, elongation and termination are tightly coordinated as 
some of the same proteins are involved in the different steps. In S. cerevisiae the 
promoter and terminator DNA sequences have been shown to loop together [22]. The 
mechanism of termination of transcription and the protein factors involved are still 
not well characterised (reviewed in [23, 24]). The DNA regions involved consist of a 
pause site or termination region as well as a polyA tract. RNAPII transcribes past the 
polyA tract, into the “terminator region”. However, the rapid degradation of the RNA 
means that all the nascent mRNA isolated is only as long as the polyA tract. Upon 
transcription termination mRNA is cleaved, poly-adenylated and transported to the 
cytoplasm [23, 24]. 
Transcription re-initiation involves the recycling of some GTFs to the 
promoter and dephosphorylation of RNAPII CTD by phosphatases (reviewed in [2]). 
Serine 5 is dephosphorylated by SSU72 and small CTD phosphatases (SCPs) while 
serine 2 is dephosphorylated by FCP1. TFIIF was also shown to be important for re-
initiation in vitro [17].  
1.2 The Substrate for Transcription 
The substrate for transcription is tremendously complex. A wide variety of regulatory 
DNA sequence elements bind the transcription machinery. The transcription of a gene 
is effected by the DNA regulatory elements present, the local environment of the gene 
with respect to nucleosome positioning and histone modifications, the higher order 
structure of the chromatin that packages the gene and the position of the gene in the 
nucleus (reviewed in [25], [3] and [26]). In general, actively transcribed genes are 
thought of as being more accessible, at the levels of higher order chromatin structure 
and individual nucleosomes. 
1.2.1 The core promoter 
The core promoter is defined as the minimal DNA sequence that can direct accurate 
transcription initiation by the RNAPII machinery. The core promoter differs slightly 
from gene to gene. In general it is around 70 bp long spanning the initiation site 
(position +1) and contains a selection of motifs (reviewed in [18]). These are TATA 
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(TBP binding element), Inr (initiator), BRE (TFIIB recognition element) and DPE 
(downstream core promoter element) (Figure 2).  
 
 
Figure 2. The core promoter. The motifs involved in transcription from RNAPII promoters are 
shown. Transcription starts from +1 in TATA containing promoters. The Initiator in Homo sapiens 
(Hs) and Drosophila melanogaster (Dm) has the consensus sequences shown where Py is pyrimidine, 
T (thymine) or C (cytosine) and N is any base. Where 2 or more bases are shown at the same position, 
either can be present. Picture taken from [18]. 
 
TBP and TRFs (TBP related factors) bind directly to the TATA box. TATA is 
not present in all promoters, and current estimates based on computer predictions are 
that it is present in approximately 20-25% of all gene regulatory regions [27]. 
Transcription normally initiates at A+1 of the Inr consensus sequence (Py-Py-A+1-N-
T/A-Py-Py). RNAPII and TFIID via TAF1 (TAFII250) and TAF2 (TAFII150) can 
interact with Inr [28, 29].  Two sequence specific DNA binding proteins, TFII-I and 
YingYang, also bind Inr at selected promoters [30, 31].  
The DPE binds TFIID (but not TBP) via TAF6 (dmTAFII60) and TAF9 
(dmTAFII40) and is present more commonly in TATA less promoters [32]. It is 
located at +28 to +32 and the distance between Inr and DPE is critical. Negative 
cofactor 2 can repress TATA dependent transcription whilst activating DPE 
dependent (TATA less) transcription, indicating the mechanism of transcription 
initiation by these two DNA elements is different [33].  
BRE has been shown to act positively or negatively on transcription and to 
bind to TFIIB [34]. CpG islands are stretches of DNA (about 0.5 to 2 kbp) that 
contain promoters (often TATA/DPE less), and GC boxes (binds the Sp1 transcription 
factor). In general, transcription from these promoters starts from multiple weakly 
active sites, unlike the specific single start site in TATA/DPE containing promoters.  
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The function of the core promoter is to correctly position the RNAPII 
machinery as well as to regulate transcription initiation via regulation of GTFs. Some 
promoters contain two TATA boxes that can be differentially used according to the 
cellular state, also resulting in regulation of transcription. Different TATA boxes are 
responsive to different stimuli, presumably because of differences in TFIID 
compositions and TAF activities (reviewed in [18]).  
1.2.2 Enhancers, proximal promoters, silencers and Insulators 
Proximal promoters are situated around -250 to +250 bp from the transcription start 
site, while enhancers and silencers can be close to the start site or many kbp up or 
downstream from the start site [35]. A diagram of a typical simple yeast control 
region of a gene and a complex metazoan control region of a gene is shown in Figure 
3. Promoters and enhancers generally activate transcription (together with trans-
activating regulators), whereas silencers repress transcription. Metazoan enhancers 
often regulate tissue or cell type specific transcription, are around 500 bp long, and 
have an average of about ten binding sites for many different transcription factors 
(TFs). Enhancers integrate signals, to regulate transcription of a specific gene 
according to the cell type and cellular status (reviewed in [36]).   
Insulators prevent inappropriate regulation of promoters by enhancers when 
positioned between the two elements. They also reduce the effect of chromosome 
position on transcription of synthetically integrated genes (reviewed in [37]). Insulator 
elements and the protein complexes associated with them are thought to have a role in 
regulation of the higher order chromatin structure (Section  1.2.3). 
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Figure 3. Control elements for a typical yeast gene (a) and a more complex metazoan gene (b). 
TATA, INR, DPE, Insulator, Silencers and Enhancers are described in the text. Enhancers can be 
downstream, upstream or distal from the gene and bind to transcription factors (ovals and rectangles). 
Transcription factors also bind to response elements (RE) in the proximal promoter and upstream 
activating sequences (UAS) in yeast. Picture taken from [38]. 
 
1.2.3 Nucleosome structure 
In cells the DNA sequence elements described above are coiled around an octamer of 
histones to form nucleosomes. The core particle of the nucleosome consists of 147 bp 
DNA, a tetramer of two histone 2As (H2As) and two H2Bs and two dimers of H3 and 
H4. The crystal structure (Figure 4b) has been solved indicating the electrostatic 
interactions and hydrogen bonds between the DNA and nucleosome [39]. Sequence 
specific DNA binding proteins are usually unable to recognise their binding site on 
such a contorted surface. The histone amino-terminal (NT) tails are accessible to the 
solute and can be post-translationally modified.  
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Figure 4. Chromatin. (a) DNA is wrapped around core particles to form nucleosomes that are 
packaged into higher order structures to ultimately form the metaphase chromosomes. (b) Nucleosome 
structure at 2.8Å. One DNA strand is in orange, the other green. The histones are in blue (H3), green 
(H4), yellow (H2A) and pink (H2B) as ribbon models. Picture taken from [3]. 
1.2.4 Histone structure and the histone code 
The important function of core histones is indicated by their very high conservation 
among eukaryotic species. The core histones are small basic proteins sharing a similar 
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globular domain consisting of a helix-turn-helix motif. This domain allows 
dimerisation and interactions with DNA. Core histones also have a long, mainly 
unstructured NT “tail”. Most histone tails (except H4) are not necessary for 
nucleosome assembly and 30 nM compaction [40], although they are the major sites 
of post-translational modifications (PTMs). This indicates that the NT tails are 
unlikely to directly regulate the structure of single nucleosomes. However, since 
histone tails may be able to regulate interactions between nucleosomes, or between 
nucleosomes and linker DNA, it may be that histone tails can regulate higher order 
chromatin structures. In this way they might also indirectly influence the structure and 
stability of single nucleosomes. Some of the globular parts of core histones encircled 
by the DNA in the nucleosome are also modified, leading to the possibility that these 
could directly affect the stability of single nucleosomes.  
There are three ways in which nucleosomal structure can be modified and 
therefore the local accessibility of DNA to TFs (and other proteins) can be regulated. 
These are the selective use of histone variants (reviewed in [41]), PTM of histones 
and other chromatin proteins (reviewed in [42]) and ATP-dependent remodelling of 
nucleosomes (reviewed in [43]). Histone variants are often included in the chromatin 
at specialised chromatin structures or during specific signalling events in the cell. For 
example, H3.3 is incorporated into chromatin at active genes without the need for 
DNA replication [44] and macroH2A is found at higher than normal concentrations in 
the inactive X chromosome (of female mammals) [45]. 
It has been shown that regions of the genome that are actively transcribing 
generally contain more acetylated histones in the chromatin [46]. However, the simple 
model of “more acetylation, more transcription” is not accurate. To date, the 
following histone modifications have been found at specific sites: acetylation, 
ubiquitination, sumoylation and methylation on lysine residues, methylation on 
arginine residues, phosphorylation on serine and threonine residues, mono ADP-
ribosylation on glutamic acid residues [47]. Many of these modifications are inter-
dependent and can be present on histones in the cytoplasm or nucleus. It has been 
proposed that the pattern of these modifications form a histone code. This code might 
reflect the competence of the surrounding DNA sequences for various processes such 
as transcription and DNA repair.  
In yeast it has been shown that H3 lysine 9 and 14 (H3K9 and H3K14) 
acetylation, H4 acetylation and H3K4 tri-methylation (me3) at transcriptional start 
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sites correlates with gene transcription [48]. The acetylation reduces towards the 3’ 
end of the transcribed gene, indicating acetylation at these residues might be generally 
involved in transcription initiation events. Unlike H3K4me3, H3K4 di-methylation 
(me2) peaked in the middle of the coding sequences of the yeast genes and H3K4 
mono-methylation (me) peaked at the end of the genes [48]. These results indicate the 
complexity of the histone code. Similar studies on human chromosomes have 
confirmed the results of the H3K4 methylation pattern found in yeast [49]. Many 
extensive ChIP on CHIP (chromatin immunoprecipitation followed by micro-array 
analysis of DNA isolated) studies of the human genome in different cells and under 
different conditions are needed to validate the histone code hypothesis and decipher 
the code properly.  
Histone modifications can affect the accessibility of protein factors by two 
mechanisms (reviewed in [42]). The first is by regulating protein-protein interactions 
between modified histones and effector proteins such as transcriptional regulators. 
Chromodomains and bromodomains are protein domains that can recognise 
methylated and acetylated lysines respectively, and are present in many transcription 
cofactors (reviewed in [50, 51]). The second is to affect the protein-protein or DNA-
protein contacts within and between nucleosomes, therefore affecting the stability of 
the nucleosomes and accessibility of effector proteins.  
1.2.5 Higher order chromatin structure 
Chromatin is the complex of DNA and protein, and functions to package the DNA in 
the nucleus in a regulated manner (reviewed in [3]). The nucleosomes pack together 
to form higher order structures, which fold up in an ordered way to form 
chromosomes. The dynamic structure of chromatin regulates DNA accessibility to 
protein factors involved in all forms of DNA metabolism, such as transcription, 
replication and DNA repair. A major mechanism of regulation of transcription is by 
altering the chromatin structure surrounding genes and their regulatory elements. By 
electron microscopy, an 11 nm fibre (looking like beads on a string) can be seen. This 
is thought to be the individual nucleosomes separated by linker DNA (between 10 and 
80 bp long in humans). Chromatin 30 nM fibres are also seen, upon addition of linker 
H1, and this structure is thought to be packing of the 10 nM fibre by superhelical 
coiling or zigzagging (reviewed in [52]) (Figure 4).  
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There has been an explosion in whole genome analysis in recent years, with 
the aim of determining where nucleosomes are positioned on the genome in the living 
cell, which histone modifications the nucleosome contains, and how this correlates 
with transcription. These genome wide studies coordinate data from real time RT-
PCR (which quantifies mRNA expression), and ChIP on CHIP studies. In yeast it has 
been shown that nucleosomes occupy DNA less densely at promoters of transcribed 
genes than at the promoters of inactive genes [48]. 
A model for further organisation of the chromatin by a series of loops involves 
the insulator DNA elements and associated protein complexes (reviewed in [53]). 
Individual insulator complexes might multimerise in such a way to cause the open 
“active” chromatin loops to surround a core of closed “inactive” chromatin. The 
insulator complexes could be anchored to the nuclear periphery. Matrix attachment 
regions (MARs) are also involved in higher order chromatin structure, by fixing 
specific A/T rich sequences to the nuclear lamina. MARs are only equivalent to 
Insulators in some cases. However the precise structure of chromatin compaction and 
regulation of the compaction is not known.  
1.2.6 Heterochromatin and Euchromatin 
Heterochromatin is a form of chromatin that is highly condensed throughout the 
cell cycle. The nucleosomes within heterochromatin have a slightly different structure 
to those in euchromatin, having a shorter linker region and longer region of protection 
from micrococcal nuclease [54]. The differences seen in nucleosome or higher order 
structure of the chromatin can be explained by the nucleosomal histones having 
different modifications, occurring as variants and being in complexes with other 
chromatin proteins. Heterochromatin histones (e.g. in the pericentromeric region and 
in inactive X chromosome) are generally less acetylated than euchromatin histones 
(reviewed in [55]). Methylation of H3K9 by SuVar39 is involved in heterochromatin 
formation. Heterochromatin protein 1 (HP1) binds to methylated H3K9 residues 
(reviewed in [56]). However, the code of histone modifications determining the state 
of heterochromatin is more complex. For example H3K9 trimethylation and H3K27 
monomethylation is found to be more abundant in pericentromeric heterochromatin 
than euchromatin (which contains mono or dimethylated H3K9 residues at silenced 
regions). 
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Telomeric heterochromatin in S. cerevisiae is silenced by Repressor activator 
protein 1 (RAP1) binding to telomeric repeats, recruiting large complexes including 
the Silent information regulator (SIR) proteins. One SIR protein is a histone 
deacetylase (HDAC), which probably marks the histones in the area for transcription 
repression (reviewed in [56]). Often telomeric complexes and other heterochromatin 
domains are found near the nuclear periphery indicating that there may be a 
relationship between transcriptional activity, and nuclear position [57]. 
Heterochromatin formation is often associated with RNA containing complexes. For 
example, during development one of the X chromosomes in female mammals is 
randomly and heritably inactivated, by formation of a heterochromatin state 
dependent on a special RNA, called Xist (reviewed in [58]).  
1.2.7 Transcription factories 
The chromosomes are positioned in precise locations in the nucleus, surrounded by 
nuclear sub-organelles interconnecting the molecular processes of gene expression 
(reviewed in [59]). There are thousands of sites where active transcription occurs in 
the nucleus called transcription sites (factories). These sites in the nucleoplasm are 
sometimes close to nuclear speckles (which contain mRNA processing proteins) 
probably due to the connection between mRNA splicing and transcription. In G1 
phase only, some transcription factors are localised only in 1-3 sites called OPT 
domains (Oct-1/PTF/transcription) and these sites do not contain factors for RNA 
processing [60]. Transcription factories are places where active transcription of 
different genes co-localise, resulting in the hypothesis that upon activation, a gene 
migrates to the transcription machinery in the transcription factory [61]. The dynamic 
transcription factories and other nuclear structures can regulate gene expression at the 
level of transcription and mRNA processing events [62]. De-regulation of the nuclear 
features can lead to de-regulation of gene expression and diseases such as cancer [63]. 
Protein complexes the size of spliceosomes can move through the nucleus in minutes 
by diffusion, indicating an active system of transport for nuclear proteins may not be 
necessary [64, 65]. 
1.2.8 Nuclear Structure 
Within the nucleus there are many subcompartments with specialised functions 
(Figure 5).  
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Figure 5. Nuclear Organisation of gene activity and silencing. Nuclear compartments involved in 
gene expression are shown. Each feature could be involved in allowing or preventing access of TFs 
such as NF-κB to genes. In the text chromosome territories, heterochromatin, nuclear laminar are 
described. The nuclear bodies involved in transcription, or gene regulation are PLM bodies, 
interchromatin granule clusters (IGCs) and cajal bodies. PML bodies are a target of virus infection and 
there are 10-30 per nucleus. PML bodies are involved in transcription regulation since they contain TFs 
and chromatin modifying, although actively transcribing RNAPII was not found [67].There are 1-10 
dynamic Cajal bodies per nucleus that contain pre-mRNA splice factors. It is thought that small nuclear 
ribonucleoprotein particles (snRNP) biosynthesis and trafficking occur there, and are then moved 
towards the speckles. Gems (Gemini of cajal bodies) are next to or overlapping with cajal bodies and 
could be involved in snRNP maturation. Cleavage bodies are found diffusely and in 1-4 foci (next to or 
overlapping with cajal bodies) and contain Cleavage stimulation factor and cleavage and 
polyadenylation proteins. IGCs are probably a store of proteins for mRNA processing, and 
transcription is tightly coordinated with mRNA processing. The model is therefore that actively 
transcribing genes often found close to these nuclear bodies. Picture taken from [26].  
 
Genes are preferentially located on chromosome territory surfaces whereas intergenic 
regions are buried within the chromosome territory. Transcription occurs on the 
invaginated surface of the chromosomes, on the interface with the interchromatin 
compartment containing many nuclear bodies involved in regulation of gene 
expression (reviewed in [26] [65]). The positioning of chromatin territories, actively 
transcribing loops and nuclear bodies can regulate the pattern of gene expression by 
altering the access of transcription factors to the chromatin, the RNA processing 
enzymes to the nascent RNA, and the processed RNA to the nuclear pores. 
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A fluid double membrane surrounds the nucleus. On the inner surface of the 
nuclear membrane is the peripheral nuclear lamina. It consists of lamin A/C and B 
proteins, which link chromatin to the edge of the nucleus (reviewed in [26] [65]). 
Location of a gene near the nuclear periphery is thought to be an indication that the 
gene is repressed (reviewed in [26]). The repression is not necessarily due to 
heterochromatin formation. For example, the silent immunoglobulin heavy chain 
(IgH) locus is not associated with heterochromatin [66].  
1.3 Regulation of Transcription  
1.3.1 Transcription Factors (TFs) 
TFs coordinate cellular signals to regulate transcription and therefore gene expression 
[1]. The basic model is that stimuli activate signal transduction pathways to activate 
TFs that can then bind to enhancers or proximal promoters to regulate transcription. 
TFs regulate transcription at all the different steps in the transcription cycle, 
especially the early step of PIC formation. Transcription can be positively regulated 
(transcription activation) or negatively regulated (transcription repression) (reviewed 
in [68]). Activation requires the generation of an accessible DNA template and 
transcription promoting protein-protein interactions (e.g. between TFs and GTFs). 
Repression can be thought of as the generation (or maintenance) of a stable repressive 
chromatin structure or by prevention of the transcription promoting protein-protein 
interactions.  
Transcription activation by enhancer bound transcription factors is thought to 
be through recruitment of GTFs or transcription co-activators (Section  1.3.2) to the 
core promoter via looping of the DNA (Figure 6, left). However, CHIP experiments 
have shown that RNAPII is complexed with many enhancers before the core 
promoters (reviewed in [36]). In these cases, the enhancer bound TFs recruit GTFs 
and co-activators to the enhancers. Gene specific transcription occurs after looping of 
the DNA and RNAPII binding to the promoter (Figure 6, right). It is likely that both 
situations represent specific cases at different promoters. This could be due to the 
order of promoter versus enhancer recruitment to GTF/RNAPII containing 
transcription factories. The order of cofactor recruitment is discussed further in 
Section  1.3.2. 
 22
Introduction 
 
Figure 6. Two models for enhancer bound transcription factor transactivation. Transcription 
factors (Act) bind to enhancer regions and recruit nucleosome remodellers (Rem), histone 
acetyltransferases (HAT) and GTFs directly to the promoter (left picture) or first to the enhancer (right 
picture). The GTFs shown are TFIID, TBP, Mediator (Med) and RNAPII (pol II). Picture adapted from 
[36]. 
 
Many TF binding sites are free from positioned nucleosomes, providing easy 
access for the activated TF to bind to DNA. However, when DNA binding sites are 
not easily accessible due to positioned nucleosomes and varying degrees of 
nucleosome stability and higher order compaction, TFs can often still function. The 
mechanism of how TFs do this is dependent on each gene and transcription factor, but 
can involve: 
I. Positioned nucleosomes. Although the DNA of nucleosomes is not normally 
able to bind TFs, nucleosomes are not always repressive to TF binding. Many 
reports indicate that various TFs can bind to arrays of nucleosomal DNA. Often 
the positioning of nucleosomes is critical for the transcriptional potential of the 
gene (reviewed in [69]). This is because the TFs can sometimes bind the linker 
DNA, or at the edges of the nucleosomes (where transient disassociation of 
histone-DNA interactions occur [70]) or on the outer surface of the DNA as it 
coils around the histone tetramer.  
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II. Cooperativity between TFs. Most eukaryotic genes are regulated by many TFs, 
which activate transcription synergistically. This can be due to the weak binding 
of one TF to nucleosomal DNA enhancing the affinity of another TF to bind the 
DNA through TF-TF interactions or distortion of the histone-DNA interactions.  
III. Dynamic and flexible nucleosomes. Despite the many contacts between histones 
and DNA in the nucleosome, there is strong evidence that nucleosomes are not 
static structures, and the contacts are dynamic, allowing access to DNA even 
within the nucleosome [71]. 
IV. Histone exchange. It is possible that some TFs bind to DNA during transient 
periods of histone exchange. For example, during S phase of the cell cycle, 
histones are deposited onto the newly synthesised strand of the DNA.  Some 
TFs could remain closely associated with chromatin and bind to their cognate 
sequences as they emerge from the replication machinery. 
1.3.2 Transcription cofactors  
Transcriptional cofactors are defined as proteins that regulate transcription without 
directly binding to DNA sequences. Like transcription factors, the transcription 
cofactors can either activate or repress transcription by regulation of DNA 
accessibility, or by forming a bridge between TFs and GTFs or RNAPII (reviewed in 
[72]). Transcriptional cofactors normally fulfil their functions when part of multi-
protein complexes, and some proteins are found in many different complexes. The 
cofactor complexes that are involved in regulating chromatin accessibility contain 
enzymatic subunits (reviewed in [73]). Histone acetyltransferases (HATs) acetylate 
the lysine groups of histone and non-histone proteins. Histone deacetylases (HDACs) 
remove the acetylation. Histone methyltransferases (HMTs) methylate arginines and 
lysines of histones and sometimes non-histone proteins. ADP-ribosyltransferases also 
modify histones and non-histone proteins. ATP-dependent nucleosome remodelling 
factors contain subunits of the SNF2 ATPase superfamily of proteins and are involved 
in the re-positioning of whole nucleosomes.  
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Complex Mechanism or Subunit RelA/p65?
p300/CBP bridges and HAT mainly p300/CBP Yes
PCAF bridges and HAT PCAF (GNAT family) Yes
SAGA bridges and HAT hGCN5L (GNAT family) Yes? TAFs
TFTC bridges and HAT hGCN5L (GNAT family) Yes? TAFs
TFIID bridges and HAT TAF1 (HAT) and TAFs Yes
STAGA bridges and HAT hGCN5L (GNAT family) Yes? TAFs
SRC-1 bridges and HAT various:e.g. CBP, PRMT1 Yes
SRC-2 bridges and HAT? various:e.g. CBP, PRMT1 Yes
SRC-3 bridges and HAT various:e.g. CBP, PRMT1 Yes
tip60 HAT and tip60 (MYST family) Yes
MAF2 HAT MOF (MYST family)
AML1 HAT and MOZ (MYST family)
MORF HAT and MORF (MYST family)
HBO1 HAT HBO1 (MYST family)
TFIIIC HAT one of three TFIIIC proteins
Elongator HAT Elp3
CIITA HAT CIITA
hBRM remodeller Brm (SNF2 subfamily)
hBRG remodeller Brg (SNF2 subfamily) Yes
hBAF remodeller Baf (SNF2 subfamily)
RSF remodeller ? hSNF2h (ISWI subfamily)
hACF/WCRF remodeller ? hSNF2h (ISWI subfamily)
hCHRAC remodeller ? hSNF2h (ISWI subfamily)
hWICH remodeller ? hSNF2h (ISWI subfamily)
NoRC remodeller ? hSNF2h (ISWI subfamily)
NuRD remodeller/HDAC Mi-2, HDAC1/2 (CHD1 subfamily)
N-CoR HDAC HDAC1/2 and/or HDAC3 (class 1) Yes
SMRT HDAC HDAC1/2 and/or HDAC3 (class 1) Yes
co-REST HDAC HDAC1 and/or 2 (class 1)
sin3-SAP HDAC HDAC1 and 2 (class 1)
sir2 HDAC sir2p (class 3) SIRT1
PRMT1,2,4 HMT (arginine) PRMT1,2,4 PRMT1/4
PRMT5 HMT (arginine) PRMT5
SET HMT (lysine) and various
Mediator bridges and ? Nut1 Yes
PARP1 ADP-ribosyltransferase mainly PARP1 Yes
 
Table 1. Common cofactors of transcription. Columns:  Complex is the name of the cofactor 
complex. Mechanism is whether the cofactor regulates transcription by interaction with TFs and GTFs 
or pol II (bridges), or by the indicated enzymatic activity. ? or ? or ? indicates whether the complex 
activates or represses transcription  or its effect is unknown. Complexes in bold are capable of 
repression. Subunit indicates which protein subunits have enzymatic activity. RelA(p65)? indicates 
which complexes or subunits are involved in regulation of RelA(p65) dependent transcription. The 
HATs and remodellers are grouped in families according to sequence homology. SNF2 subfamily: 
large (2MDa) complexes, bromodomain and ATPase domain, destabilise/disrupt nucleosomes. ISWI 
subfamily: smaller (500-800 kDa) complexes, SANT domain and ATPase domain, stabilise/assemble 
nucleosomes. CHD1 subfamily: mid-size (1-1.5 kDa) complexes, chromodomain and DNA binding 
motif and HDAC activity. HDAC classes are according to homology to the yeast proteins Rpd3 (class 
1), Hda1 (class 2), Sir2 (class 3). Class 1 proteins are ubiquitous and nuclear, while class 2 proteins are 
tissue specific and some are cytosolic proteins. HDAC activity of Class 3 is by an alternative NAD+ 
dependent mechanism. References used [74-79]. 
 
Common human transcriptional cofactor complexes are listed in Table 1, which 
indicates the mechanisms they use, their effect on transcription (positive or negative), 
their main enzymatic subunits and whether they are known to be involved in 
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transcription regulation by the main NF-κB family member, RelA(p65). Further 
details for the RelA(p65) cofactors are described in Section  2.6. Yeast homologues of 
many of these cofactors exist, but these are not included in the table.  
From Table 1 it is evident that the same complex can activate or repress 
transcription, depending on the experimental system. This means it is sometimes 
difficult to label a cofactor of transcription as a co-activator or co-repressor. Many 
cofactors can interact with the same transcription factor to coordinate the regulation 
of a specific gene. An example of how this is achieved temporally is exemplified by 
extensive ChIP studies performed on the estrogen receptor responsive gene pS2 gene 
[80]. This study illustrates common themes in the current thinking of cofactor 
recruitment (reviewed in [73]):  
I. Different cofactor complexes can be recruited to the gene in an ordered manner, 
and assist the function of others. 
II. The recruitment of a specific cofactor complex may be cyclical. 
III. Different transcription factors recruit different cofactor complexes. 
IV. The same transcription factor may recruit different cofactor complexes at different 
gene control regions. 
V. The order of cofactor recruitment may depend on the TFs present, the promoter 
and enhancers of the gene, and the chromatin status around the gene.  
 
Regulation of transcription can also occur by RNA mediated mechanisms. Recently, it 
has been shown that duplex RNA targeted to promoter regions of specific mammalian 
genes can repress transcription and gene expression of that gene. The mechanism of 
the process is not fully characterised, and only sometimes involves CpG island 
methylation (reviewed in [81]).  
2 NF-κB dependent Transcription 
2.1 The Mammalian NF-κB family members 
NF-κB proteins were given their name as they were first identified as nuclear factors 
that could bind to a kappa (κ) immunoglobulin light chain enhancer from mature B 
cells [82]. The NF-κB family of inducible transcription factors has seven members, 
RelA(p65), c-Rel, RelB, p50, p52, p105 and p100 (reviewed in [83]). All family 
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members share a conserved Rel Homology Domian (RHD), which is involved in 
DNA binding, dimerisation between family members and interaction with the 
inhibitor of NF-κB (IκB) family of proteins. p100 and p52 are coded by the NF-κB2 
gene and p100 is inducibly proteolytically cleaved to form p52. p105 and p50 are 
coded by NF-κB1 gene and p105 is constitutively proteolytically cleaved to form p50. 
RelA(p65), c-Rel, RelB, p50 and p52 proteins homo- and heterodimerise to form 
active and inactive transcription factors. Most possibilities of heterodimers and 
homodimers of NF-κB have been identified, apart from RelB that does not 
homodimerise or heterodimerise with RelA(p65) or c-Rel. However, the dimers are 
formed with different affinities, where the RelA(p65) and p50 have a particularly high 
affinity to dimerise. The dimers are complexed with IκBs in the cytoplasm of most 
cell types. The inhibitors share homology with the amino terminal (NT) of p100 and 
p105, which also inhibit NF-κB function. Figure 7 shows the domain structure and 
important features of the NF-κB and IκB family of proteins. 
2.2 Signal transduction pathways 
There are many signals that lead to activation of NF-κB members, and transcription 
of response genes. Activating signals include bacterial, viral and parasite products, 
cytokines, stress conditions, antigens and mitogens, indicating NF-κB is activated in 
response to infection, inflammation and cellular stress (reviewed in [84]). The simple 
view of NF-κB regulation is that NF-κB is normally held inactive in the cytoplasm by 
IκB proteins, and activation through various signal transduction pathways leads to 
IκB degradation and the nuclear accumulation of specific NF-κB molecules. NF-κB 
then binds to consensus sequences to activate target gene expression. Termination of 
NF-κB activation occurs due to negative feedback (since activated NF-κB upregulates 
IκBα expression) [85] as well as ubiquitin mediated proteosomal degradation of NF-
κB [86].  
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Figure 7. The NF-κB and IκB proteins. This figure shows the domain structure of (a) the NF-κB and 
(b) the IκB family membezs. All NF-κB family members share a Rel Homology Domain (RHD) and a 
nuclear localisation signal (N). RelA (also called p65), c-Rel and RelB contain non-homologous C-
terminal transcription activation domains (TD). The ankaryin repeats (ANK) domains (protein-protein 
interaction domains) are shown. The inducible phosphorylation sites required for IκB degradation are 
shown in bold. The glycine rich region (GRR) and the phosphorylation sites required for C-terminal 
processing of p100 and p105 are shown. The proteolytic cleavage site is shown with an arrow. The 
leucine zipper (LZ) of RelB is shown. Three important inducible phosphorylation sites of RelA(p65) 
are shown which enhance the transcription potential of NF-κB. Picture taken from [83]. 
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It is now thought that before stimulation NF-κB/IκBα complexes shuttle 
between the nucleus and cytoplasm, whereas after stimulation, and IκB degradation, 
the NF-κB complex is mainly found in the nucleus [87]. RelA(p65) and p50 each 
have a nuclear localisation (NLS), but when bound to IκBα, the NLS of RelA(p65) is 
masked [88]. Therefore, before stimulation the equilibrium of the NF-κB/IκBα 
complex is towards cytoplasmic localisation due to the complex containing one 
efficient nuclear export signal (NES) of IκBα and only one NLS (of p50). Upon 
stimulation and degradation of IκBα, the NES is lost, an accessible NLS (of 
RelA(p65)) is gained and therefore nuclear accumulation of NF-κB occurs. For non-
stimulated NF-κB complexes containing IκBβ or ε, the mechanism for the bulk 
cytoplasmic retention and stimuli dependent nuclear accumulation of NF-κB is 
slightly different. IκBβ containing NF-κB complexes show no pre-stimuli 
nucleo/cytoplasmic shuttling since IκBβ does not contain an NES, and IκBβ binding 
to NF-κB masks both the RelA(p65) and the p50 NLS [89]. There is also some 
evidence that the main role of IκB proteins in NF-κB inhibition is not by cytoplasmic 
sequestration, but by another mechanism suppressing the basal transcription of NF-κB 
genes [90]. Support for this hypothesis comes from the observation that GFP-p65 is 
nuclear when overexpressed, but when a DNA binding deficient mutant  is  used  it is 
cytoplasmic [90]. However, further investigations are needed to clarify the precise 
role of the IκB proteins in cytoplasmic sequestration of NF-κB.  
There are two main signalling pathways that activate NF-κB nuclear 
accumulation (reviewed in [91]). In the classical pathway, pro-inflammatory 
cytokines and other stimuli activate the tumour necrosis factor (TNF) receptors, Toll 
like receptors and interleukin 1 (IL1) receptors. This leads to activation of the IκB 
kinase (IKK) complex and IKKβ dependent phosphorylation of IκB at positions 
corresponding to serine 32 and serine 36 in IκBα. Phosphorylation of IκB results in 
lysine ubiquitination (lysine 21 and 22 in IκBα) and subsequent degradation by the 
26S proteosome. The classical pathway leads to activation of RelA(p65)/p50 
heterodimers, as well as RelB and c-Rel containing dimers and is important for 
expression of proteins involved in innate immunity (Figure 8a). There are many 
variations of the classical NF-κB pathway, with multiple signals all eventually 
leading to activation of the IKK complex (Figure 8a). 
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Figure 8. The classical and an alternative pathway for NF-κB activation. (a) Multiple signals such 
as cytokines, viruses, toll like receptor ligands and antigens activate the classical pathway. IκBα (or β) 
is degraded, and NF-κB (here RelA(p65)/p50 heterodimers) translocates to the nucleus to activate 
transcription of genes involved in innate immunity. (b) An alternative pathway, activated by specific 
cytokines, leads to IKKα dependent phosphorylation of p100. Proteolytical cleavage results in 
p52/RelB heterodimers entering the nucleus and activating transcription of genes involved in adaptive 
immunity. Picture taken from [91]. 
 
An alternative pathway is important for adaptive immunity (mediated by T 
and B cells) (Figure 8b). The response of fully developed T and B cells to chemokines 
is mediated through various receptors such as BAFF, LTβR, and CD40. Cytokine 
stimulation of these receptors leads to IKKα phosphorylation of p100 and the 
processing of p100 to p52. This results in the nuclear translocation of RelB/p52 and 
activation of specific genes. Other alternative NF-κB activating pathways have also 
been observed. For example, endoplasmic reticulum stress or amino acid starvation 
leads to the dissociation of IκB-NF-κB but not degradation of IκB. The activation 
requires to phosphorylation of a translation elongation factor (eIF2α) [92].  
 
2.3 Signal specificity of the NF-κB response 
Many signals activate NF-κB, through many different signalling pathways. Figure 8 
describes two major pathways that explain how genes involved in the innate immune 
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response can be regulated separately from genes involved in the adaptive immune 
response. However, there are more layers of specificity since one signal will activate 
only a small subset of specific genes. This section describes the layers of regulation, 
which could activate NF-κB dependent transcription of specific genes.  
2.3.1 Degradation of specific IκB proteins 
Some signals, or combination of signals lead to degradation of specific IκBs. For 
example, in 70Z/3 pre-B cells lipopolysaccharide (LPS) and IL1 could induce 
degradation of IκBα and IκBβ whereas only IκBα was degraded upon phorbal 12-
myristate 13-acetate (PMA) stimulation [93]. This leads to differences in the kinetics 
of the responses, since IκBα is involved in a quick but transient NF-κB response 
whilst IκBβ controls a slower, more prolonged response. Also, specific IκB proteins 
can associate preferentially with some dimers. For example IκBε complexes mainly 
with c-Rel and RelA(p65) [94]. The degradation of specific IκB proteins can then 
lead to the nuclear accumulation of specific NF-κB dimers. 
2.3.2 Activation of transcription by specific NF-κB dimers 
It has been shown that some signals lead to binding of specific dimers at particular 
promoters, leading to differential regulation of specific genes. For example, it was 
found that upon LPS stimulation RelA(p65) is recruited to the IL8 promoter, whereas 
c-Rel is recruited to the IL-12p35 promoter in dendritic cells [95]. At the ECL and 
MDC promoters, first RelA(p65) was detected to bind after LPS stimulation, and then 
RelB, leading to RNAPII recruitment. At the IL-12p40 promoter a similar exchange 
of RelA with RelB occurred after LPS stimulation but with disassociation of RNAPII 
and decrease in mRNA synthesis [95]. The exchange of NF-κB dimers was not seen 
with TNFα stimulation at the ECL promoter, and this indicates that there can be a 
stimuli specific exchange of NF-κB dimers on the promoter resulting in modulation 
of transcriptional activity [95]. Different promoters have been shown to be dependent 
on specific NF-κB proteins for activity, although the sequence of the κB site does not 
correlate with the ability of specific dimers to regulate the particular gene [96]. 
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2.3.3 Cooperation with other TFs and cofactors 
Some signals can activate NF-κB, as well as activate or repress other TFs or cofactors 
that function with NF-κB to activate, or repress particular genes. Activation of a 
single TF may not lead to activation of a gene that requires coordinated activation of 
many TFs. Therefore, only appropriate stimulation would lead to activation of the TFs 
involved and transcription of the gene. An example of this kind of cooperativity 
between NF-κB, IRF1, c-Jun and HMGI(Y) at the interferon beta (IFNβ) 
enhanceosome is discussed in Section  2.7 (reviewed in [97]). 
2.3.4 Post translational modifications (PTMs) 
Some signals release IκB as well as induce PTMs of NF-κB or cofactors, which could 
result in the regulation of specific genes. RelA(p65) has been shown to be inducibly 
phosphorylated, acetylated, ubiquitinated and prolyl-isomerised (reviewed in [98]). 
The analysis of the effect of the PTMs is normally limited to its effect on general 
transcriptional ability of RelA(p65). For example, protein kinase A (PKA) mediated 
phosphorylation of RelA(p65) at serine 276 leads to enhanced transactivation, due to 
increased interactions with p300 and cyclic AMP response element binding protein 
(CBP) co-activators [99]. However, signal specific PTMs of RelA(p65) or cofactors 
could also result in the regulation of specific genes.  
2.4  κB binding in vitro and in vivo  
NF-κB dimers bind to the consensus DNA sequence of the κB site 
GGGRNNYYCC (N= any, R= purine A/G, Y= pyrimidine C/T). The κB consensus 
sequence is degenerate since different dimers bind to slightly different sequences with 
different affinities in vitro, and specific NF-κB dimers can bind to many variations of 
the consensus κB sites (reviewed in [100]). The crystal structures of NF-κB 
(RelA(p65)/p50)) bound to κB sites show some structural features that may explain 
the ability of NF-κB to bind to different DNA sequences [88, 101]. The RHD consists 
of two β-sheet immunoglobulin-like folds. The NT β fold makes base specific 
contacts with the major groove using amino acid residues on flexible loops extending 
from the rigid β-sheet immunoglobulin folds. The C-terminal (CT) β fold makes 
hydrogen bonds and hydrophobic interactions with the CT β fold of the other subunit, 
forming strong bonds between the two subunits of the dimer. However, this CT β fold 
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only interacts with the phosphoribose backbone of the DNA, and does not make base 
specific contacts. Since there is some flexibility between the two β folds of the RHD 
this may explain why there is flexibility in the consensus κB sequence.  
Although different homodimers showed different affinities to different κB sites 
in vitro [102], it is currently difficult to predict which NF-κB dimer will bind to a 
particular κB site in vivo. It has been shown that the sequence of the κB site does not 
correlate with the ability of some specific dimers to regulate particular genes [96]. 
However, certain κB sites are thought to bind only selective dimers. For example, 
RGGAGAYTTR is in the promoter regions of some genes activated by the alternative 
pathway (Section  2.2, page 27) and has been shown to bind only the RelB/p52 
heterodimer [103]. The κB sites in many promoters are conserved through evolution 
indicating that the sequence has an important function for selectivity. Experiments 
using lentiviral-based κB reporters in different NF-κB knock out cells indicated that 
the κB sequence does confer the requirement for specific NF-κB subunits to be 
present in fibroblasts for transcriptional activity [104]. However, the κB sequence 
does not primarily determine which NF-κB dimer binds, instead it determines which 
NF-κB dimer can activate transcription by forming a productive interaction with 
signal specific cofactors [104].  
It is predicted that NF-κB would not be able to bind a κB site if it was tightly 
packed into a nucleosome due to steric hindrance (reviewed in [105]). However, it has 
been shown that in vitro p50 homodimers can bind to a nucleosomal κB site, without 
disturbance of histone-DNA contacts [106]. Whether this could also be the case for 
p50 homo- or heterodimers on chromatin in vivo is unknown. It would be expected 
that not only the presence of nucleosomes would effect the NF-κB binding to κB 
sites, but also the “status” of nucleosomes and histones. ChIP have shown that some 
promoters containing κB sites are more accessible to NF-κB binding than others. LPS 
induced the binding of RelA(p65) to some promoters more quickly than to other 
promoters in Raw (macrophage) cells [107]. The promoters that could recruit 
RelA(p65) quickly (20 min) had a low level of constitutive H4 acetylation, whereas 
the promoters that recruited RelA(p65) slowly (approx 1 hour 30 min) did not [107].  
One extensive ChIP on CHIP study found 209 TNFα inducible RelA(p65) 
binding sites on the non-repetitive regions of chromosome 22 in HeLa S3 cells [108]. 
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Approximately 30% of the sites were within 5 kbp from the 5’ end (ATG) of an 
annotated gene and 40% of binding sites were found in intronic regions. Only half of 
the bound fragments contained a consensus κB site indicating that this is not always a 
requirement for NF-κB chromatin association.  
2.5 Transcription activation domain (TAD) of RelA 
Transcription activation domains (TADs) of TFs are grouped into classes, although 
many TADs contain elements of more than one class (reviewed in [109]). The classes 
are formed according to amino acid composition and are acidic, proline, glutamine or 
serine/threonine rich. TADs are thought to activate transcription by forming 
interactions with cofactors and GTFs. How this is achieved is not clear, due to the 
lack of intrinsic stable structures of most TADs. However, many TADs (including the 
TAD of RelA(p65)) can be induced to form structures under certain conditions. 
RelA(p65) contains two acidic transcription activation domains (TA1 and TA2) with 
conserved repeated amino acid motifs [110, 111]. Together they make the 
transcription activation domain (TAD). TA1 consists of the last 30 amino acids of 
RelA(p65) (amino acids 521-551), and TA2 consists of amino acids 441-521. They 
were identified by performing transient transfection experiments using a GAL4 driven 
chloramphenicol acetyl transferase reporter and the DNA binding domain of GAL4 
(GAL4-DBD) fused to different deletion mutants of RelA(p65) [110]. Mutagenesis 
indicates that important features of TA1 are the acidity and position of the repeated 
motifs in a modelled potential α-helix. A model of the α-helical motifs is shown in 
Figure 9. 
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Figure 9. The modelled helix of the conserved repeated motifs in RelA(p65) TAD. The repeated 
motifs are: 
Inner circle : TA1 from human/mouse  (531-549) DEDFSSIADMDFSALLSQ 
2nd circle: TA1 from Xenopus               (508-525) GDSLTSLFELDFSSLLSN 
3rd circle: TA2 from Human/mouse      (463-480) FTDLASVDNSEFQQLLNQ 
Outer circle: TA2 from Xenopus           (430-447) CTSLSSIDNSDFSQLLSE  
The red line shows the path of the TA1 from human or mouse, and the yellow circles indicate the 
positions of serines found to be phosphorylated in the human TAD. Picture adapted from [111]. 
 
Nuclear magnetic resonance showed that the TAD (428-551) is unstructured 
(random coil) in solution [112]. Circular dichroism measurements of TA1 (521-551) 
confirmed that the TA1 is normally unstructured. However, addition of a hydrophobic 
compound, resulted in an α-helical structure (modelled in Figure 9). This indicates 
that if the amino acids in TA1 are protected from water interactions, as could happen 
in a large protein complex, then it could form an α-helical structure, and make 
specific protein-protein interactions. The transcription activation domain of VP16 is 
also an unstructured acidic domain, and like RelA(p65)-TAD, the VP16-TAD can 
interact with TFIIB and TFIID components [113]. Interestingly, VP16-TAD was 
shown to form an α-helix upon binding to TAF9 (TAFII31). VP16-TAD interaction 
with TAF9 was dependent on the hydrophobic residues that are also conserved in the 
repeated motifs in RelA(p65)-TAD [114]. Many cofactors are known to interact 
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directly with the RelA(p65)-TAD; these are p300 [115], TFIIB, TBP, TAFII250, 
TAFII80, TAFII28 [116, 117], TAFII105 [118], Silencing mediator for retinoic acid 
and thyroid hormone receptor (SMRT) [119] and the Mediator complex [120].   
2.5.1 Phosphorylation of RelA(p65)-TAD 
The TAD of RelA(p65) has been found to be phosphorylated at many residues, as 
described in Table 2. The phosphorylation of the TAD was mainly shown to activate 
transcription. Three of the five phosphorylation sites occur in the serine rich region of 
the α-helical model of the TAD motifs (Figure 9). Phosphorylation of these residues 
would increase negative charged patches to form on one side of the helix. This could 
alter the interaction surface available to proteins, and explain the differences in 
interaction partners of TAD upon phosphorylation.  
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Site Stimuli Kinase Pathway Cells tested Function Ref 
Ser536-P 
(TA1) 
IL-1 IKKα/β 
p38 
PI3K/Akt NIH3T3, 293 Transcription 
from reporter 
increased, 
cooperation with 
p300/CBP 
[121-
123] 
 TNFα IKKα/β 
(cytosol) 
TRAF2,5 
and TAK 
HeLa, 293 
MEFs 
 [124, 
125] 
 LPS IKK2   Monocytes, 
macrophages 
Activates reporter [125, 
126] 
 Lymphotoxin-β 
receptor 
activation 
IKK1  HT29 cells Activates reporter [127] 
 PMA + A23187   Jurkat  [125] 
 doxorubicin and 
etoposide  
RSK1 
(nuclear) 
p53 
activation 
Saos 2 Activates by 
reduced RelA/IκB 
interaction 
[128] 
 PMA + 
ionomycin 
cytosol  Jurkat T cells  [129] 
Ser529-P 
(TA1) 
TNFα Casein 
Kinase II 
cAMP HeLa Transcription 
from reporter 
increased 
[130] 
Ser535-P 
(TA1) 
 CaMKIV Maybe 
MAPK 
HeLa Transcription 
from reporter 
activated, CBP 
interaction 
[131, 
132]  
Ser468-P 
(nucleus) 
(TA2) 
PMA + 
ionomycin 
IKKε   Jurkat T cells Transcription 
from reporter 
increased 
[129] 
 TNFα IKKβ  Various No effect detected [133] 
 IL1 IKKβ  Various No effect detected [133] 
  GSK-3β  fibroblasts Possible 
repression of 
basal level 
[134] 
?Thr505-P   ARF, ATR  ARF represses 
transcription, via 
HDAC1  
[135] 
?-P (TA2) PMA   HeLa Transcription 
from reporter 
increased 
[111] 
Table 2. Phosphorylation sites in RelA(p65) TAD. Columns: Site indicates the known 
phosphorylation sites, unsure sites are indicated with a question mark (?). When identified other 
features are listed in the columns. A blank column indicates an unknown feature. Ser stands for serine, 
thr for threonine, P for phosphorylation. 
 
2.6 Known Cofactors of RelA(p65) dependent Transcription 
Hundreds of different proteins regulate the NF-κB response. The regulation normally 
involves IκB degradation and nuclear import of NF-κB. However, NF-κB dependent 
transcription is also regulated once inside the nucleus, by cofactors of transcription. 
Some proteins activate NF-κB dependent transcription (co-activators), while other 
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proteins repress transcription (co-repressors). However, proteins that are usually co-
activators of transcription can also act as co-repressors under some specific 
circumstances, and vice versa.  
2.6.1 TBP, TAFs, PC4 and TFIIB 
TBP and TFIIB are general transcription factors involved in accurate transcription 
initiation by RNAPII. Both proteins interact with the TAD of RelA(p65) [116]. TAF 
proteins are components of TFIID, as well as other co-activator complexes, like 
SAGA, STAGA and TFTC [136-139]. These complexes normally contain HAT 
activity and are involved in transcription regulation of large groups of genes, so are 
sometimes considered GTFs. TAFs and positive cofactor 4 (PC4) were shown in vitro 
to be necessary for RelA(p65) directed transcription and TAF1 (TAFII250), TAF6 
(TAFII80) and TAF11 (TAFII28) were found to bind directly to the TAD of 
RelA(p65) [117]. TAF1 is a large protein and has many different functions (reviewed 
in [140]). It is a member of many complexes, and stabilises these complexes by 
making contacts with other TAFs within the same complex. TAF1 can interact with 
many TFs, and also binds directly to initiator elements. It has acetylation, kinase and 
ubiquitin ligase activity, and can modify histones as well as GTFs. TAF6 binds to 
DPE in core promoters, is related to H4 and can bind DNA with a histone fold like 
domain [141]. TAF11 interacts with TFIIA at core promoters, so is likely to be 
important for PIC formation [142].  
2.6.2 Mediator 
Mediator is a large multi-protein complex containing around 30 proteins [143]. It was 
initially purified in many ways by different groups and therefore is known by many 
different names, although a unified nomenclature is now in use [144]. Most of the 
Mediator proteins are conserved between yeast and human, indicating the crucial role 
of the Mediator complex in transcription [145]. The Mediator complex interacts with 
RNAPII to form a holoenzyme [146], which is often the form of RNAPII recruited to 
the promoter region upon transcription activation. Two structurally distinct forms of 
Mediator have been shown, one with RNAPII and one without, indicating that a 
structural change could occur in the Mediator upon binding to RNAPII [147]. In 
yeast, a core Mediator subunit Med17 (Srb4) is as crucial for RNAPII transcription as 
the largest subunit of RNAPII itself, implying that Mediator has a role in regulating 
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transcription of nearly all genes [148]. Various subunits are responsible for binding to 
different TFs (listed in [149]), and in the case of the Nuclear hormone receptors 
(NHRs) the interaction is often ligand dependent. It is thought that through the 
interaction of TFs, the Mediator can coordinate many different signals, to regulate 
transcription by RNAPII appropriately. Mediator is known to interact with RelA(p65) 
via the TAD [120]. It was also shown to be important for NF-κB dependent reporter 
expression in vitro [150]. However, at one promoter (A20) Mediator was detected to 
be associated even before TNFα stimulation in Jurkat cells [151].  
2.6.3 PARP-1 
Poly ADP-ribosylpolymerase 1 (PARP-1) catalyses the transfer of ADP-ribose from 
NAD+ to nuclear proteins, including chromatin proteins, to form long, branched 
polymers (reviewed in [152]). A role for PARP-1 in transcription was first indicated 
with the identification that PARP-1 was the main active component of TFIIC, which 
is required for accurate initiation of RNAPII transcription under some circumstances 
[153, 154]. PARP-1 has been found to activate NF-κB dependent reporter expression 
in transient transfection experiments independent of its enzymatic and DNA binding 
activity [155, 156]. PARP-1 activation of NF-κB is synergistic with p300 [157], 
which can acetylate PARP-1 to increase its interaction with p50 [158]. The 
acetylatable residues of PARP-1 were found to be important for Mediator and p300 
activation of NF-κB dependent transcription [158].   
2.6.4 p300/CBP 
The homologous proteins p300 and CBP are large multi-domain proteins that can 
bind directly to many TFs and activate transcription of a wide variety of genes 
(reviewed in [159]). They regulate transcription by acting as a bridge between TFs 
and GTFs  (TBP, TFIIB, TFIIE and TFIIF)  (reviewed in [160]) and other cofactors 
(e.g. P/CAF [161]) and also by use of their acetyltransferase activity (reviewed in 
[162]). p300/CBP interacts with many proteins and is a component of enhanceosomes 
[163]. p300/CBP can acetylate core histones and non-histone proteins in vitro, 
providing a model whereby these HAT cofactors activate transcription by modifying 
nucleosomes and TFs in the cell upon activation (reviewed in [159, 164]). In vitro 
transcription experiments revealed that acetyl Coenzyme A (coA) [165] and histone 
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tails [166] are necessary for p300 activated transcription from promoters on DNA 
templates reconstituted with regularly spaced nucleosomes (“chromatin” templates).  
p300 and CBP were found to activate NF-κB reporter gene expression [167] 
and to bind the TAD of RelA(p65) [115]. The TAD interaction with CBP was found 
to be independent on phosphorylation, while a RHD interaction was dependent on 
PKA phosphorylation of serine 276 [99]. Activation of RelA(p65) by p300/CBP 
acetyltransferase activity is also due to direct lysine acetylation of RelA(p65) (as well 
as acetylation of the histones) [168, 169]. The precise mechanism of how p300/CBP 
activates transcription is investigated using in vitro transcription experiments and is 
thought to be similar for all TFs regulated by p300. p300 activated transcription when 
added before PIC formation indicating that it functions by providing an effective 
transcriptional template for productive PIC formation [170]. It also has been shown to 
activate transcription synergistically with the transcription elongation factor, TFIIS 
[171], indicating it can also activate transcription by enhancing effective elongation 
by RNAPII. 
There is evidence that p300 can also repress transcription in vitro using 
“chromatin” templates made with purified factors, and transcription reactions using 
purified RNAPII and GTFs [172]. In this system, p300 did not effect transcription of 
activated transcription with or without acetyl CoA on naked templates. However, on 
“chromatin” templates p300 repressed activated transcription when added without 
acetyl CoA and did not effect the transcription with acetyl CoA. By altering the time 
of addition of p300 the authors show p300 was specifically inhibiting a stage of 
transcription before initiation of the first phosphodiester bond, and could prevent 
initiation despite the presence of a pre-assembled initiation complex. In this system, 
neither p300 nor steroid receptor co-activator 1 (SRC-1) could activate transcription 
further, indicating that the purified system did not recapitulate a fully functional 
transcription assay.  However, in a system for assaying productive transcription 
elongation, a similar effect was seen, indicating the possibility that acetyl CoA levels 
in the cell might regulate the transcriptional activation or repression by p300 [171]. 
2.6.5 P/CAF  
P/CAF is a HAT protein, homologous to GCN5 and a member of various large 
complexes that acetylate histones as well as non-histone proteins. P/CAF has been 
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shown to be an NF-κB co-activator [173], and also to acetylate RelA on specific 
lysines to regulate the duration of transactivation [169].  
2.6.6 p160/SRC family 
Three homologous HAT proteins make up this family called steroid receptor co-
activator 1, 2 and 3 (SRC-1, SRC-2 and SRC-3). There are many alternative names: 
SRC-1 = NcoA-1; SRC-2 = NcoA-2, GRIP1, TIF2 and SRC-3 = NcoA-3, ACTR, 
TRAM1, AIB1, RAC3, P/CIP. They were first identified as factors interacting ligand 
dependently with nuclear hormone receptors to activate transcription (reviewed in 
[174]). They are found in large HAT complexes, which can activate transcription 
driven from many different TFs (reviewed in [175]). All three proteins have also been 
shown to have a role in NF-κB transcriptional regulation. The role for SRC-1 was 
shown by injection of anti-SRC-1, which led to inhibition of NF-κB reporter 
expression [173]. This was relieved upon overexpression of SRC-1 but not -2 or -3. 
ASC2, a protein upregulated in some cancers is a component of specific SRC-1 and 
p300/CBP containing complex (distinct from the standard SRC-1 complex) [176]. 
ASC2 also interacted with p50 and RelA(p65) and activated reporter genes in 
transient transfection experiments [177]. SRC-2 and SRC-3 were also reported as NF-
κB co-activators [173, 178]. SRC-3 is present in the cytoplasm of cells grown in 
serum free media, and in the nucleus of cells stimulated with TNFα or insulin [179], 
probably due to phosphorylation of SRC-3 by the IKK complex [180]. 
ChIP experiments in 293T cells investigating transcriptional cofactor 
recruitment to the NF-κB regulated IκBα promoter showed differences in the SRC 
recruitment. SRC-2 was found to be present at the promoter even before TNFα 
stimulation [181]. Upon TNFα stimulation, SRC-1 associated with the promoter 
while SRC-2 dissociated and left the nucleus. SRC-3 associated quickly with the 
promoter upon TNFα treatment, then dissociated and re-associated later.  This 
indicates that the function of each SRC protein in the regulation of the IκBα gene 
may be different.  
2.6.7 PRMT1 and 4 
Protein arginine methyl-transferases (PRMTs) are transcriptional co-activators that 
methylate histone and non-histone proteins. PRMT4 (also called CARM1) was shown 
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to activate a subset of NF-κB dependent genes in vivo [182]. It interacts with the 
RHD of RelA(p65), and forms a complex with p300 and NF-κB in nuclear extracts 
[182]. Unpublished data from our group also indicates PRMT1 as a co-activator of 
NF-κB (Covic and Hottiger, unpublished).  
2.6.8 Brg1  
Interestingly there are very few reports demonstrating that ATP dependent 
remodellers are required or recruited by RelA(p65) for transcription regulation. 
Indeed, in vitro, Brg1 had no effect on human immunodeficiency virus 1 - long 
terminal repeat (HIV1-LTR) transcription controlled by RelA(p65) [183]. However, 
Brg1 could be involved in transcription of specific NF-κB genes since Brg1 was 
shown to be recruited to the IL-8 gene upon IL-1β stimulation [184]. Also reporter 
assays using the major histocompatibility class 1 promoter indicated that Brg1 and 
P/CAF synergistically activated NF-κB dependent reporter expression [185]. 
Additionally Brg1 was recruited to oligonucleotides containing NF-κB binding sites 
in the granulocyte, macrophage colony stimulating factor (GM-CSF) promoter [186]. 
Brg1 was also shown to be important for IFNγ enhanceosome activity, indicating that 
chromatin remodellers may be important for transcription of certain genes, including 
ones regulated by NF-κB [187]. 
2.6.9 P-TEFb 
The positive elongation factor b (P-TEFb) consists of cyclin T1 and Cdk9 (reviewed 
in [12]). It stimulates transcription elongation by phosphorylation of the RNAPII 
CTD. Cdk9 was shown to activate HIV1-LTR (contains two NF-κB binding sites) 
driven reporter expression, whereas Cdk9 kinase deficient mutant repressed reporter 
expression [188]. RelA(p65) was found to interact with cyclin T1 from cellular 
extracts and P-TEFb was recruited to IL-8 promoter upon TNFα stimulation. This 
coincided with RNAPII recruitment and phosphorylation at serine 2 and 5 of the 
CTD. Therefore, P-TEFb is an NF-κB cofactor that can regulate transcription at a 
stage after PIC formation, during the elongation of RNAPII. 
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2.6.10 HDACs 
HDAC containing co-repressor complexes contain the homologous proteins N-CoR 
and SMRT. These proteins interact directly with unliganded nuclear hormone 
receptors and other TFs to repress their activity (reviewed in [78]). HDACs de-
acetylate histones as well as non-histones to regulate transcription. HDACs are also 
members of other complexes, that often contain chromatin remodelling factors 
(reviewed in [78]). HDACs fall into three classes by sequence homology, class 1 
members are Rpd3 (yeast), HDAC1, 2, 3, and 8 (human), class 2 members are Hda1 
(yeast), HDAC 4, 5, 6, 7, 9 and 10 (human), class 3 members are Sir2 (yeast) and the 
SIRT proteins (1 to 7 in humans). Micro-array analysis of bladder or breast cancer 
cells treated with various HDAC inhibitors, identified that as many genes were 
upregulated as downregulated upon treatment implying that HDAC activity is not 
always involved in transcriptional repression [189].   
There is evidence that N-CoR, SMRT and HDAC1, 2 and 3 are involved in 
regulation of NF-κB. SMRT was shown to repress NF-κB dependent expression of an 
IL-2 reporter, and this was relieved upon treatment with the HDAC inhibitor, 
trichostatin A (TSA) [190]. In a different report, HDAC 1 and 2 as well as N-CoR 
(but not SMRT) were found to repress TNFα stimulation of NF-κB dependent 
reporter expression in NIH3T3 cells [191]. Treatment with TSA led to activation of 
IL-8 (an NF-κB regulated gene) and coincided with increased acetylation of the 
promoter region. The HDACs were suggested to be recruited to NF-κB dependent 
promoters and this could be through direct interaction of HDAC 1 with the RHD of 
RelA(p65) [191]. However, in vitro transcription reactions using a  “chromatinised” 
HIV1-LTR template activated by RelA(p65), showed that repression by HDAC1 
required Gal4 sites and Gal4-HDAC1 [192]. This indicates that HDAC1 recruitment 
by HDAC1/RelA(p65) interaction may not be general and could be gene specific. 
Alternatively a whole repressor complex could be recruited by multiple 
protein/RelA(p65) interactions. The tumour suppressor protein ARF was shown to 
inhibit NF-κB by inducing association between RelA(p65) and HDAC1 from extracts 
[135]. This was dependent on the ATR kinase and on threonine 505 of RelA(p65). 
HDAC3 (not HDAC 1 or 2) was found to repress NF-κB synthetic reporter 
expression in 293T cells [193]. HDAC3 (not 1) was also shown to interact with 
RelA(p65) by co-immunoprecipitation studies [193]. One difference to the report 
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described above where HDAC1 and 2 repressed NF-κB dependent expression, and 
HDAC1 associated with RelA(p65) was the different cell types used. Over-expression 
of HDAC3 led to less acetylated RelA(p65), relocation of RelA(p65) to the cytoplasm 
(dependent on IκBα) and increased interaction with IκBα in the presence of TNFα in 
293T cells [193]. This supports a model whereby de-acetylation of nuclear RelA(p65) 
is involved in transcription termination by RelA(p65) association with IκBα and 
relocation to the cytoplasm. Another report confirmed the interaction between 
HDAC3 and RelA(p65) in vitro and showed that HDAC3 could directly de-acetylate 
RelA(p65) [169]. After cells were stimulated by attachment to laminin, RelA(p65) 
and co-activators were recruited to the IL-8 and cIAP-2 promoters, whilst HDAC3 
was transiently released from the promoters, and this release was dependent on IKKα 
[194]. IKKα was found to phosphorylate SMRT, and the phosphorylated innactive 
form was bound to the promoter region, with the same kinetics as the co-activators 
[119]. IKKα phosphorylated SMRT could not interact with RelA(p65) in vitro, 
resulting in derepression of NF-κB [119]. This is an example of a switch from a co-
repressor bound RelA(p65) containing promoter/enhancer complex to a co-activator 
containing complex.  
ChIP experiments investigating transcriptional cofactor recruitment to the NF-
κB regulated IκBα promoter showed differences in the HDAC protein recruitment 
and therefore in their functions [181]. HDAC1 protein was found to be present at the 
promoter in 293 cells before stimulation, but surprisingly for a co-repressor its 
presence was found to be enhanced at 30 min and 120 min after THFα stimulation, 
showing some oscillation (the same pattern as for SRC-3). In contrast, there were no 
obvious differences in the HDAC2 and HDAC3 levels found at the IκBα promoter. 
However, HDAC2 did not regulate IκBα reporter gene expression when over-
expressed or when knocked down, whereas HDAC3 was found to be a classical co-
repressor in these experiments. SMRT association at 30 min was stimulated by TNFα, 
while NcoR associated at 60 minutes [181]. Together these studies indicate that the 
repression of NF-κB is mediated through many different HDAC containing co-
repressor complexes. However, the components of the complexes, order of 
recruitment and targets are probably gene, stimuli and cell type specific.  
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2.6.11 SIRTs 
SIRT proteins are class 3 HDACs that are NAD+ dependent for HDAC activity 
(reviewed in [195]). SIRT1 has been found to de-acetylate histones and non-histone 
proteins. SIRT1 interacts with RelA(p65) and de-acetylates lysine 310 [196]. SIRT1 
was shown by ChIP to bind to the promoter regions of some genes (e.g. cIAP-2) but 
not others (e.g. IκBα). Upon TNFα treatment, SIRT1 was released from the cIAP-2 
promoter, whilst RelA(p65), p50, RNAPII were recruited. Acetylation of H3K14 was 
also increased. In the presence of Resveratol (an agonist of SIRT1) and TNFα, 
recruitment of the activators of transcription was delayed whilst SIRT1 remained 
associated [196].    
2.6.12 IκBα in the nucleus 
Expression of IκBα is under the control of NF-κB and upon IκBα synthesis, it can 
enter the nucleus, and bind to promoter/enhancer bound NF-κB resulting in NF-κB 
removal from the chromatin, and translocation to the cytoplasm [197]. The expression 
of the other IκB proteins are not controlled by NF-κB, therefore only IκBα is 
involved in termination of the NF-κB response, and allows transient activation of 
gene expression.  
2.6.13 Other proteins 
Many other proteins have been shown to activate or repress NF-κB dependent 
transcription in transient transfection reporter assays, without affecting IκB 
degradation or RelA(p65) nuclear import. For example, E1A 13S (adenovirus early 
region 1A) [198], TLS/FUS [199], 53BP2 (p53 binding protein 2) [200] and BRCA1  
(breast cancer 1) [201] activate NF-κB dependent transcription, while papilloma virus 
proteins E6 [202], c-Myc [203], HSCO (over-expressed in hepatocellular carcinomas) 
[204], SINK (p65-interacting inhibitor of NF-κB) [205]. Epstein-Barr virus BZLF-1 
(a basic leucine zipper DNA binding protein)[206] repress.  
2.7 Enhanceosomes 
Enhanceosome is the term coined to describe the complex composed of trans-
activating factors and chromatin components that integrate signals to precisely 
regulate transcription of a particular gene, or set of genes. One of the most well 
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studied enhanceosomes contains RelA(p65) and the interferon beta (IFN-β) enhancer 
and illustrates the key functions of enhanceosomes to temporally, specifically and 
combinatorially control gene expression [163, 207]. The IFN-β gene is activated by 
virus infection, by induction of NF-κB, interferon regulatory factors (IRFs) and ATF-
2/c-Jun heterodimer. Together with HMG I(Y), these transcription factors 
cooperatively bind the cognate DNA sequences resulting in transcriptional synergy. 
After the initial binding and looping of DNA to accommodate the binding, 
enhanceosome assembly is dynamic and cofactors are sequentially included into the 
enhanceosome at precise times after virus infection. Early in cofactor recruitment, the 
enhanceosome recruits non-phosphorylated RNAPII, which is competent for 
transcription initiation [207]. The histone acetyl transferase, GCN5, is recruited and 
acetylates histones and HMG I(Y), followed by hSWI/SNF mediated chromatin 
remodelling. The resulting chromatin is able to bind to TFIID, and TBP binding to the 
TATA box results in the shifting of a positioned nucleosome away from the 
transcription start to 36 nucleotides downstream [187]. From these events it follows 
that the IFN-β enhanceosome activates transcription by increasing the rate of PIC 
formation [207]. The position of the nucleosome is crucial in enhanceosome function, 
as synthetically positioning the nucleosome to the downstream site led to the loss of 
temporal control of IFNβ expression, as well as loss of signal specificity [208]. The 
series of acetylation and deacetylation events described for the activation of IFNβ 
gene transcription by the enhanceosome is complex. Recently is was shown that 
HDAC6 activates enhanceosome transcription initiation through IRF3, while HDAC1 
and 8 repressed the transcription [209]. 
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3 Cell type specific regulation of NF-κB  
3.1 Cell types and Cell differentiation 
In our bodies we have many different tissues and cells, all of which perform a specific 
function due to the presence of specialised cells. Most of the cells are terminally 
differentiated and in order to renew these cells, a small number of stem cells have the 
ability to replicate, and to differentiate into a number of specific types of cell. 
Differentiated cells have a specific morphology and physiology resulting from a 
precise pattern of gene expression. This pattern is achieved during differentiation by 
genomic imprinting (e.g. DNA methylation patterns), chromatin remodelling events, 
heterochromatin formation and special nuclear structures (reviewed in [26]). 
3.2 Accessibility to gene control regions 
One of the major ways of regulating transcription of specific genes (including NF-κB 
dependent genes) in different cell types is by regulating the accessibility of the gene 
control regions (reviewed in [73]). This can be through cell type specific patterns of 
nuclear structures, like chromosome territories and heterochromatin, as well as local 
chromatin structures. All of these levels of chromatin structure are interdependent. 
For example, the cell type specific positioning of a chromosome within the nucleus 
will affect its heterochromatin status. 
3.2.1 Local chromatin structure 
Different cell types have different patterns of histone modifications and positioned 
nucleosomes in the region of specific genes. An example where the local chromatin 
structure directly regulates the transcriptional potential of RelA(p65) is the chromatin 
structure surrounding the E-selectin promoter [210]. E-selectin is an adhesion protein 
expressed only in endothelial cells and is involved in the binding of leukoctyes at sites 
of infection and inflammation. Expression of E-selectin has been found to be up-
regulated by inflammatory cytokines (like TNFα) and is regulated by NF-κB, ATF-
2/c-Jun and HMGI(Y). When the proximal promoter of E-selectin was used in 
reporter assays, it was activated in non-endothelial cells, indicating the endogenous E-
selectin expression is regulated by its endogenous chromatin status. The E-selectin 
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promoter region was found to be more accessible to micorcoccal nuclease treatments 
in HUVEC (human umbilical vein endothelial cells) than in UASMC (umbilical 
artery smooth muscle cells) [210]. This indicates that this particular gene control 
region is more accessible to protein factors in endothelial cells than in the other cell 
type. How this is achieved is not known, although it was shown to probably be 
independent of H3K9 methylation. Upon TNFα stimulation there was no change in 
the micrococcal nuclease accessibility of the E-selectin promoter in UASMC cells, 
whereas the promoter region in HUVEC cells became more accessible and 
transcription factors and co-activators were recruited [210].    
3.2.2 Heterochromatin and higher order chromatin structure 
Electron microscopic studies show that the nucleus of stem cells generally 
have very little heterochromatin “keeping the options open” whereas once the cell is 
committed to a specific differentiated cell type it has a specific pattern of 
heterochromatin (reviewed in [62]). Analysis of various types of mouse cells, 
indicated that the positioning of heterochromatin is cell type specific [211]. This 
allows the repression of a vast number of genes, whose protein products are not 
necessary for the function of the specific differentiated cell. Other aspects of 
chromatin structure are also cell type specific, although the mechanism of higher 
order chromatin structure regulation in different cell types is mostly unknown. 
However, special AT rich binding protein 1 (SATB1) is an example of a cell type 
specific protein that can regulate higher order chromatin structure, nuclear 
architecture and gene expression [212]. SATB1 binds to DNA at base unpairing 
regions (BURs), which are found at many places in the genome. The BURs 
surrounding the immunoglobulin heavy chain intronic enhancer (contains an NF-κB 
site) are necessary for tissue specific transcription (in B cells) [213]. SATB1 is 
expressed mainly in T cells, and binds to the bases of looped out chromatin [214]. It is 
thought to regulate chromatin structure and transcription by recruitment of chromatin 
remodeling complexes [212] and establishment of specific histone modification 
patterns over SATB1 controlled regions [215]. Cell type specific heterochromatin and 
chromatin structure are likely to have a large role in the regulation of NF-κB 
dependent transcription. However, the effect of higher order chromatin structure on 
cell type specific, NF-κB dependent transcription has not directly been studied.  
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3.2.3 Chromatin territories and the nuclear periphery 
Cell specific alteration of the position of a gene within the nucleus could regulate the 
potential transcriptional activity of this gene. Genes situated on the outside of a 
chromatin territory (looped into the interchromatin compartment) are usually more 
active than those within the chromatin territory or at the nuclear periphery (Section 
 1.2.8) (reviewed in [26]). For example, fluorescence in-situ hybridisation analysis 
showed that the IgH and κ light chain loci (both regulated by NF-κB) are localised to 
the nuclear periphery in non-B cells, whereas they are localised internally in 
chromatin territories in pro-B cells (immature B cells) [66]. A model is proposed that 
for IgH and Igκ genes, transcription and recombination at these loci is restricted in the 
default state by association with the nuclear periphery. Looping out of gene regions 
from the chromatin territories into the interchromatin space can activate the gene 
locus in a specific cell type. For example, the IgH locus is looped from the chromatin 
territory in developing B cells, bringing together V and H regions, facilitating 
recombination (reviewed in [216]). In non-B cells like pro-T cells there is only 
limited expression of some germline V transcripts from the IgH loci, while in pro-B 
cells the V array of transcripts is transcribed, and this allows VDJ recombination to 
occur. Ultimately the immunoglobulin locus positioning allows NF-κB dependent 
transcription of germline transcripts during class switching as well as 
immunoglobulins in stimulated mature B cells (reviewed in [26] and [216]).    
3.3 Receptors/signalling cascades 
Different cell lines express different cell surface receptors and signal transduction 
molecules. This means that each cell is responsive to a particular pattern of stimuli. 
For example, LPS is a NF-κB activating compound found on the outer membrane of 
gram-negative bacteria (reviewed in [217]). LPS binds to CD14 cell surface protein 
expressed on monocytes, monocyte derived macrophages and other myeloid cells. 
LPS binding to CD14 results in the activation of Tol like receptor 4 (TLR4) and the 
activation of various signalling pathways and TFs that regulate the expression of 
many different inflammatory cytokines. Since CD14 and TLR4 are only expressed on 
the surface of myeloid cells, LPS can activate NF-κB only in these cells. In a similar 
way, only B cells express B-cell receptors, and only T cells express T-cell receptors, 
both of which signal to NF-κB to activate a specific set of genes.  
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Other proteins that contribute to NF-κB signalling are also expressed in 
certain cell types. One of the major upstream activators of NF-κB is the PKC family 
of kinases. They are differentially expressed in different cell types, and activated by 
different stimuli, resulting in the activation of many different signalling cascades 
including IKK phosphorylation and ultimately NF-κB activation [218, Castrillo, 2001 
#251].  
3.4 Expression pattern of NF-κB family members 
Different cell types have specific expression patterns of the NF-κB proteins. The 
major NF-κB dimer consists of RelA(p65) and p50 and both are widely expressed. 
RelB is expressed in parts of the thymus, lymph nodes and Peyers patches while c-Rel 
is expressed in haematopoietic and lymphocyte cells (reviewed in [219]). This limits 
the possible pattern of formation of NF-κB dimers in different cell types. The 
different functions of the NF-κB proteins in different cell types can be seen by the 
differences in phenotype of the knock out mice. RelA(p65) -/- mice die as embryos at 
gestation day 15-16 [220]. However, the other NF-κB knock out mice do not have 
developmental defects, but they do show defects in immune responses (reviewed in 
[83]). For example, NF-κB1 -/- and NF-κB2 -/- mice develop normally, but have 
deficient adaptive immune responses; in particular, they cannot activate lymphocytes. 
RelB -/- mice also have defective adaptive immunity and dendritic cell development, 
and die on birth due to organ inflammation. c-Rel -/- mice also have adaptive 
immunity defects as well as macrophage defects (reviewed in [83]).  
Electromobility gel shift assays (EMSA) have shown that the DNA binding 
dimers that form in each tissue changes during development [221]. In mature B cells, 
the most prominent NF-κB dimer is the heterodimer c-Rel/p50 [222] [223]. By 
contrast, stimulation of the pre-B cells 70Z/3 (κ light chain locus is rearranged but not 
transcriptionally active) led to the activation of RelA(p65)/p50 dimers. Upon B cell 
maturation c-Rel expression was found to increase, and the predominant active NF-
κB in the mature B cell line WEHI 231 was found to be the constitutive nuclear c-
Rel/p50 [222]. The reason for the constitutive nuclear localization of c-Rel/p50 in 
mature B cells is not fully understood. The expression pattern and DNA binding 
activity of nuclear NF-κB was also analysed in monocytes, monocyte derived 
macrophages and dendritic cells [224]. p50 homodimers were detected in all three cell 
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types in non-stimulated conditions. Upon LPS stimulation RelA(p65)/p50 and 
RelB/p50 shifts were up-regulated in macrophages and dendritic cells. The RelB/p50 
gel shift was extremely increased in LPS treated dendritic cells compared to the other 
cell lines [224]. In fibroblasts the majority of TNFα regulated NF-κB genes are 
transcribed by RelA(p65)/p50 heterodimers, since TNFα treated NF-κB1-/- RelA-/- 
fibroblasts showed no NF-κB gel shift, no transcription of various κB reporters and 
very little NF-κB responsive endogenous mRNA was detected [96]. Each dimer is 
likely to activate a different, but overlapping set of genes since there is some 
functional redundancy of these proteins as transcription factors [96]. 
The tissue specificity of NF-κB protein expression is further complicated by the 
inducible expression of many NF-κB proteins. For example, expression of RelB, c-
Rel, p105, as well as IκBα are regulated by NF-κB itself. Therefore, the availability 
of active NF-κB proteins is determined by the cell type, as well as cell status and 
leads to a specific pattern of NF-κB dimers.  
3.5 Cofactors of transcription 
Transcription of genes is coordinated by the action of transcription factors and 
cofactors (Section  1.3). If these proteins are expressed only in a subset of cell types, 
then they will only be able to regulate transcription in a subset of cell types. For 
example, the protein Ikaros was found to be a lymphocyte transcriptional repressor 
that can bind to control regions of terminal deoxynucleotidyltransferase and other 
lymphoid regulated genes to recruit them to heterochromatin [225].  
There is so far only one known cell type specific cofactor of NF-κB dependent 
transcription, which is TAF4b (also called TAFII105 [226]), a TAF4 (TAF II130) 
homologue. It is expressed in many cell types, but it is probably part of TFIID only in 
B cells and mouse gonads [227]. TAFII105 was found to interact with the 
transcription activation domain of RelA(p65) and to enhance transcription of reporter 
genes [118]. Dominant negative TAFII105 sensitized 293T cells to TNFα induced 
apoptosis indicating TAFII105 might normally be involved in the transcription 
activation of anti-apoptotic genes. Accordingly anti-apoptotic A20 gene was 
upregulated by TNFα treatment in normal cells, but not in cells expressing dominant 
negative TAFII105. Also A20 expression rescued the TNFα sensitivity of TAFII105 
dominant negative expressing phenotype [228]. In agreement with TAFII105 having a 
 51
Introduction 
specific role in activating NF-κB dependent anti-apoptotic genes, transgenic mice 
with the dominant negative TAFII105 show lymphocyte apoptosis and have lower 
levels of A20 [229]. The dominant negative TAFII105 mice also produced lower 
levels of antigen specific antibodies. The mode of transcriptional activation by 
TAFII105 could be by bridging the interaction between NF-κB and the GTFs.  
TAF II105 knock out mice are viable and were not detected to have a major 
defect in development or metabolism [230]. A defect in B cells was not detected in 
the knock out mice, indicating that other TAFs might be able to carry out some of the 
processes normally done by TAF II105 [230]. However, knock out female mice were 
infertile, despite being able to mate, ovulate and carry surrogate pregnancies. The 
ovaries of the knock out mice were half the weight of wild type counterparts 
indicating that mice lacking TAFII105 had oocyte developmental defects. Micro-array 
analysis indicated that 1% of ovarian genes in knock out cells were down regulated 2 
fold or more, and some of these are known to be involved in oocyte development. Of 
these genes, there are at least 2 (cyclin D2 [231] and aromatase [232]) that are 
regulated by NF-κB. However, it is likely that TAFII105 exerts important effects 
through other transcription factors, like c-Jun [233]. 
 
 52
  53
Aim 
 
 
4 Aim of thesis 
NF-κB is an important transcription factor for the regulation of over 300 genes. 
Precise control of the pattern of NF-κB dependent gene expression in each cell type is 
required for the coordinated reaction of each cell in an organism. Cell type specific 
regulation of NF-κB gene expression can be regulated in many ways. One way would 
be through the use of cell type specific transcription cofactors, although so far only 
one has been detected. Therefore, the aim of this thesis was to identify other cell-type 
specific cofactors of NF-κB, in particular RelA(p65), and to investigate their effect on 
NF-κB dependent gene expression. 
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Results 
5 Research Articles 
5.1 Identification of Novel and Cell Type Enriched Cofactors 
of the Transcription Activation domain of RelA (p65 NF-
κB). 
 
5.2 MYBBP1a is a novel co-repressor of NF-κB. 
 
5.3 Modulatation of gene-expression by p300-mediated 
acetylation of RelA/p65. 
My contribution to this paper was the in vitro transcription experiments on 
chromatinised templates, and the interaction studies between p300 and GST-
RelA/p65 wild type or KTR mutant. 
 
5.4 Acetylation of Poly(ADP-ribose) Polymerase-1 by 
p300/CREB-binding protein regulates coactivation of NF-
κB-dependent transcription. 
My contribution to this paper was the initial experiments identifying Mediator 
interactions with PARP-1 and in particular the Med14 (DRIP150) as an interaction 
partner for PARP-1. 
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Transcription Activation Domain of RelA (p65 NF-KB)
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RelA (NF-κB) is a transcription factor inducible by distinct stimuli in many different cell types. To find
new cell type specific cofactors of NF-κB dependent transcription, we isolated RelA transcription
activation domain binding proteins from the nuclear extracts of three different cell types. Analysis by
electrophoresis and liquid chromatography tandemmass spectrometry identified several novel putative
molecular partners. Some were strongly enriched in the complex formed from the nuclear extracts of
specific cell types.
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Introduction
The mammalian NF-κB family of inducible transcription
factors is responsible for regulating specific sets of genes in
many cell types (reviewed in ref 1). There are 7 proteins within
this family (RelA/p65, c-rel, RelB, p105, p50, p100, p52) which
can form combinations of homo- and heterodimers. NF-κB
responsive elements are found in the enhancer and proximal
promoter regions of a wide variety of genes; notable examples
are immunoglobin genes and the long terminal repeat of the
HIV-1 genome. Misregulation of NF-κB is linked to a wide
variety of human diseases, for example various lymphomas,
myelomas, leukaemia’s, carcinomas and adenocarcinomas
(reviewed in ref 2). The critical role of NF-κB, in particular the
RelA/p65 transcription factor, in maintaining normal cellular
events is apparent in RelA knockout mice that die at E15.5-
E16.5 and show TNF-dependent liver apoptosis and defects in
active lymphocyte development.3
RelA contains a bipartite carboxyl terminal acidic trans-
activation domain (TA). When fused to the Gal4 DNA binding
domain, the TA of RelA activates expression of Gal4 dependent
reporter genes.4 NMR and circular dichroism experiments
indicate that the TA has no stable secondary structure, although
the TA could form an alpha-helix when in an hydrophobic
solvent implying that the TA may form a stable structure when
part of a higher order complex.4 Full transcriptional activity of
RelA-TA is dependent on repeats within the conditional alpha-
helix, which is modeled to be an amphipathic helix.5 The TA
has subsequently been shown to regulate transcription by
interaction with transcription cofactors, which can have a
positive (coactivators) or negative (corepressors) effect upon
inducible transcription.
Transcriptional coactivators reported to be involved in the
regulation of NF-κB dependent genes are CBP/p300,6,7 SRC-1/
NcoA-1,8 P/CAF,9 TBP, TAFII250, TAFII80, and TAFII28, TFIIB,10
TAFII10511,12 Mediator,13 PC4,13 E1A 13S,14,15 TLS/FUS,16 RAC3,17
53BP218 and BRCA-1,19 RNA helicase A,20 PRMT4,21 and PARP1.22
There are also many transcriptional corepressors that have
been shown to mediate repression of NF-κB dependent gene
expression, such as HDAC1 and 2,23 HDAC3,24 HSCO,25 SINC,26
and ASC-2.27 Many of these cofactors are known to interact
with the transcription activation domain of RelA (CBP, p300,
Mediator, TBP, the TAFs, and TFIIB). Only one cell type specific
cofactor of NF-κB is known, TAFII105. This B-cell enriched
coactivator is a component of TFIID and can bind directly to
the RelA-TA.11,12 Interestingly, it is required for expression of a
subset of NF-κB dependent genes, including antiapoptopic
A20.28
In this work, we attempt to identify new cofactors of RelA
that interact with the transcription activation domain of RelA,
and in particular, cell type enriched or specific cofactors. We
isolate proteins that interact with the transcription activation
domain of RelA (RelA-TA) from the nuclear extract of 3 different
human cell types by affinity purification. The cell types used
were Jurkat cells (acute T cell leukaemia), THP1 cells (acute
monocytic leukaemia) and HeLa-S3 (cervix epithelial adeno-
carcinoma). These cell lines are responsive to specific sets of
NF-κB stimuli and therefore could contain different sets of
transcriptional cofactors involved in NF-κB dependent tran-
scription. We identified the high molecular weight (over 100
kDa) interaction partners of RelA-TA by electrospray mass
spectrometry after electrophoretic separation. This required
adjustment and optimization of the standard purification
procedures to yield a protocol that we find to be very
reproducible. We confirm that CBP, p300, and subunits of the
* To whom correspondence should be addressed. E-mail: hottiger@
vetbio.unizh.ch.
† University of Zurich.
‡ University of Lausanne.
§ These authors contributed equally to this work.
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Mediator complex are RelA-TA binding proteins and extend
the knowledge by analyzing the interaction of RelA-TA with
specific in vitro translated subunits of the Mediator complex.
We find Med14 (drip150, trap170), Med17 (drip77, trap80) and
Med24 (drip100, trap100) can interact weakly with the RelA-
TA. We have found novel RelA-TA interacting proteins such as
the transcriptional regulators TRRAP and MYBBP1a. Other
proteins with the potential to bind to the RelA-TA are the
catalytic subunit of DNA-dependent protein kinase (DNA-
PKcs), ATR, IQGAP3, DRIM, hGCN1L1 as well as some unchar-
acterized hypothetical proteins. We also found some cell type
enriched RelA-TA binding proteins such as MYBBP1a and
DRIM (from Jurkat nuclear extracts), IQGAP3 (from THP-1), and
hGCN1L1 (from HeLa). Our results indicate that these proteins,
most of which are hypothetical or poorly characterized, could
have a role in transcription regulation in different cell types.
Experimental Section
Apparatus. A Typhoon 9400 fluorescence scanner was used
for gel analysis. A SCIEX QSTAR Pulsar i (Concord, Ontario,
Canada) hybrid quadrupole-time-of-flight instrument equipped
with a nanoelectrospray source and interfaced to an LC-
Packings Ultimate (Amsterdam, Holland) HPLC system was
used for all mass spectrometry measurements.
Procedures. Cell Culture Technique and Nuclear Extract
Preparation. Nuclear extracts were prepared from suspension
cells cultured by standard sterile techniques in RPMI (Gibco),
10% FCS, plus penicillin and streptomycin. 1-2 L of cells were
harvested when growing exponentially at a density of 0.5-1 ×
106 cells/ml and cell pellets were washed in PBS. All the
following steps were performed at 4 °C. The cell pellet was
resuspended in buffer A (10 mM HEPES-KOH pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 1 mM DTT, 0.2 mM PMSF, 1 µg/mL
pepstatin, bestatin, and leupeptin), transferred to multiple 2
mL tubes and incubated on ice for 5 min. Cells were centrifuged
at 425 × g for 1 min, resuspended in 1 mL buffer A (per 2 mL
tube) and centrifuged as above. Cells were resuspended in 3
pellet volumes (V) of buffer A* (buffer A plus 0.1% NP40), and
centrifuged at 10 621 × g for 5 min when the cell cytoplasmic
membrane was disrupted. This was between 3 and 5 min, as
determined under the microscope by the movement of trypan
blue dye into the cell. Supernatant (cytoplasmic extract) was
discarded and the nuclei containing pellet washed in 1 mL
buffer A, resuspended in 3 volumes buffer C (20 mM HEPES-
KOH pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 25% glycerol, 1
mM DTT, 0.2 mM PMSF, 1 µg/mL pepstatin, bestatin, and
leupeptin) and rolled for 25 min. This nuclear/membrane
extract was centrifuged at 20 817 × g for 10 min, and the
supernatant containing the nuclear extract was diluted (2×)
in buffer D (20 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 25%
glycerol) to adjust salt to 158 mM NaCl. The protein concentra-
tion in this nuclear extract was measured by a Bradford assay
(BIO-RAD), flash frozen in liquid nitrogen, and stored at -80
°C for up to 1 year.
GST Pull Down Experiments with Nuclear Extracts. GST-
RelA-TA (amino acids 431-551 AGE...ISS) was expressed in E.
coli using standard protocols. The cells were lysed by passage
through a French Press, and the lysate kept at -80 °C until
use. Thawed lysates were diluted with ATP buffer (50 mM Tris-
HCl pH 7.5, 2 mM ATP, 10 mM MgCl2) for 10 min at 37 °C.
Lysate/ATP buffer was diluted with binding buffer (20 mM
HEPES-KOH pH 7.9, 0.1% NP40, 10% glycerol, 250 mM KCl,
0.1 mM EDTA, 1 mM DTT, 0.2 mM PMSF, 1µg/mL pepstatin,
bestatin and leupeptin) with 20 µL/condition glutathione
sepharose beads (Pharmacia) for 2-3 h 4 °C. Bound protein
(approximately 10 µg/condition of GST-RelA-TA) was washed
in wash buffer (20 mM HEPES-KOH pH 7.9, 0.1% NP40, 10%
glycerol, 400 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.2 mM
PMSF, 1 µg/mL pepstatin, bestatin and leupeptin) 3 times for
10 min each and in nuclear extract buffer (20 mM HEPES-KOH
pH 7.9, 0.1% NP40, 10% glycerol, 158 mM NaCl, 0.1 mM EDTA,
1 mM DTT, 0.2 mM PMSF, 1 µg/mL pepstatin, bestatin and
leupeptin) 1 time. Nuclear extracts were thawed on ice,
centrifuged 20 817 × g for 10 min and the protein concentration
of the supernatant was measured. 4-10 mg of nuclear extract
was incubated with glutathione beads/GST-RelA-TA for 4-6 h
at a concentration of 0.5 mg/mL in nuclear extract buffer with
(Figures 1 and 2) or without (data not shown) 50 µg/mL
ethidium bromide. Beads/GST-RelA-TA/nuclear proteins were
washed 3 times in wash buffer and 1 time in nuclear extract
buffer. Proteins were eluted from beads by boiling in 4 µL of
10× SDS laemmli buffer, separated on a 3-8% gradient SDS-
PAGE (Novex) and visualized by SyproRuby (Molecular Probes)
according to the protocol supplied by the manufacturer. Gels
were scanned using a Typhoon 9400 scanner (blue filter 488
nm). Image analysis and densitometry were performed with
the software Quantity One (Bio-Rad), background levels were
subtracted (50 cpm).
Mass Spectrometry. Bands were excised from gels as cubes
of 2.0 mm length. Proteins were manually in-gel digested with
trypsin according to a described protocol.29 Tryptic peptides
were recovered in the supernatant of the digestion, concen-
Figure 1. RelA-TA binds a different pattern of proteins from
nuclear extracts of different cell types. GST-RelA-TA binding
proteins from nuclear extracts were isolated, separated on a
3-8% gradient SDS-PAGE and stained with SyproRuby (Molec-
ular Probes). The nuclear extracts were prepared from 3 different
cell types as indicated (THP1, Jurkat and HeLa). Bands found in
the GST-RelA-TA lane but not in the GST control lane are boxed,
numbered and named. Bands that are found differentially
between the cell types are labeled on the left side with a star.
The proteins were identified by electrospray LC-MS/MS and
properties of the proteins are given in Table 1.
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trated by evaporation to 15 µL and analyzed by liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) on a
SCIEX QSTAR Pulsar i (Concord, Ontario, Canada) hybrid
quadrupole-time-of-flight instrument equipped with a nano-
electrospray source and interfaced to an LC-Packings Ultimate
(Amsterdam, Holland) HPLC system. Separation was performed
on a PepMap (LC-Packings, Amsterdam) reversed-phase capil-
lary C18 (75 µm I.D. × 15 cm) column at a flow rate of 200
nL/min along a 52-min gradient of acetonitrile (0-40%). The
Analyst instrument controlling software was used to perform
peak detection and automatically selecting sequentially eluting
peptides for collision-induced fragmentation (CID). The two
most intense ions in the mass range 400-1200 with charge state
+2 to +4 were selected for analysis after a 1 s survey scan. CID
spectra were accumulated for 7 s for every precursor. Analyzed
ions were excluded for 180 s from further analysis (the tolerance
window for exclusion was 0.075 amu).
CID Data Generation. Collections of tandem mass spectra
for database searching were generated from the Analyst files
with the script Mascot.dll version 1.6b4 (Matrix Science,
London). The tool was set to try to determine precursor charge
state from the survey scan, after centroiding peaks at 50%
height and merging datapoints within a distance of 0.1 amu.
Charge state information thus determined was used whenever
available, while all the default charge states +2, +3, and +4
were written when charge state could not be auto determined.
CID spectra from the same precursor were added and averaged
to yield one spectrum if they fell within a mass window of 1.0
amu and a time window of 10 measurement cycles (maximum
of 2.5 min). Spectra containing less than 10 peaks before
treatment were discarded. Accepted CID spectra were pro-
cessed as follows: peaks below 0.5% of the base peak were
removed; remaining peaks were not smoothed but were
centroided at 50% height with a merge distance of 2.0 amu.
Collections of spectra were written as flat text files in Mascot
Generic Format (.mgf).
Database Search. The UNIPROT (SWISSPROT release 46.0
+TrEMBL release 28.0, both of October 11th, 2004) protein
Figure 2. Results of the RelA-TA pull down experiments are reproducible. (A) The GST-RelA-TA interacting proteins from two separate
experiments are shown. Bands were numbered as in Figure 1 and quantified. (B) Comparison of the intensity of GST-RelA-TA interacting
protein bands from either THP1 (top), Jurkat (middle) or HeLa (bottom) nuclear extracts in two distinct experiments. The relative intensity
of each band ) intensity of band/intensity of whole lane. The relative intensity of each band from experiment 1 was compared to its
counterpart in experiment 2. (C) Comparison of the intensity of GST-RelA-TA interacting proteins between the 3 different cell types (in
experiment 1).
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sequence databases was used for all searches with the MASCOT
2.0 software (www.matrixscience.com30). Searching was limited
to the H. sapiens subset, which contained 57 308 sequence
entries. MASCOT search parameters were as follows: trypsin
cleavage specificity with maximum one missed cleavage;
carbamidomethyl cysteine as fixed modification, methionine
single oxidation as variable modification, monoisotopic masses
only were used, with peptide Mass Tolerance of (0.8 Da and
fragment mass tolerance of (0.66 Da. The instrument type
considered was ESI-QUAD-TOF. The standard (non “MUD-
PIT”) MASCOT scoring scheme was used throughout the study.
MASCOT was set up to only report peptide matches with a
score above 14.
The value of 14 was chosen after manual evaluation of more
than a thousand MS/MS spectra acquired under very similar
conditions (same instrument, database, species, data handling)
in the context of various research projects. We found this value
to be a reasonable compromise between stringency and
sensitivity of identification. Values below 10 for the threshold
resulted in large numbers of false positive identifications. With
the parameters used, the threshold for statistical significance
(p < 0.05) corresponded to a total (protein) MASCOT score of
33.
Validation of Identifications. All protein identifications with
a total MASCOT score below 80 were manually validated.
Validation included examination of the peptide rms mass error
(<120 ppm) and of individual peptide matches. Peptide
matches with score between 14 and 40 were manually verified
and validated only if at least an ion series of 4 consecutive y
ions were matched, in addition to ions belonging to other
series. Generally, only proteins matched by at least two peptides
were accepted. Exceptions, i.e., single-peptide matches are
labeled in Table 2 and are listed in the Supporting Information
(Tables 3 and 4).
GST Pull Down with in Vitro Transcribed-Translated
Mediator Subunits. DNA plasmids containing cDNA of the
Mediator subunits were obtained from Image Consortium
(cdk8, Med17/crsp6, Med7/crsp9, Med15/arc105) or kindly
provided by Len Freedman and Christophe Rachez (Med24/
drip100, Med14/drip150, Med1/drip205/trap220, Med23/
drip130). Plasmids are based on pcDNA3.1 (Invitrogen) for all
subunits except Med24 which is in pBluescriptII-sk+ (Strat-
agene). Mediator subunits were tagged with myc (cdk8, Med17/
crsp6, Med7/crsp9, Med15/arc104, Med23/drip130, Med14/
drip150) or flag (Med24/drip100) or untagged (Med1/trap220).
35S-methionine labeled proteins were synthesized by use of TNT
Quick coupled Transcription/Translation Systems kit following
the manufactures protocol (Promega). Immobilized GST-RelA-
TA or GST control were incubated with 35S-methionine labeled
Mediator subunits for 2 h at 4 °C with gentle rolling in buffer
20 mM HEPES-KOH pH 7.9, 10 mM MgCl2, 0.1% NP40, 136
mM NaCl, 1.25% glycerol, 1 mM DTT, 0.2 mM PMSF, 1 µg/mL
pepstatin, bestatin and leupeptin. Beads were then washed 3
times for 10 min with 0.8 mL buffer (20 mM HEPES-KOH pH
7.9, 10 mM MgCl2, 0.1% NP40, 120 mM NaCl, 1 mM DTT, 0.2
mM PMSF, 1 µg/mL pepstatin, bestatin and leupeptin) and
Table 1. Proteins Identified from Gel-based Separation of RelA-TA Affinity Experiment Using Nuclear Extracts from Three Cell
Types (see Figure 1)a
band acc. no.b
MW
(kDa) name
THP1
scorec
JURKAT
scorec
HeLa
scorec description new?d comment gel comparison
1 no id
2 P78527 473 DNA-PKcs 175 137 1126 DNA-dependent
protein kinase
catalytic subunit
Y PI3 protein kinase
superfamily. DNA
damage response
less in jurkat lane
3+4 Q92793 268 CBP 137 675 245 CREB-binding
protein
N Histone acetyl
transferase
Transcription
coactivator
ubiquitous
Q09472 265 p300 229 594 212 E1A-associated
protein p300
N Histone acetyl
transferase.
Transcription
coactivator
ubiquitous
O75691 318 DRIM 747 DRIM protein Y “Down regulated
in metastasis”
unknown function
only in jurkat lane
5 Q92616 293 hGCN1L1 403 KIAA0219 protein
Human GCN1
homolog
Y HEAT repeats only in HeLa lane
6 no id
7 Q09472 265 p300 111 E1A-associated
protein p300
N degradation
product of p300
more in HeLa
8 Q86VI3 185 IQGAP3 69 67e Ras GTPase-
activating-like
protein IQGAP3
Y unknown function,
contains GAP and
IQ domain
in THP1, maybe HeLa,
not Jurkat
P46940 189 IQGAP1 67e Ras GTPase-
activating-like
protein IQGAP1
Y unknown function,
contains GAP and
IQ domain
only in HeLa
9a Q9P0V5 148 MYBBP1A 187 773 351 MYB-binding
protein 1A
Y Binds and regulates
transcription factors
more in jurkat lane
9b P53621 139 COPA 305 736 Coatomer alpha
subunit
? Probably nonspecific
contaminant
ubiquitous
a See Table 3 in Supporting Information for raw data. b All database accession number are according to UNIPROT (SWISSPROT+TrEMBL). c MASCOT protein
score. d Novel interacting proteins are italicized and indicated “Y” in the New? column (known interactors are indicated “N”). e Only peptides in common to
the sequences of IQGAP1, IQGAP3 were matched, therefore it is impossible to discriminate between the two proteins.
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proteins eluted from beads with SDS-laemmli buffer. Proteins
were analyzed by 10% SDS-PAGE, gels were fixed for 30 min
(50% methanol, 10% acetic acid), washed in water for 10 min
3 times, incubated for 30 min in Amplify (Amersham), dried
and exposed to autoradiography film.
Results
Note: all database accession numbers are referred to
Uniprot (AC field, www.expasy.org).
Different Pattern of RelA-TA Interacting Proteins is Seen
from THP1, Jurkat and HeLa Nuclear Extracts. To identify new
cell type specific cofactors of RelA, we tried to find cofactors
from different human cell types that have the ability to interact
with the transcription activation (TA) domain of RelA/p65.
Since the TA domain of RelA is the domain responsible for
transcription activation and binds to known co-activators of
transcription, this domain was used as it is most likely to
interact with other unknown transcription cofactors. We per-
formed GST pull down experiments using GST-RelA-TA (amino
acids 431-551). Immobilized GST-RelA-TA or an equal amount
of GST control was incubated with up to 10 mg of nuclear
extracts from 3 different immortalised cell types (epithelial -
HeLa S3, T cells - Jurkat, and monocytes - THP1) responsive
to NF-κB activating signals. Bound proteins were analyzed by
1D gradient SDS-PAGE, stained with SyproRuby and visualized
with a Typhoon scanner under a blue light (488 nm) laser
source (Figure 1). The advantages of visualizing proteins with
this fluorescent dye is that it binds noncovalently to proteins
(enabling efficient analysis by mass spectrometry) and binds
quantitatively to proteins (allowing relative quantification of
the proteins bound to GST-RelA-TA). Since the molecular
weight region of the gel below 60 kDa is dominated by protein
bands related to GST-RelA-TA, we choose to concentrate on
the high molecular weight region. We therefore used a 3-8%
gradient gel for protein separation. The pattern of RelA-TA
binding proteins from the nuclear extracts of the three different
cell types is similar with some differences, which could be due
to the presence of cell type specific or enriched RelA-TA binding
proteins (Figure 1 and Figure 2C). Results from two separate
experiments were compared and the general pattern of the
bands was similar (Figure 2A). However, there were some
differences of the relative intensity of each band between
experiment 1 and 2 (Figure 2B).
Identification of Novel RelA-TA Binding Proteins. Protein
bands seen in the GST-RelA-TA bound lane and not in the GST
control lane are labeled in Figure 1. These proteins are
considered to be interaction partners of RelA-TA. Band 9 is a
doublet, where the lower band (9b) appears to be present in
the negative control while the higher band appears to be a
specific RelA-TA interactor. We systematically analyzed all
proteins in individual bands by in-gel tryptic digestion and
liquid chromatography-tandem mass spectrometry (LC-MS/
Table 2. Proteins Identified by a Shotgun Approach in a RelA-TA Affinity Experiment using Nuclear Extracts from Three Cell
Typesa
acc. no
MW
(KDa) protein
THP1
scoreb
Jurkat
scoreb
HeLa
scoreb function new?c
P78527 473 DNA-PKcs 95 49 955 PI3K superfamily involved in DNA damage response Y
Q9UIG2 313 Q9UIG2 66 Bromodomain PHD finger transcription factor Y
Q92616 295 KIAA0219 914 hGCN1L1, hypothetical protein with HEAT repeats Y
Q92793 268 CBP 236 261 587 histone acetyl transferase transcriptional coactivator N
Q09472 266 p300 230 354 398 histone acetyl transferase transcriptional coactivator N
Q8N3C0 252 HEL1 37 ASC-1 complex subunit p200 N
Q9UHV6 250 MED12 56 Mediator subunit transcriptional cofactor (trap230, drip/arc240) N
P46940 189 IQGAP1 615 GTPase activating like protein IQGAP1 Y
Q86VI3 185 IQGAP3 301 44d GTPase activating like protein IQGAP3 Y
Q15648 169 MED1 48d 48d Mediator subunit transcriptional cofactor (trap220, drip/arc205) N
O60244 162 MED14 68d Mediator subunit transcription cofactor (trap170, drip/arc/
crsp150)
N
Q9H0J2 158 MED23 95 44d Mediator subunit transcription cofactor (trap150b, drip/arc/
crsp130)
N
Q9P0V5 149 MYBBP1a 200 2124 726 Binds and regulates some transcription factors Y
P53621e 140 Coatomer alpha 773 349 260 ER-Golgi protein transport naf
Q9Y4C7 135 KIAA0690 67 HEAT repeats Y
Q9UPN4 130 KIAA1118 49d IQ domain Y
Q6ZUM6 126 FLJ43536 46 44 hypothetical protein Y
O75448 111 MED24 217 82 104 Mediator subunit transcriptional cofactor (trap/drip/arc/scrp100) N
Q75T13 106 PGAP1 33d GPI inositol-deacylase PGAP1 naf
P35606e 103 Coatomer beta 847 422 515 ER-Golgi protein transport naf
Q6PJT2 94 MED16 88 46d Mediator subunit transcriptional cofactor (trap95,drip92) N
Q16891e 84 Mitofilin 658 628 82 Mitochondrial inner membrane protein naf
Q6P143 78 MED25 48d Mediator subunit transcriptional cofactor (arc92) N
Q6IC31 75 MED15 41 Mediator subunit transcriptional cofactor (arc105) N
P28288e 75 ABCD3 226 653 Probable peroxisomal transporter naf
Q9NVC6 73 MED17 105 76 Mediator subunit transcriptional cofactor (trap80, drip/arc/
crsp77)
N
Q6P1MOe 72 Q6P1MO 61 Fatty acid transporter naf
Q9NVI7e 66 FLJ10709 603 617 297 Hypothetical protein (ATAD3A protein) naf
Q96T67e 65 TOB3 467 Unknown ATPase naf
Q9UNF1 65 MGD2 89 melanoma associated antigen D2 Y
a Keratins and well-known chaperones were removed from the list (see Supporting Information Table 4 for raw data). b MASCOT protein score. c Novel
interacting proteins are indicated “Y” in the New? column (known interactors are indicated “N”). d identification based on one single peptide manually validated.
e Entries in italic are likely non-specifically binding proteins (determined either by presence in the negative control or by an established nonnuclear intracellular
localization). f na: not applicable (protein is either not specific or non nuclear).
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MS). Results are summarized in Table 1, which indicates RelA-
TA binding proteins with a brief description of their known or
putative function. The new RelA-TA binding proteins found
with this approach are DNA-PKcs, DRIM, KIAA0219 (hGCN1L1),
IQGAP3, and MYBBP1a. In a separate affinity experiment
carried out with nuclear extracts of HeLa cells in the absence
of ethidium bromide (data not shown), we were able to identify
three additional proteins, TRRAP (Q9Y631, score 308), the
protein kinase ATR (Q13535, score 125), and a hypothetical
protein containing a YEATs domain, a typical feature of proteins
with transcription stimulating activity (KIAA1197, score 108).
To confirm the findings and attempt to find all possible
potential interaction partners of RelA-TA, we further analyzed
the samples with a shotgun approach. We separated the protein
mixtures eluted from glutathione sepharose beads on a 7%, 1.7
cm minigel, cut each lane into 5 segments corresponding to
varying molecular weight ranges from 60 to ∼400 kDa and
analyzed each segment containing a group of proteins by
digestion and LC-MS/MS (Table 2). The resulting collections
of CID spectra were pooled for each sample and used for a
single database search, yielding a list of identified proteins per
cell line. Table 2 presents a comparative view of this shotgun
experiment. All but one (DRIM) of the proteins listed in Table
1 were also identified by this technique, thus confirming the
results of the gel approach. Disregarding keratins and well-
known chaperones, 23 additional proteins were found (com-
pared with the band-by-band approach), among which 9
components of the Mediator complex and several hypothetical
proteins. These results emphasize the higher performance of
such a technique for the purpose of protein identification.
Some of the ubiquitous proteins found were probably non-
specific contaminants, such as mitofilin (a mitochondrial
membrane protein) and Coatomer binding proteins A and B
(COPA was seen in the GST negative controls in SDS-PAGE at
140 kDa). Several other identifications were based on relatively
low scores and were carefully validated by manual inspection
of MS/MS data.
Identification of Cell Type Enriched RelA-TA Binding
Proteins. We identified proteins present in the GST-RelA-TA
bound lane at a much higher level in certain cell types. These
proteins are labeled with stars (Figure 1) and are considered
to be cell type enriched interaction partners of RelA-TA. Due
to comigration of several proteins in some bands and high
background levels, it was difficult to obtain accurate protein
quantification by densitometry (Figure 2C). Nevertheless, we
found that MYBBP1a (band 9a), although found in all cell types,
is a Jurkat enriched binding partner of RelA-TA, while hGCN1L1
(band 5) is a highly HeLa enriched binding partner of RelA-
TA. IQGAP3 and/or IQGAP1 (band 8) were identified as RelA-
TA binding partners from THP1 and HeLa but not Jurkat
nuclear extract.
The shotgun identification round (results in Table 2) con-
firmed and complemented the gelband-based results. For low
scoring proteins, it is impossible to draw any conclusion on
the relative abundance of specific proteins binding to RelA-TA
from the nuclear extracts of the three cell types examined,
because of the limited reproducibility of the sampling by LC-
MS/MS for low-intensity signals and one pass analysis.31 It has
been previously shown31 that the sampling of complex mixture
of peptides is not complete and that, depending on complexity,
repeated analyses are needed to efficiently capture and identify
most peptides in a mixture. On the other hand, Liu et al.31 also
showed that sampling levels (i.e., number of matched peptides)
can be taken as a good measure of protein abundance over at
least 2 orders of magnitude. For high scoring proteins the
results correlated well with gel-based quantifications. KIAA0219/
hGCN1L1 was found in this approach to bind to RelA-TA
specifically from the nuclear extracts of HeLa cells. IQGAP1 and
its close homologue IQGAP3 were not detected to bind to RelA-
TA from the nuclear extracts of Jurkat cells but were found to
bind from the nuclear extracts of HeLa and THP1 cells,
respectively. MYBBP1a was found to be a RelA-TA binding
protein from the nuclear extracts of all three cell types, however
with a much higher score from Jurkat than HeLa or THP1
nuclear extracts, again supporting the data from the first gel-
based approach. Although two members of the Mediator
complex (Med12 (trap230, drip240) and Med14 (trap170,
drip150)) were found exclusively in RelA-TA binding proteins
from THP1 monocyte nuclear extract samples, they had a low
score so we cannot exclude the possibility that they were
present at low levels in the other samples. In a separate
experiment with HeLa cells (not shown), we found band 5 to
contain, in addition to hGCN1L1, the mediator subunit Med12
(trap230). This indicates that the weak band 5 in THP1 and
Jurkat lanes could indeed correspond to Med12 (which was
detected in THP1 by the shotgun approach) however in
quantities too low for detection after in-gel digestion.
Surprisingly, DRIM, which according to the gel experiment
is a Jurkat specific RelA-TA interacting protein, was not
identified in this analysis. It is most likely that DRIM was
present in the shotgun approach, but was undetected. This
could be due to the mini-gel system (used for the shotgun
approach) not being ideal for the detection of very large
proteins (>300 kDa). Consistent with this, in two (Jurkat, THP1)
of the three samples the scores for the very large protein DNA-
PKcs were lower in the shotgun approach than what was
usually seen for the same protein in the band-by-band ap-
proach using a gradient gel. This could be due to the short
migration time of the minigel, possibly leading to a proportion
of some high MW proteins not entering into the gel. Alterna-
tively, a difference in the efficiency of the digestion procedure
between the 2 gel types could explain a lower score for the
very high molecular weight protein fractions in the shotgun
approach. However, since DRIM has been identified twice in
previous gel-based experiments, its presence seems to be
reproducible.
MED14 (drip150/trap170), MED17 (drip77/trap80), and
Med24 (drip100/trap100) Specifically Interact Weakly with
RelA-TA. It has been shown before that RelA-TA interacts with
the Mediator complex,32 and this is confirmed by our results
above (Table 2). We found 9 Mediator subunits binding to RelA-
TA, however all peptides were found with low scores. We tried
to confirm the interaction by analyzing which of the Mediator
subunit(s) could interact with RelA-TA specifically. We tran-
scribed and translated in vitro in the presence of 35S methionine
all available Mediator subunits (8 in total including 6/9 subunits
found here) and incubated each separately with GST-RelA-TA
or GST control. We found a very weak interaction with Med14
(drip150/trap170), MED17 (drip77/trap80) and Med24 (drip100/
trap100) (Figure 3).
Discussion
Each cell type is responsive to a specific pattern of NF-κB
activating stimuli to give a cell type specific pattern of NF-κB
dependent gene expression. This specificity can occur through
several mechanisms as different cell types could have specific
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(a) surface receptors and signaling pathways (b) expression
levels and post-translational modification patterns of each NF-
κB dimer (e.g., RelA/p50, RelB/p52, c-rel/c-rel etc.) that have
different promoter/enhancer binding preferences (c) modifica-
tion patterns within the chromatin resulting in different regions
of the genome being accessible for transcriptional control, and
(d) active cofactors that are able to bind to NF-κB to regulate
subsets of genes. This could be due to differences in the
expression levels or activity of cofactors in the different cell
types or differences in the NF-κB binding potential of a cofactor
from different cell types. To investigate this, we identified and
compared the pattern of proteins that could bind to the GST-
RelA-transcription activation domain (TA) from the nuclear
extracts of 3 different immortalised cell types (epithelial-
HeLaS3, T cell- Jurkat, and monocyte-THP1). It was considered
useful to use high amounts of the TA domain as no known
RelA-TA interacting transcriptional cofactors were found in an
extensive study that identified RelA interacting proteins by co-
immunoprecipitation of full length TAP tagged RelA from 293
HEK cells.33 Nuclear extracts were used as it is thought that
most cofactors of transcription are found predominantly in the
nucleus. Interacting proteins were identified by electrospray
mass spectrometry.
New RelA-TA Interacting Proteins. Many proteins were
found in this study that have previously been reported to
interact with RelA-TA. These are p300/CBP7 and subunits of
the Mediator complex.32 Also found here were many new
interacting proteins of RelA-TA, which are described in detail
below. These proteins were not found in the co-immuno-
precipitation study mentioned above (although a member of
the IQGAP family was found to bind to RelA), where mainly
cytoplasmic molecular partners were found. The RelA-TA that
we use in these experiments was expressed and purified from
bacteria and therefore does not contain the same pattern of
post-translational modifications that a cellular transcriptionally
active RelA-TA is expected to contain. Therefore, other RelA
cofactors that interact with RelA-TA in a way dependent on
post-translational modifications may not have been detected
in this study. It is also important to consider that the approach
used here cannot distinguish between proteins that directly
interact with RelA-TA and those that are pulled down in a
complex with a RelA-TA binding partner (second-order interac-
tions).
1. DNA-PKcs, ATR, and TRRAP. DNA-PKcs (DNA-dependent
protein kinase catalytic subunit), ATR (ataxia telangiectasia
mutated and Rad3 -related protein) and TRRAP (transforma-
tion-transactivation domain-associated protein) are proteins
of the phosphatidylinositol kinase (PI3K) superfamily, which
contain a PI-3 like kinase domain. DNA-PKcs and ATR, together
with another member of this family, ATM (ataxia telangiectasia
mutated), are serine/threonine kinases recognizing the con-
sensus motif Ser/Thr-Gln-Glu.34 They are activated in the
nucleus early during cellular genotoxic stress, and phos-
phorylate many proteins involved in cell cycle checkpoints,
DNA repair and apoptosis. One of their targets is the transcrip-
tion factor p53, which is phosphorylated and activated by ATM,
and possibly also by ATR and DNA-PKcs in response to
genotoxic stress such as gamma irradiation, UV, heat shock,
and nitric oxide.35-38 NF-κB may be involved in the response
to these signals as NF-κB binding sites have been found in
genes regulated by many of these genotoxic signals. DNA-PKcs
and ATM have been shown to regulate NF-κB dependent
transcription by the direct or indirect phosphorylation of IκBR
in response to DNA damage which resulted in IκBR degradation
and activation of NF-κB DNA binding.39,40 Here, we show that
the RelA-TA can bind to the kinases DNA-PKcs and ATR. This
indicates that the regulation of NF-κB dependent transcription
by genotoxic stress could happen directly through the RelA
subunit as well as via phosphorylation of IκBR. DNA-PKcs and
ATR may also have general roles in transcription. Cell extracts
lacking DNA-PKcs were deficient in multiple rounds of tran-
scription as assayed by in vitro transcription on a supercoiled
DNA template.41 ATR is part of the NRD (nucleosome remodel-
ing and deacetylating) complex which contains HDAC2.42
TRRAP was found to be a member of four different histone
acetyltransferase complexes, STAGA (contains GCN5-L),43 PCAF
(contains P/CAF),44 TFTC (contains GCN5-L),45,46 and NuA4
(contains tip60).47 This indicates that TRRAP, which has no
known kinase activity, has a role in DNA metabolism processes
that require remodeling of chromatin. A microarray gene
expression comparison between TRRAP conditional knockout
mouse embryonic fibroblast and TRRAP containing cells
indicated that TRRAP is responsible for the regulation (usually
Figure 3. Mediator subunits (Med14, Med17, Med24) interact
weakly with RelA-TA. 35S methionine labeled Mediator subunits
(cdk8, Med17/crsp6, Med7/crsp9, Med15/arc105, Med24/drip100,
Med14/drip150, Med1/drip205, Med23/drip130) were synthesized
from rabbit reticular lysate using TNT Quick (Promega). Mediator
subunits were incubated with immobilized GST-RelA-TA or GST
control, bound proteins were washed then analyzed by SDS-
PAGE and autoradiography. Inputs are 4% of total protein used
in each pull down. GST and GST-RelA-TA inputs are shown
(below, right).
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activation) of specific sets of genes.48 TRRAP has been shown
to bind to the transactivation domains of c-myc and E2F and
the TRRAP/c-myc interaction is necessary for transcription of
a subset of proliferation genes such as cyclinD2 and TERT, but
not for other basally expressed genes.49 Other transcription
factors such as p53 and the oestrogen receptor require HAT
complexes containing TRRAP to transcribe specific genes.50,51
Since RelA is known to be acetylated by P/CAF,52 and can
interact with TRRAP (shown here) it may be that recruitment
of P/CAF to RelA could be via the TRRAP component of the
PCAF complex.
2. MYBBP1a. MYBBP1a (p160) and a related protein (p67)
were first identified by their ability to bind the leucine zipper
region within the negative regulating domain of the c-Myb
proto-oncogenic transcription factor.53 p67 was found to be an
amino terminal fragment of MYBBP1a formed by proteolytic
cleavage only in some cell types and although both p67 and
MYBBP1a could bind c-myb, only full length MYBBP1a could
bind the Jun transcription factor.54 Here we find that MYBBP1a
can also bind to the RelA-TA but since we were focusing on
RelA-TA binding proteins that were above 100 kDa we did not
test whether p67 could also bind. Expression of a short version
of MYBBP1a (approximating p67) could repress c-myb depend-
ent transcription in a reporter assay, whereas MYBBP1a had
little affect.54 Interestingly, MYBBP1a was found to be predomi-
nantly nucleolar.54 It can also interact with the acidic activation
domain of AhR transcription factor and activates transcription
of a AhR responsive reporter gene.55 MYBBP1a was found to
interact with the negative regulatory domain of PGC-1R co-
activator of transcription, and inhibit its activity.56 The mech-
anism of transcriptional regulation is not known. The interac-
tion between RelA-TA and MYBBP1a indicates the possibility
that MYBBP1a might affect NF-κB dependent gene expression.
3. IQGAP1 and 3. IQGAP1 protein is a GTPase activating
protein (GAP) with IQ (calcium independent calmodulin bind-
ing) domains. It is thought to function in the cytoplasm or
plasma membrane, although a nuclear localization has not
been disproved. IQGAP1 is involved in the negative regulation
of cell-cell adhesion through Rac1 and Cdc42 GTPases.57 It is
up regulated in some cancer cell lines and promotes cellular
invasion.58 We identified IQGAP1 as a possible interacting
partner of RelA-TA, although since it is thought that the
proteins localize to different cellular compartments, this in-
teraction seems unlikely to occur in vivo. However, it has also
been found that IQGAP1 can activate transcription by the
plasma membrane/cytoplasm/nuclear shuttling transcription
factor beta-catenin,59 suggesting that interaction with other
transcription factors could be possible. IQGAP3 is 58% identical
(75% similarity) to IQGAP1 and up regulated in gastric cancers.
Nothing is known about its cellular localization or its function.
Previously, IQGAP2 was found to bind to full length RelA in a
large study of the NF-κB pathway, indicating that members of
the IQGAP family could be NF-κB interactors.33
4. DRIM. DRIM (down regulated in metastasis) was found
by comparison of nonmetastatic breast cells with metastatic
cells.60 The function or subcellular localization of DRIM is not
known, although it contains HEAT repeats that occur in many
intracellular transport proteins. Interestingly, ATR and
KIAA0219 (hGCN1L1) which we also found to interact with
RelA-TA, contain HEAT repeats.
5. KIAA0219 - Human GCN1L1. KIAA0219 - Human
GCN1L1 (GCN1 general control of amino acid synthesis 1-like
1) is a hypothetical protein.61 It contains HEAT repeats and 3
ARM (Armadillo/beta-catenin-like) domains. By sequence align-
ment, this protein is believed to be the human counterpart of
the yeast GCN1 translational regulator. However, yeast GCN1
contains 30 HEAT repeats, while the human KIAA0219 only 3.
No other information on the localization or function of this
protein is available.
Cell Type Enriched RelA-TA Interacting Proteins. In this
study, we compare RelA-TA binding proteins from 3 different
cell types (Figure 1, Tables 1 and 2). Since all cell lines used
were transformed cell lines, we cannot distinguish between
RelA-TA binding proteins enriched due to the cell type or due
to the different transformation process that have occurred
within each cell type. However, we consider both groups of
proteins interesting for future studies. It is possible that the
proteins enriched in the various cell types, listed below, are
involved in the differential transcription regulation by RelA/
p65 seen in these different cell types. The differences in the
recovery of these proteins bound to RelA-TA may be due to
differences in overall expression levels or due to specific
targeting to RelA-TA in the different cell types. To distinguish
these possibilities, it would be necessary to quantify the
expression levels of these proteins in the different cell types,
however this could not be determined due to the absence of
commercially available antibodies. Measurement of mRNA
levels could give an indication of the relative expression levels
in the three cell types studied.
1. IQGAP1/3. The combined evidence from both the band-
by-band and the shotgun approach indicate that IQGAP3 is
uniquely recovered in THP-1 samples, while IQGAP1 is pre-
dominant in HeLa. None of these proteins was detected in
samples from Jurkat cells. Nothing is known about the function,
expression pattern, or cellular localisation of IQGAP3.
2. MYBBP1a. More MYBBP1a was found to interact with
RelA-TA from Jurkat nuclear extract than from HeLa or THP1
nuclear extract. MYBBP1a transcripts were expressed in all mice
tissues and human cell lines tested, although the abundance
of the transcript varied.54,62 This could indicate that MYBBP1a
is a Jurkat enriched interactor of RelA-TA. Our future work will
be the investigation of MYBBP1a as cell type specific RelA
cofactor.
3. KIAA0219 (hGCN1L1). We found more of the hypothetical
protein KIAA0219 bound to RelA-TA from HeLa nuclear extract
than from Jurkat or THP1 extract. We therefore provisionally
name this protein RELAH (standing for Rel A binding protein
from HeLa).
Confirmation of Mediator Interaction with RelA-TA. In the
shotgun approach (Table 2) we find totally 9 subunits of the
Mediator that bind to RelA-TA. Only high molecular weight
proteins (>60 kDa) were analyzed so we have no information
for the lower molecular weight Mediator proteins. These data
agree with the previous report of Mediator interacting with
RelA-TA.32 The Mediator complex is composed of 4 domains
(head, middle, tail, and cdk8 domain) and is thought to regulate
transcription (positively and negatively) through interaction of
polII and DNA binding transcription factors (reviewed in ref
63). We found subunits from all domains of the Mediator
complex, increasing the likelihood that the whole Mediator
complex binds to RelA-TA in the conditions tested. Analysis of
the interaction of individual in vitro translated Mediator
subunits with RelA-TA indicates Med14 (trap170/drip150),
Med17 (trap80/drip77), and Med24 (trap100/drip100) have the
ability to interact weakly with RelA-TA. We tested the 8
Mediator subunits available (cdk8, Med17/crsp6, Med7/crsp9,
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Med15/arc105, Med24/drip100, Med14/drip150, Med1/drip205,
Med23/drip130) leaving the possibility remaining that other
subunits also interact with the RelA-TA. The weakness of the
interactions observed could be due to the need for other
domains of RelA or for several Mediator subunits to be present
in order to form a high-affinity binding complex.
Methodology, Performance and Confidence of the Identi-
fication Results. Despite the use of a relatively large amount
of bait protein and cell extract, the quantity of proteins purified
for analysis was medium to very low. This could be due to the
fact that transcription activators and cofactors are often
expressed at low levels in most cells and our washes were very
stringent. The gel separation analysis offers the possibility to
compare band patterns among samples from different cell lines
as well as relative to a negative control, thus verifying the
specificity of the bands analyzed. However, this approach is
not comprehensive, as bands close to or just below the
detection sensitivity are neglected. In addition, we found in-
gel digestion with acrylamide bands below 6% percentage to
yield poorly reproducible results, thus making comparisons of
protein identifications among bands difficult. The shotgun
approach we have adopted subsequently is faster and results
in a more complete mapping of the global composition of the
samples. We also found this method to be more sensitive since
the limited migration increases the protein concentration in
the gel resulting in better digestion yields. Ideally, shotgun
experiments should be performed without gel separation (in
liquid phase), to ensure reproducibility of the digestion condi-
tions and comparability between experiments. However, in our
situation the partial separation offered by the gel step allowed
the elimination of a high level of background due to the GST-
RelA-TA fusion protein (approximately 10 µg/sample). In
addition the SDS extraction is very efficient to detach all
proteins recovered in the affinity step. However, no information
is obtained about the relative quantities of proteins in different
samples for low-scoring identifications, especially since the
shotgun experiment was performed only once due to the
limited amount of sample available. To improve the shotgun
technique, a strategy allowing accurate quantification of pro-
teins present in low amounts should be developed and used,
such as the multiplexed labeling proposed recently.64 However,
this was not available during this study.
Contaminant and Non-physiological Interacting Proteins.
Several proteins were detected in the shotgun experiment, for
which we have no information on possible specificity of their
interaction with RelA-TA. Some proteins with a well-character-
ized cytoplasmic or nonnuclear location (e.g., mitochondrial)
can be ruled out as in-vivo binding partners of RelA. These
include the coatomer binding proteins and mitochondrial or
peroxisomal proteins (Q16891, P28288, and Q9NVI7). Well-
known heat shock proteins, chaperones, and keratins were
found and are not listed in Table 2 since they are ubiquitous
in pull-down experiments (see Supporting Information, Table
4). For other poorly characterized molecules such as the
melanoma-associated antigen Q9UNF1 found in HeLa cells,
precise quantitative data relative to its presence in the negative
control are necessary to discern about its specificity of interac-
tion with the bait protein (RelA-TA). The possibility that DNA-
PKcs, ATR, and TRRAP were contaminating proteins in the pull
down experiments cannot be disregarded. Since DNA-PKcs and
ATR can bind directly to DNA, if small amounts of DNA were
present in the nuclear extract and other RelA-TA interacting
proteins could bind to the DNA, this could lead to contamina-
tion of the RelA-TA bound sample with DNA binding proteins.
However, this is unlikely as washes were extensive and stringent
and no other general DNA binding proteins were found. Also,
ethidium bromide (preventing most DNA-protein interactions)
was used in most pull downs including those where DNA-PKcs
was detected.
Conclusions
The technique used here was successful in identifying new,
and also cell type enriched RelA-TA interacting proteins.
Further investigations of the cellular localization pattern, cell
type expression pattern, and effect on RelA dependent tran-
scription of these proteins are necessary to establish their role
as cofactors of RelA-dependent transcription.
Abbreviations: ATR, Ataxia telangiectasia mutated and rad3
related protein; CBP, Creb binding protein; CID, Collision
induced dissociation; DNA-PKcs, DNA-dependent protein ki-
nase catalytic subunit; HATs, Histone acetyl transferases; LC-
MS/MS, Liquid chromatography-tandem mass spectrometry;
MYBBP1a, Myb binding protein 1a; NF-κB, Nuclear factor
kappa B; TA, Transcription activation domain; TRRAP, trans-
formation-transactivation domain-associated protein.
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 Synopsis 
NF-?B is an inducible transcription factor activated in many different cell types by 
inflammatory and stress signals. The transcription of a wide variety of NF-?B genes 
is regulated by the coordinated action of transcription co-activator and co-repressors. 
Previously we identified Myb binding protein 1a (MYBBP1a) as an interaction 
partner of the transcription activation domain of RelA/p65. MYBBP1a has been 
shown by others to regulate various transcription factors, through largely unknown 
mechanisms. Here we present evidence that MYBBP1a is a novel co-repressor of NF-
?B. Expression of MYBBP1a in cells repressed NF-?B dependent reporter 
expression. In vitro, MYBBP1a inhibited transcription from chromatinised templates 
at a step before pre-initiation complex formation. MYBBP1a was found to compete 
with the histone acetyl transferase co-activator, p300, for interaction with the 
transcription activation domain of RelA/p65. Expression levels of MYBBP1a are 
dependent on the cell type, and are particularly high in Jurkat T cells. These results 
indicate that MYBBP1a is a novel NF-?B co-repressor of transcription that competes 
with p300 and may function to regulate cell type specific genes. 
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NF-kappa B, RelA, p65, transcription, co-repressor, MYBBP1a   
 
Abbreviations 
HDAC, histone de-acetylase; I?B, inhibitor of NF-?B; LTR, long terminal repeat; 
MN, micrococcal nuclease; MYBBP1a, Myb binding protein 1a; PMA, phorbal 12-
myristate 13-acetate TAD, transcription activation domain.            
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 Introduction 
RelA (also called p65) is a member of the NF-?B family of inducible 
transcription factors (reviewed in [1]). Other members of this family are c-Rel, RelB, 
p105/p50 and p100/p52. NF-?B regulates the expression of a wide variety of human 
genes including cell cycle regulators, apoptosis factors, proliferation inducers and 
immuno-regulatory proteins (reviewed in [2]). There are also NF-?B response 
elements in the regulatory regions of viruses, such as in the Long Terminal Repeat 
(LTR) of HIV-1 [3]. NF-?B activity is aberrantly regulated in many diseases, 
including cancer (reviewed in [4] and [5]). For these reasons many aspects of the 
regulation of transcription activation by NF-?B are well studied.   
RelA/p65 can be regulated in both positive and negative ways. The “inhibitor 
of NF-?B” (I?B) family of proteins are major inhibitors of NF-?B transactivation of 
target genes. In most cells, the majority of NF-?B is found in the cytoplasm in a 
complex with I?B. Once the appropriate cell is stimulated by a specific signal, 
phosphorylation and activation of the I?B kinase complex is triggered, leading to I?B 
phosphorylation, ubiquitinylation, and finally degradation. This results in the 
accumulation of RelA/p65 in the nucleus (for recent reviews see [6] and [7]). 
RelA/p65 can also be repressed in the nucleus, by association with I?B proteins [8-
10] or transcriptional co-repressor histone deacetylase complexes [11-13]. 
RelA/p65 contains a C-terminal acidic transcription activation domain (TAD) 
consisting of TA1 and TA2 sub-domains [14]. The TAD contains conserved amino 
acid motif repeats and has been described as a random coil by NMR studies [15]. 
However, TA1 peptides in a hydrophobic solution were measured by circular 
dichroism to have alpha helical properties [15], indicating an induced structure may 
be formed when the TAD is part of a higher order complex. The TAD of RelA/p65 
can be modelled as an alpha helix, and this model has features highly conserved 
between species. Five positions in the modelled helix consist of hydrophobic amino 
acids and these are interspersed mainly with acidic residues [16]. On the opposite side 
of the modelled helix is a region of conserved serines. At least three of these serines 
(S529, S536 and S468) are inducibly phosphorylated, forming negatively charged 
patches on this surface, and leading to enhancement of the transcription potential of 
RelA/p65 ([17, 18] and reviewed in [19]). Many groups have identified different 
proteins that bind to the TAD of RelA/p65 and may form a variety of higher order 
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 protein complexes with different influences on the transcriptional potential of 
RelA/p65 [20-26].  
Previously we identified MYBBBP1a as an interacting partner of the TAD of 
RelA/p65 [20]. Higher levels of MYBBP1a were found to bind to the TAD from 
Jurkat (T cell) nuclear extracts than from THP1 (monocyte) or HeLa (epithelial) 
nuclear extracts. MYBBP1a was first identified as a protein that could interact with 
the negative regulatory region of the transcription factor Myb [27]. It is a 150 kDa 
protein encoded by a single 4.5 kbp mRNA expressed to varying levels in all cell 
lines and mouse tissue tested. In some cell types an N terminal fragment of 
MYBBP1a (p67) was also found [27]. MYBBP1a was shown to be present mainly in 
the nucleolus in NIH 3T3 fibroblasts and 293T cells [27, 28]. Its role in the nucleolus 
is unknown but is consistent with the nucleolar localisation of a S. pombe homologue 
called POL5 [29]. Over a region of 880 amino acids, MYBBP1a and POL5 are 21% 
identical, and 41% similar. MYBBP1a and POL5 share an acidic domain of unknown 
function and LXXLL motifs that often mediate interactions with nuclear hormone 
receptor transcription factors (reviewed in [30]). However, MYBBP1a does not 
contain any polymerase domains that were found to be active in POL5. Unlike other 
DNA polymerases, POL5 has an important role in rRNA transcription [29]. This 
indicates MYBBP1a might also have a role in rRNA transcription by pol I in the 
nucleolus, but this has not yet been investigated. However, there is some evidence 
that MYBBP1a has a role in pol II dependent transcription regulation. It has been 
shown to bind to the transcription factors Myb [27], c-Jun [27], AhR [31] and PGC-
1? [32], although the influence of MYBBP1a on transcription was variable.  
Here we investigate the role of MYBBP1a on NF-?B dependent transcription. 
MYBBP1a was found to interact with the transcriptional activation domain (TAD) of 
RelA/p65, and this interaction is likely to be direct. In transient transfection reporter 
assays MYBBP1a repressed transcription from the NF-?B responsive promoter 
HIV1-LTR. We found that MYBBP1a is present in Jurkat (T) cells at higher levels 
than in THP1 (monocyte) or HeLa (epithelial) cells. Consistent with previous reports, 
we found myc-tagged MYBBP1a in the nucleolus of Jurkat (T) cells. MYBBP1a 
competed with the co-activator p300 for interaction with RelA/p65-TAD. In vitro 
transcription experiments with “chromatinised templates” as the substrate for 
transcription showed that MYBBP1a could inhibit transcription activated by 
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 RelA/p65 and p300. MYBBP1a was able to inhibit transcription at a stage after 
RelA/p65 binding to DNA and before pre-initiation complex formation. These results 
indicate that MYBBP1a might be enriched in T cells and is a co-repressor of NF-?B 
dependent transcription, by competing with the co-activator p300.   
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 Experimental 
Plasmid DNA 
The NF-?B dependent luciferase reporter constructs pGL2-HIV1-LTR-WT and 
pGL2-HIV1-LTR-??B(MUT) are described in [33]. The p53 dependent reporter 
constructs BS2-WT and BS2-MUT were described in [34]. Expression plasmid for 
p53 and p65 were based on pcDNA3 and were described in [35]. Expression plasmid 
for MYBBP1a (pcDNA3kmMYBBP1a) was constructed by PCR amplification of 
MYBBP1a from the IMAGE clone 5495483. The forward primer 5’ TAT AAG CGG 
CCG CGA TGG AGA GCC GGG ATC CC 3’ and reverse primer 5’ TAT AAT CTA 
GAC TAT CAG GGC TTC CCT GCC TTC C 3’ allowed Not1/Xba1 digestion and 
insertion into a pcDNA3 based vector with a myc-tag in frame. The resulting 
construct was sequenced and the NT amino acid sequence consisting of the first 
methionine, the myc tag polylinker and the first methionine of MYBBP1a is 
MEQKLISEEDLKLIDGSRAAAM. Expression in 293T was tested after transient 
transfection of the construct.  
 
Antibodies 
Anti-p65 C20, anti-PCNA PC10 and anti-p300 C20 were purchased from Santa Cruz, 
anti-his (tetra-his mouse monoclonal IgG1 antibody) from Qiagen, anti-PARP from 
Cell Signalling, anti-tubulin from Sigma, and anti-c-myc antibody from Roche. 
Whole serum for anti-MYBBP1a was a kind gift from Rebecca Keough (School of 
Molecular and Biomedical Science, University of Adelaide).  
 
Transient transfection reporter assays 
Jurkat cells (EAECC) were maintained in RPMI 1640 medium + L-glutamine 
(Gibco), 10 % fetal calf serum, penicillin and streptomycin. 5-10 million cells were 
used per sample, and samples were always in duplicate. Transfection was performed 
according to the standard DEAE-dextran. DNA was purified with the Quiagen ENDO 
free maxi prep KIT. 2 μg of reporter plasmid DNA was used, with the indicated 
amounts of test plasmid DNA. Control plasmids (empty vectors) were used in the 
appropriate amounts to keep the number of each promoter constant in each sample, to 
avoid promoter squelching. Stimulation with 17.5 nM PMA (phorbal 12-myristate 13-
acetate purchased from Alexis Biochemicals) was for 4-5 hours. After transfection the 
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 cells were left 24-36 hours, before being harvested, washed with PBS and lysed in 
Reporter lysis buffer (Promega). Luciferase levels were measured using Luminol 
substrate (Promega) and the Lumat LB 9507 luminometer. The luciferase levels were 
normalised against the protein concentration of the extracts, and the mean was taken 
of the duplicate samples. The experiments were repeated three times, and the mean of 
the three experiments was taken, and the standard deviation calculated.  
 
GST pull down experiments 
GST-pull downs were performed under standard conditions. Bacterial extracts (GST 
or GST-RelA/p65-TAD) or Sf21 extracts (GST-RelA/p65) expressing the GST fusion 
protein of interest were incubated with rolling 1 h, 4°C, with Glutathione Sepharose 
beads (Amersham) in GST binding buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 10 
% glycerol, 0.1% NP40, 1.5 mM MgCl2, 1 mM DTT, 0.2 mM PMSF, PLB). 
Immobilised GST proteins were washed with GST wash buffer 3 times (20 mM 
HEPES pH7.5, 380 mM NaCl, 10 % glycerol, 1.5 mM MgCl2, 1 mM DTT, 0.2 mM 
PMSF, PLB) and then 1 time with MYBBP1a binding buffer (20 mM HEPES pH 7.5, 
10% glycerol, 1.5 mM MgCl2, 1 mM DTT, 0.2 mM PMSF, PLB, 50/80/120 mM 
NaCl as indicated in the figures. Proteins (his-MYBBP1a or his-p300 or BSA) were 
added to the binding reaction of total volume 500 μl and incubated with rolling 2 hr 
4°C. In figure 1D and E this brought the salt conditions to 97/135 mM NaCl. 
Immobilised proteins were washed in MYBBP1a binding buffer 3 times, and 
denatured with 10X SDS loading buffer. Proteins were analysed by SDS-PAGE and 
either coomassie staining or western blotting. For the reactions with micrococcal 
nuclease digestions the basic prototol from Nguyen 2006 was followed [36]. All 
proteins were MN treated (GST proteins when immobilised) with 12U/100 μl reaction 
MN (MBI) in MYBBP1a binding buffer supplemented with 5 mM CaCl2 at 30°C 10 
min.   
 
Nuclear Extract Preparation 
Following the modified Dignam method [37] described in full previously [20]. Cells 
were stimulated with 175 nM PMA (Alexis Biochemicals) for 1 hr. 
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 Immunoflourescence 
Jurkat cells were transfected with the same number of molecules of MYBBP1a 
expression plasmid or empty vector control corresponding to 5 μg 
pcDNA3kmMYBBP1a or 2.87 μg pcDNA3 using the DEAE-dextran method. After 
40 hr, cells were treated for a total of 1 hr at 37 °C with 17.5 nM PMA or 175 nM 
PMA (Alexis Biochemicals) or 30 ng/ml TNF-? (Sigma). Cells were attached to 
poly-L-lysine (Sigma) coated chamber slides (LabTech) at 37 °C for the last 30 min 
of stimulation. Cells were fixed with 4% formaldehyde in PBS 20 min, room 
temperature, rocking gently. Fixed cells were washed 2 times, 5 min with PBS, 
permeabilised with 0.2 % triton X 100 in PBS, 10 min and washed again. Slides were 
blocked in 2% BSA in PBS 1 h, washed, incubated with anti-myc antibody (Roche), 
washed, incubated with anti-mouse-FITC antibody (Jackson Immunology) and 
washed. Cells were stained with DAPI, washed, and mounted with Vector Shield 
(Vector Laboratories).  
 
Expression and Purification of his-MYBBP1a, his-p65 and his-p300 
His-MYBBP1a was expressed in insect Sf21 cells using the BacPAK Baculovirus 
Expression System (Clontech). MYBBP1a was PCR amplified from the IMAGE 
clone 5495483 using a forward primer containing a 6X his tag and XhoI restriction 
site 5’ AAT ACT CGA GAC CAT GCA CCA CCA TCA CCA CCA TGG TAT 
GGA GAG CCG GGA TCC C 3’. The reverse primer contained 2 stops and a NotI 
restriction site 5’ TAA TAG CGG CCG CCT ATC AGG GCT TCC CTG CCT TC 
3’.  The 4 kbp insert was XhoI/NotI digested and inserted in the pBacPAK8 vector. 
The resulting 9.5 kbp plasmid (pak8hisMYBBP1a) was sequenced and used to create 
baculoviruses according to the manufacturers protocol (Clonetech).  
His-MYBBP1a was expressed by infection of Sf21 cells for 3.5 days with 
baculovirus. Cell pellets, were washed with PBS, resuspended and homogenised in 
homogenisation buffer (10 mM tris pH 7.5, 500 mM NaCl, 10 % glycerol, 0.1 % 
NP40, 2 mM betamercapto ethanol, 20 mM imidazole, 0.2 mM PMSF, PLB). The 
extract was centrifuged at 14 krpm 4 °C 30 min and filtered before loading onto a 1 
ml his-TRAP column (Amersham). Bound proteins were and washed with 
homogenisation buffer and eluted with an imidazole gradient. Fractions were pooled, 
diluted and concentrated (Amicon) when required. 
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 His-p65 was produced in a similar way using baculoviruses created with the BakPAK 
system and his-p300 was provided as a generous gift from Lee Kraus, Cornell 
University. These proteins were purified in batch using Ni2+-beads (ProBond, 
Invitrogen). 
 
Regularly spaced nucleosome assembly and in vitro transcription 
Plasmid DNA (pGL2-HIV-LTR?tar) containing the HIV LTR with 2 NF-?B binding 
sites and a luciferase reporter gene was assembled into regularly spaced nucleosomes 
(often referred to as “chromatinisation”) using drosophila S190 as described 
previously (Bulger and Kadonaga 1994) and drosophila histones purified and kindly 
provided by Dr. Andreas Ladurner. During  “chromatinisation” recombinant proteins 
were added at the times indicated in the figure legends. In vitro transcription reactions 
were carried out as previously described [38] using HeLa nuclear extract as the source 
of general transcription factors [39]. Final concentrations of proteins in the reaction 
were 100 nM for p65, 15 nM for p300 and 50 nM for MYBBP1a. The RNA formed 
by the reactions was analysed by primer extension using a primer complementary to 
the luciferase reporter gene of the plasmid (5’ GGA TAG AAT GGC GCC GGG 
CCT TTC 3’) labelled 5’ with ATP?32P. The DNA products were analysed by an 8 % 
urea PAGE in 1X TBE, and the signal was detected and quantified by a Phosphor 
Imager (Molecular Dynamics).  
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Results 
MYBBP1a interacts with RelA/p65. 
Previously we identified MYBBP1a from nuclear extracts as an interacting protein of 
the transcription activation domain (TAD) of RelA/p65 [20]. In order to determine 
whether MYBBP1a interacts directly with RelA/p65, GST pull-down experiments 
were performed using immobilised GST-control, GST-RelA/p65 full length or GST-
RelA/p65-TAD and purified his-MYBBP1a (Figure 1A and 1B).  Western blot 
analysis of bound material indicated that his-MYBBP1a could bind to both GST- 
RelA/p65 full length and TAD but not to GST alone (Figure 1C). To investigate 
whether contaminating DNA or RNA mediated the interaction between RelA/p65 and 
MYBBP1a, a similar GST pull down experiment was performed after micrococcal 
nuclease (MN) treatment of the proteins to remove single and double stranded DNA 
and RNA [36]. Coomassie staining of the experiment performed with or without MN 
treatment, allowed rough quantification of the binding (Figure 1D and 1E). About 20 
% of the his-MYBBP1a input bound to GST-RelA/p65-TAD with or without MN 
treatment. More than 20 % of the his-MYBBP1a input bound to GST-RelA/p65 in the 
absence of MN treatment while less than 20 % bound in the presence of MN 
treatment. The binding was reduced at higher salt concentrations (120 mM NaCl for 
the washing steps). This indicates that full length RelA/p65 and the TAD domain can 
interact with MYBBP1a. The RelA/p65 interaction with MYBBP1a may be stabilised 
by DNA or RNA, while the TAD interaction with MYBBP1a is not stabilised by 
DNA or RNA. 
 
Over-expression of MYBBP1a represses NF-?B dependent reporter 
transcription. 
To analyse the effect of MYBBP1a on RelA/p65 dependent transcription, transient 
transfection reporter assays were performed in Jurkat T cells. Expression of RelA/p65 
activated reporter expression under the control of the HIV1- Long Terminal Repeat 
(LTR) (black bar in Figure 2), which contains two binding sites for NF-?B but not of 
the same reporter where the two consensus binding sites were mutated (white bar in 
Figure 2). Expression of MYBBP1a repressed this activation in a concentration 
dependent manner (Figure 2A). Levels of the mutated HIV1-LTR reporter gene were 
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 not significantly affected by MYBBP1a expression. In Jurkat cells, endogenous NF-
?B activated by 17.5 nM PMA (phorbol 12-myristate 13-acetate) stimulation could 
also be repressed by expression of MYBBP1a (Figure 2B). Expression of the mutated 
HIV1-LTR reporter gene was slightly activated by PMA, and MYBBP1a also 
inhibited this activation. This indicates that the transcription activation by both over-
expressed RelA/p65 and endogenous RelA/p65 activated by PMA stimulation is 
inhibited by expression of MYBBP1a in Jurkat cells in an NF-?B dependent manner. 
Since MYBBP1a has been shown to effect the activity of other transcription 
factors both positively and negatively, the effect of MYBBP1a expression on p53 
dependent reporter gene expression was also tested. Expression of MYBBP1a did not 
significantly reduce the transactivation by p53 (Figure 2C). This indicates that 
MYBBP1a represses only a subset of transcription factors, of which RelA/p65 is one, 
and p53 is not.  
 
MYBBP1a is a cell type enriched protein with a nucleolar cellular localisation in 
Jurkat (T) cells. 
Previously we found that higher levels of MYBBP1a bound to RelA/p65-TAD from 
Jurkat nuclear extracts than from HeLa or THP1 nuclear extracts. To identify whether 
this is due to higher levels of MYBBP1a in Jurkat nuclear extracts than in the other 
cell types western blot analysis was performed (Figure 3A). MYBBP1a was detected 
in the nuclear extracts of all the three cell types, with higher levels in Jurkat nuclear 
extract. No MYBBP1a was detected in the cytoplasmic extract from any cell type. 
Stimulation of Jurkat cells with 175 nM PMA did not alter the levels of MYBBP1a 
seen in nuclear, cytoplasmic or insoluble extracts (Figure 3B).  
Previously, MYBBP1a was shown to be localised mainly in the nucleoli of 
NIH 3T3 cells [27], and also in 293T cells when expressed as a flag tagged protein 
[28]. To identify whether MYBBP1a is also a nucleolar protein in Jurkat T cells we 
performed immunoflourescence. Due to the unavailability of specific antibodies 
against MYBBP1a suitable for immunoflourescence, cells over-expressing myc-
tagged MYBBP1a were used and stained with an anti-myc antibody. In Jurkat cells 
myc-MYBBP1a localises to the nucleolus (Figure 3C). These results indicate that 
MYBBP1a is expressed more in Jurkat (T) cells than in HeLa (epithelial) or THP1 
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 (monocyte) cells and that MYBBP1a is found mainly in the nucleolus of Jurkat (T) 
cells.  
 
MYBBP1a and p300 compete for RelA/p65-TAD binding. 
Since the transcriptional cofactor p300 is known to interact with the TAD of 
RelA/p65 [21], we investigated whether both p300 and MYBBP1a could bind to 
RelA/p65-TAD at the same time. GST pull down experiments were performed using 
limiting amounts of GST-RelA/p65-TAD and 15 nM p300 together with varying 
amounts of MYBBP1a (Figure 4). Upon addition of increasing amounts of MYBBP1a 
(5-25 nM) we found that more MYBBP1a bound to GST-RelA/p65-TAD while less 
p300 bound to GST-RelA/p65-TAD (Figure 4B). Addition of 25 nM BSA had no 
effect on the p300 binding to GST-RelA/p65-TAD (Figure 4B). No p300 or 
MYBBP1a bound to GST under the same conditions (Figure 4C). This indicates that 
MYBBP1a and p300 cannot bind to the RelA/p65-TAD at the same time, implying 
that there is competition between the activator (p300) and repressor (MYBBP1a) for 
interaction with RelA/p65-TAD. 
 
MYBBP1a is a co-repressor of transcription in vitro. 
To further investigate NF-?B regulated transcription by MYBBP1a and p300, in vitro 
transcription experiments were performed on template DNA with regularly spaced 
nucleosomes (referred to as chromatinised templates) as shown in the scheme in 
Figure 5A.  Nucleosomes were regularly spaced after chromatinisation in the presence 
or absence of RelA/p65 (Figure 5B). Without addition of transactivating factors 
transcription from naked (non nucleosomal) templates was detected but not from 
“chromatinised” templates.  Addition of RelA/p65 activated transcription from the 
“chromatinised” templates 11.6 fold (Figure 5C, lane 5). Addition of MYBBP1a 
repressed this activation to 5.7 fold (Figure 5C, lane 6). p300 alone activated 
transcription slightly by 4.2 fold (Figure 5C, lane 3) and MYBBP1a repressed this 
activation to 1.4 fold (Figure 5C, lane 4). RelA/p65 and p300 activated transcription 
synergistically to 62 fold (Figure 5C, lane 7) and this was repressed to 13.3 fold when 
MYBBP1a was added to the reaction 30 minutes before p300 addition (Figure 5C, 
lane 8). When MYBBP1a was added to the reaction after p300, less repression was 
detected (figure 5C, lane 9). To exclude the possibility that MYBBP1a contained 
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 RNAses, MYBBP1a was added at a later stage, just before the addition of HeLa 
nuclear extracts, but before the synthesis of RNA. MYBBP1a did not repress the 
transcription when added at this stage (Figure 5D). This also indicates that MYBBP1a 
repression of NF-?B regulated transcription occurs at a stage after transcription factor 
binding to chromatin, but before pre-initiation complex formation. MYBBP1a was 
also found to repress transcription from naked DNA templates, when added 1 hour 
before the nuclear extracts (Figure 5E) but not when added just before the HeLa 
nuclear extracts (Figure 5F), suggesting that MYBBP1a might also associate with 
naked DNA to form a transcriptionally repressive complex. 
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Discussion 
MYBBP1a represses NF-?B dependent transcription. 
Here, MYBBP1a was found to interact with the TAD of RelA/p65 (Figure 1) and to 
repress expression of an NF-?B dependent reporter gene in vivo driven by expression 
of RelA/p65 or by PMA stimulation (Figure 2). Previous work indicated that 
MYBBP1a might also repress the transcription factor Myb and the PPAR? co-factor 
PGC-1? [27, 32]. Although full length MYBBP1a had no effect on Myb reporter 
gene expression, the N terminal of MYBBP1a (p67) strongly repressed transactivation 
in CV-1 cells [27]. Transfection of both MYBBP1a and p67 repressed PPAR?/PGC-
1? reporter expression in HIB1B cells. Gal4-DNA binding domain fused to 
MYBBP1a repressed Gal4 dependent reporter gene expression indicating MYBBP1a 
may have an intrinsic transcriptional repression function [32]. However MYBBP1a 
does not generally repress transactivation by all transcription factors as expression of 
MYBBP1a did not significantly effect p53 reporter gene expression (Figure 2C) and it 
was reported that in mouse hepatoma cells expression of MYBBP1a increased AhR 
dependent reporter expression [31]. This indicates that MYBBP1a may be 
appropriately recruited to the regulatory DNA elements by specific transcription 
factors in order to repress transcription. For NF-?B regulated genes this is likely to be 
through the direct interaction of MYBBP1a and RelA/p65-TAD (Figure 1).  
Since MYBBP1a dependent repression occurred in vivo when using PMA 
activated endogenous RelA/p65 these results indicate that under some circumstances 
MYBBP1a may repress transcription of endogenous RelA/p65 dependent genes. 
Further work is needed to investigate which genes are regulated by MYBBP1a and 
under which cellular conditions. MYBBP1a could repress NF-?B dependent 
transcription in Jurkat T cells, which were found to have higher levels of MYBBP1a 
than THP1 monocyte or HeLa epithelial cells (Figure 3). This indicates that the 
MYBBP1a levels in Jurkat cells may not be saturating. Also, it is not known how high 
the cellular levels of MYBBP1a are in comparison to other transcriptional regulators. 
The only other known cell type enriched cofactor of NF-?B dependent transcription is 
TAF4b (TAFII105). This TAF is part of the TFIID complex in B cells, and was found 
to interact with RelA/p65 and to be required for the expression of a subset of genes, 
through an unknown mechanism [24, 40]. B and T cells with blocked TAF4b function 
14
80
 had an increased apoptosis sensitivity indicating that TAF4b has an anti-apoptotic 
effect [41]. However, TAF4b-/- mice do not have B cell defects indicating that other 
TAFs are able to carry out TAF4b functions [42].  
 
Mechanism of MYBBP1a mediated NF-?B repression. 
MYBBP1a was detected to repress HIV1-LTR driven transcription in vitro using 
chromatinised templates as the substrate (Figure 5). In the experiments RelA/p65 was 
pre-bound to the DNA. MYBBP1a could repress transcription when added to the 
chromatin RelA/p65 complex before addition of p300, but not when added at a later 
stage (Figure 5). This indicates that MYBBP1a can repress transcription at a step after 
NF-?B binds to DNA, but does not directly repress assembly of the pre-initiation 
complex containing general transcription factors and pol II. This is the same stage of 
transcription at which p300 can activate transcription by acetylation events [43]. p300 
mediates acetylation of core histone tails and other transcription regulatory proteins at 
specific promoters by interaction with DNA binding transcription factors. We do not 
exclude the possibility that MYBBP1a can also repress other steps in the NF-?B 
activation pathway. Here we show that MYBBP1a can interact with the 
transcriptional activation domain (TAD) of RelA/p65 (Figure 1) and competes for this 
domain with the transcriptional co-activator p300 (Figure 4). The interaction between 
MYBBP1a and TAD could inhibit the transcriptional potential of the TAD by 
exclusion of p300. Therefore, these results support the hypothesis that MYBBP1a 
might function as a co-repressor of transcription by altering the accessibility of the 
promoter by competition with p300 histone acetyltransferase activity. It is also 
possible that MYBBP1a could be part of or recruit a transcriptional repressor 
complex. Evidence for such an histone deacetylase containing repressor complex 
(HDAC) is that the repression of reporter gene expression by Gal4-MYBBP1a is 
relieved upon HDAC inhibitor (trichostatin A) treatment [32].  
In vitro MYBBP1a also repressed transcription from naked templates when 
added one hour before the nuclear extracts. This indicates that MYBBP1a repressed 
transcription of naked DNA template possibly by associating with the DNA template, 
causing a transcriptionally repressive state. Further experiments are required to 
determine the characteristics of this slow association and whether it is relevant for 
transcription repression in the cellular context. An association with MYBBP1a and 
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 chromatinised templates is less likely than with naked DNA due to the presence of 
nucleosomes and other chromatin proteins. Therefore, the repression of RelA/p65 and 
p300 activated transcription on chromatinised templates may be mainly due to the 
MYBBP1a competition with p300.  
 
Regulation of MYBBP1a repression. 
In this work we show that MYBBP1a and p300 compete for RelA/p65-TAD 
interaction (Figure 4). The equilibrium between these proteins bound to RelA/p65 is 
likely to determine the transcriptional potential of RelA/p65 and could be carefully 
regulated at specific promoters to create the appropriate pattern of gene expression. 
This equilibrium could be regulated by the levels of p300 and MYBBP1a present in 
different cell types and also by signalling events. p300 was previously shown to be 
limiting in cells [44, 45]. Although MYBBP1a mRNA transcripts were found in most 
tissues and cell lines tested [27] [46], it cannot be assumed that MYBBP1a protein is 
present since the degradation of MYBBP1a to the stable p67 degradation product was 
detected only in a subset of cell types [27]. The expression levels of p67 in various 
cell types and the function of p67 in NF-?B dependent transcription are unknown. 
Data from micro-array analysis on the Human Gene Atlas website 
(http://symatlas.gnf.org/SymAtlas/) [47], shows that mRNA expression was three 
times above median for many cells of the immune system, indicating that these cells 
might have elevated levels of MYBBP1a and/or p67. Here we show that MYBBP1a 
protein level is higher in Jurkat T cells than THP1 monocytes or HeLa epithelial cells 
(Figure 3). This indicates that the level of MYBBP1a can be different in specific cells 
types, and may be particularly high in T cells, implying it may have a special role in T 
cell signalling. Proteomic approaches would be ideal to determine the difference in 
levels of MYBBP1a in various normal tissues and cells. 
Signalling events could also lead to specific patterns of post-translational 
modification of RelA/p65, p300 and MYBBP1a, regulating the interaction between 
them. This would be analogous to co-activator/co-repressor exchange during nuclear 
hormone receptor activation by ligand binding. It has been shown that 
phosphorylation of RelA/p65-TAD by calcium/calmodulin dependent kinase IV 
increased the interaction between RelA/p65-TAD and CBP (a close p300 homologue) 
whilst reducing the affinity between RelA/p65-TAD and the co-repressor complex 
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 SMRT [48]. In the interaction studies presented here non-modified RelA/p65-TAD 
was used which may favour the interaction with specific proteins such as 
transcriptional repressor proteins. 
Here we show that expressed myc-MYBBP1a localised mainly to the 
nucleolus of human Jurkat T cells (Figure 3). Endogenous MYBBP1a is also present 
mainly in the nucleolus of mouse NIH 3T3 fibroblasts [27] and human HeLa cells 
[49]. MYBBP1a was previously shown to have nuclear import and export signals and 
to move between the nucleus and cytoplasm [28]. As a flag tagged exogenously 
expressed construct it moved from the nucleoli in one nucleus to another nucleoli in a 
different cell in a heterokaryon (fused cell) experiment [28]. It is not known whether 
the nucleolar/nuclear/cytoplasmic shuttling of MYBBP1a is regulated within the cell, 
although preliminary data suggest that upon PMA stimulation there may be some 
nucleolar to cytoplasmic shuttling of over-expressed myc-MYBBP1a (H. Owen and 
M. Hottiger, unpublished).   
Since RelA/p65 is not known to have a transcription function in the nucleolus 
perhaps the small amount of MYBBP1a found diffuse in the nucleus is able to 
regulate RelA/p65 and other pol II transcription factors. It is also possible that 
MYBBP1a could sequester RelA/p65 in the nucleoli, thereby inhibiting RelA/p65 
dependent transcription. RelA/p65 was previously shown to be sequestered in the 
nucleolus upon cell stimulation with the pro-apoptotic signals aspirin, UV-C and 
serum deprivation [50]. This sequestration led to an inhibition of NF-?B dependent 
reporter transcription.  
To conclude, we find that MYBBP1a is a novel co-repressor of NF-?B 
dependent transcription. MYBBP1a repressed PMA activated endogenous NF-?B as 
well as RelA/p65 over-expressed mediated induction of NF-?B dependent reporter 
expression in transient transfection assays. MYBBP1a also inhibited RelA/p65 and 
p300 activated transcription in reactions performed with chromatin templates in vitro. 
MYBBP1a repression was seen at a stage after RelA/p65 binding to DNA, but before 
addition of general transcription factors from a nuclear extract source. MYBBP1a 
interacts with RelA/p65-TAD in a competitive manner with the transcriptional co-
activator p300. This indicates that MYBBP1a might function as a co-repressor of 
transcription at a stage before PIC formation by competing with p300.  
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Figure Legends 
Figure 1. MYBBP1a interacts with the transcription factor RelA/p65 via the 
transcription activation domain. 
(A) and (B) Proteins used for the GST pull down experiments analysed by 
SDS-PAGE and coomassie staining. Arrow heads indicate the positions of GST, 
GST-RelA/p65, GST-RelA/p65-TAD (A) and his-MYBBP1a (B). 
(C) GST pull down experiment was performed using the proteins shown in A 
and B and binding and washing conditions of 50 mM NaCl or 80 mM NaCl. Bound 
material was analysed by western blot using an anti-his antibody to detect his-
MYBBP1a. 5% and 20% of input his-MYBBP1a were included on the western blot. 
His-MYBBP1a interacts with GST-RelA/p65 and GST-RelA/p65-TAD but not GST. 
D) GST pull down experiments were performed using binding/washing 
conditions of 97/80 mM NaCl or 135/120 mM NaCl, and bound material was 
visualised by coomassie staining. Positions of GST, GST-RelA/p65, GST-RelA/p65-
TAD, his-MYBBP1a are indicated with arrow heads. An Asterix shows the position 
of MYBBP1a binding at 97 mM NaCl. 
(E) GST pull down experiments were performed as in D, with an additional 
micorococcal nuclease digestion step before the interaction study, to digest 
contaminating single and double stranded oligonucleotides. 
 
Figure 2. Expression of MYBBP1a represses NF-?B dependent reporter gene 
expression. 
(A) Graph to show the fold activation of HIV1-LTR reporter gene expression 
in Jurkat cells when induced by RelA/p65. Cells were transiently transfected with 
pGL2-HIV1-LTR wild type (black bar) or pGL2-HIV1-LTR-??BMUT (white bar) 
reporter, and the indicated expression plasmids. Luciferase levels were normalised 
against total protein level. Samples were in duplicate and the mean used. The graph 
shows the results for the mean of three independent experiments, where the bars are 
the standard deviation of the three experiments. 
(B) Graph to show the fold activation of HIV1-LTR reporter gene expression 
in Jurkat cells when induced by 17.5 nM PMA. Cells were transfected and luciferase 
levels were measured as in A. The graph shows the results for the mean of three 
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 independent experiments, where the bars are the standard deviation of the three 
experiments. 
(C) Graph to show the fold activation of BS2 reporter gene expression in 
Jurkat cells when induced by p53. Cells were transfected and luciferase levels were 
measured as in A. Reporters used were BS2-wild type (black bars) and BS2-mutant 
(white bars). The graph shows the results for the mean of three independent 
experiments, where the bars are the standard deviation of the three experiments. 
 
Figure 3. Higher levels of MYBBP1a are present in Jurkat (T) cells than in 
THP1 (monocyte) or HeLa (epithelial) cells and myc-tagged MYBBP1a localises 
to the nucleolus in Jurkat cells.   
(A) Western blot analysis of nuclear and cytoplasmic extract from Jurkat (T), 
THP1 (monocyte) or HeLa (epithelial) cells. Antibodies against tubulin, PCNA, 
PARP and RelA/p65 were used as loading controls. PARP is a nuclear protein, while 
in non-stimulated cells RelA/p65 is cytoplasmic. 
(B) Western blot analysis of nuclear, cytoplasmic and insoluble extracts from 
Jurkat (T) cells with and without 175 nM PMA stimulation for 1 hr. 
(C) MYBBP1a is mainly nucleolar in Jurkat T cells. Immunoflourescence of 
Jurkat cells transfected with a myc-MYBBP1a expression vector. Cells were stained 
with anti-myc (left) and DAPI (middle). Light fields were also visualised to 
distinguish nucleoli (right). Two representative transfected cells are shown, with 
bright green staining. Faint dark green staining is the background signal.  
 
Figure 4. MYBBP1a competes with p300 for binding to RelA/p65-TAD. 
(A) Proteins used for the GST pull down experiments analysed by SDS-PAGE 
and coomassie staining were GST, GST-RelA/p65-TAD, BSA, his-p300 and his-
MYBBP1a.  
(B) GST pull down experiment performed with GST-RelA/p65-TAD and salt 
conditions of 80 mM NaCl for binding and washing. Constant amount of his-300 was 
used whilst MYBBP1a amount was increased as indicated. BSA was used as a 
negative control. Bound material was analysed by western blot using antibodies 
against p300 or MYBBP1a. 
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 (C) GST pull down experiment performed with GST control and salt 
conditions of 80 mM NaCl for binding and washing. Bound material was analysed by 
western blot using antibodies against p300 or MYBBP1a. 
 
Figure 5. MYBBP1a represses transcription in vitro of HIV1-LTR reporter DNA 
assembled into regularly spaced nucleosomes. 
(A) Transcription scheme. S190 extract is incubated with drosophila core 
histones for 30 min at RT. RelA/p65 or elution buffer is incubated with pGL2-HIV1-
LTR-WT for 20 min on ice. RelA/p65-DNA is incubated with the S190-histones, plus 
an MgATP generation mix at 27 °C for 3 h 30 min. Transcription reactions are then 
performed as described in the scheme and in the Experimental section. HNE stands 
for HeLa nuclear extracts. PIC stands for Pre-initiation complex formation. RT stands 
for room temperature. 
(B) Samples of the chromatinisation reactions carried out in the presence and 
absence of RelA/p65 are analysed by micrococcal nuclease digestion to ensure 
efficient deposition of regularly spaced nucleosomes.  
(C) Transcription reactions were carried out with the combination of proteins 
indicated. MYBBP1a was added at A or B as shown in the transcription scheme in 
Figure 5A. Transcription reactions were analysed by primer extension with a 32P 
labelled primer and 8% urea PAGE. The experiment was performed three times and 
an example radiograph is shown. Most samples were in duplicate and the mean taken. 
The fold activation for each experiment was calculated by setting the sample without 
proteins added (lane 1) as 1. The mean fold activation (F.A.) and the standard 
deviation (S.D.) for the three experiments was calculated and is shown. 
(D) Transcription reactions were carried out as in C, although MYBBP1a (M) 
was added just before the HeLa nuclear extracts at time point C in the transcription 
scheme in Figure 5A. 
(E) Naked transcription reactions (on non-chromatinised DNA) were carried 
out. MYBBP1a (M) was added 1 h before the HeLa nuclear extracts at time point A in 
the transcription scheme in Figure 5A. 
(F) Naked transcription reactions were carried out. MYBBP1a (M) was added 
just before the HeLa nuclear extracts at time point C in the transcription scheme in 
Figure 5A. 
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Nuclear factor kappaB (NF-κB) has 
an important role in the transcriptional 
regulation of genes involved in immunity and 
cell survival. We show here that RelA/p65 is 
acetylated by p300. Acetylation sites were 
mapped in vitro to lysine K310, K314 and 
K315. Genetic complementation of RelA/p65  
-/- cells with wild type and non acetylatable 
mutants of RelA/p65 (K310R, K314R and 
K315R) revealed that neither shuttling nor 
DNA binding of RelA/p65 was affected by 
acetylation. Microarray analysis of these cells 
treated with TNFα  identified a specific set of 
genes that was regulated differently by wild 
type or acetylation deficient RelA/p65. 
Specific genes were identified to be either 
stimulated or repressed by the acetylation 
deficient mutant when compared to RelA/p65 
wild type. These results support the 
hypothesis that p300-mediated acetylation of 
RelA/p65 at defined sites is important to 
regulate the specificity of gene expression. 
 
The inducible transcription factor family 
nuclear factor κB (NF-κB) consists of dimeric 
proteins involved in many diverse processes 
such as immune and stress responses and even 
the opposing processes of proliferation and 
apoptosis (1-3). NF-κB is induced in almost all 
cell types by different extracellular stimuli 
causing the activation of an enormous array of 
target genes (4). Thus it is not surprising that the 
specificity of NF-κB responses is very important 
for the fate of a cell. It has been shown that 
abnormal NF-κB activity, that is not always 
associated with genetic alterations, plays a role 
in different inflammatory diseases and cancer 
(5,6).  
NF-κB specificity is regulated at 
different levels in the cell (7). One level of 
regulation is the selective activation of different 
NF-κB complexes after induction by diverse 
stimuli. In mammals there are five family 
members, c-Rel, RelB, p65 (RelA), p105/p50 
(NF-κB1) and p100/p52 (NF-κB2) that can form 
a range of homo- and heterodimers (8). After 
regulated IκB (inhibitor of NF-κB)-dependent 
NF-κB translocation to the nucleus these dimers 
bind with variable affinities to consensus NF-κB 
binding sites in the promoter and enhancer 
regions of their target genes, often cooperatively 
with other transcription factors (e.g., at the IFNβ 
promoter (9)). This integrates other signal 
transduction pathways with the NF-κB pathway 
giving additional levels of specificity and 
regulation to the transcriptional control of 
responsive genes. The interaction with cell type 
specific co-factor proteins has been shown to 
influence the transcriptional potential of NF-κB 
(10). One of the co-factors of NF-κB is the co-
activator p300 and its homolog CBP (CREB-
binding protein). They have been shown to 
interact with the RelA/p65 and the p50 subunit 
(9,11-13) serving as molecular bridges between 
NF-κB and the transcription machinery. They 
also contain intrinsic histone acetyltransferase 
activity catalyzing the acetylation of lysine 
residues in histones and non-histone proteins 
(14,15). A growing number of transcription 
factors are acetylated and regulated by 
p300/CBP including p53 (16), GATA-1 (17), 
E2F-1 (18,19) and YY1 (20). Post-translational 
acetylation influences different properties of 
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these transcription factors such as DNA binding, 
protein-protein interactions, protein stability and 
transcriptional potential (reviewed in (21)).  
NF-κB is subjected to a variety of post-
translational modifications (e.g., 
phosphorylation (22), ubiquitination (23) or 
prolyl-isomerisation (24)) that modulate NF-κB 
activity. Phosphorylation of the RelA/p65 
subunit by the PKAc, MSK1 and PKCζ kinases 
enhances its interaction with the co-activator 
p300/CBP and stimulates the NF-κB 
transcriptional activity (25-27). In contrast, 
ubiquitination of RelA/p65 on the promoter 
specifically terminates the NF-κB response (23). 
It has recently been shown that RelA/p65 and 
p50 are reversibly acetylated by p300 and PCAF 
((28-30)). Chen et al. identified lysine residues 
(K) 218, 221 and 310 of RelA/p65 as acceptor 
sites for p300 acetylation. They reported that 
acetylated lysine 221 enhanced DNA binding 
activity of NF-κB in vitro and abolished the 
interaction with IκBα leading to a prolonged 
NF-κB response in the nucleus. The acetylation 
at lysine residue 310 was required for full 
transcriptional activity of RelA/p65 (31). 
Kiernan et al. identified lysine 122 and 123 in 
RelA/p65 as acetylation sites modified by both 
p300 and P/CAF. In contrast to K218, K221 and 
K310, acetylation of K122 and K123 decreased 
the DNA binding of RelA/p65 facilitating the 
removal of RelA/p65 from the DNA and the 
export from the nucleus by IκBα resulting in a 
faster termination of the NF-κB response (29). 
These data question the precise role of RelA/p65 
post-translational acetylation in NF-κB 
dependent gene regulation in vivo. 
The aim of this study was to identify the role of 
RelA/p65 acetylation in vivo. We found that 
p300 efficiently acetylated RelA/p65 in vitro at 
lysines 310, 314 and 315. We generated 
acetylation deficient lysine to arginine 
substitution mutants of RelA/p65 and stably 
complemented RelA/p65-/- cells with these 
mutants. The nuclear-cytosolic shuttling and the 
DNA binding of the acetylation deficient 
mutants were similar to that of wild type 
RelA/p65. However, whole genome microarray 
analysis indicated that the expression of specific 
genes was affected by the K/R mutation. Our 
results imply that although general 
transcriptional activity of RelA/p65 was not 
affected by acetylation at lysine 310, 314 and 
315, the expression of a specific set of genes was 
modulated. Thus, acetylation can serve as a 
molecular mechanism to promote specificity of 
NF-κB-dependent gene expression. 
 
Experimental procedure 
 
Plasmids - hGCN5L, mP/CAF and hTip60 were 
cloned into pFastBacHTb vector in frame with a 
N-terminal 6xHis-tag. pph-CMV-Km-RelA/p65 
wild type was previously described in (13). pph-
CMV-Km-RelA/p65K310R, pph-CMV-Km-
RelA/p65K314/K315R and pph-CMV-Km-
RelA/p65K310R/K314/K315R were generated 
by site-directed mutagenesis according to the 
QuickChange protocol (Stratagene) using the 
following oligonucleotides: K310R: 
5’CGTAAAAGGACATACGAGACCTTCAGG
AGCATCATGAAGAAGAGTCC3’ and 
5’GGACTCTTCTTCATGATGCTCCTGAAG
GTCTCGTATGTCCTTTTACG3’, 
K314/315R:5’CCTTCAGGAGCATCATGCGG
AGGAGTCCTTTCAGCGGACCC3’ and 
5’GGGTCCGCTGAAAGGACTCCTCCGCAT
GATGCTCCTGAAGG3’ (bold letters represent 
K/R mutation). All introduced mutations were 
confirmed by sequencing. 
Reagents and Antibodies - Mouse TNFα, 
Trichostatin A (TSA), Nicotinamide (NAM), 
acetyl-Coenzyme A and calf thymus core 
histones (H7755) were purchased from Sigma. 
14C-labeled acetyl Coenzyme A (MC269) was 
obtained from Moravek Biochemicals. Most of 
antibodies were purchased from Santa Cruz 
Biotechnology: anti-RelA/p65 (C-20, sc-372), 
anti-p300 (C-20, sc-585) and anti-α-tubulin 
(TU-02, sc-8035). The anti-p50 antibody was a 
generous gift from N. Rice (National Cancer 
Institute, Frederick, MD). Anti-myc 9E10 
antibody was purified from hybridoma cells 
according to the standard protocol. The tetra-his 
mouse monoclonal IgG1 antibody was from 
Qiagen. The specific antibody against acetylated 
lysine 310 in RelA/p65 was generated in 
collaboration with Abcam.  
Tissue culture, cell transfections - 
Complemented RelA/p65-/- NIH 3T3 mouse 
embryonic fibroblasts (MEFs) and HEK 293T 
cells were maintained in DMEM supplemented 
with 10% FCS, 100 Units/ml 
penicillin/streptomycin and non-essential amino 
acids (GIBCO). Cells were transfected using 
calcium phosphate precipitation method.  
Generation and purification of baculovirus 
expressed proteins - All recombinant proteins 
were expressed in Sf21 cells using the Bac-To-
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Bac (GIBCO) or BacPAK (Clontech) system. 
Recombinant His-tagged proteins were purified 
over Ni2+-beads (ProBond, Invitrogen). 
In vitro acetylation assay - 1µg of recombinant 
human wild type or mutant RelA/p65 was 
incubated with 0.5-1µg recombinant p300 or 
CBP or equimolar amount of hGCN5L, mP/CAF 
or hTip60 in HAT buffer (50mM Tris-HCl pH 
8.0, 100mM NaCl, 10% glycerol, 1mM DTT, 
1mM PMSF, 1µg/ml pepstatin, bestatin, 
leupeptin, 1mM Sodium butyrate) supplemented 
with 1.5nmol [14C]-Acetyl CoA for 45 min at 
30°C. The reactions were stopped by adding 10x 
Laemmli-buffer. The proteins were resolved on 
SDS-PAGE and visualized by Coomassie 
brilliant blue or SyproRuby staining. The gel 
was immersed in 1M Sodium salicylate for 20 
min at RT. After drying, the gel was exposed to 
X-ray films (Contatyp) at -80°C. 
In vitro transcription assay - Plasmid DNA 
(pGL2-HIV-LTR∆tar) containing the HIV LTR 
with 2 NF-κB binding sites and a luciferase 
reporter gene was assembled into regularly 
spaced nucleosomes (often referred to as 
chromatinisation) using drosophila S190 extract 
as described previously (32) and human histones 
purified from HeLa cells as described in Current 
Protocols in Molecular Biology (21.5.1). During 
chromatinisation recombinant proteins were 
added at the times indicated in the figure 
legends. In vitro transcription reactions were 
carried out as previously described (33) using 
HeLa nuclear extract as the source of general 
transcription factors (34). Briefly, the RNA 
formed by the reactions was analyzed by primer 
extension using a primer complementary to the 
luciferase reporter gene of the plasmid (5’-GGA 
TAG AAT GGC GCC GGG CCT TTC- 3’) 
labeled 5’ with ATPγ32P. The DNA products 
were analyzed by an 8 % urea PAGE in 1X 
TBE, and the signal was detected and quantified 
by a Phosphor Imager (Molecular Dynamics). 
All reactions were performed in duplicate and 
each experiment was repeated a minimal of three 
times.  
Electrophoretic mobility shift assay (EMSA) - 
Binding reactions were done in a total volume of 
20 µl containing 10mM Tris-HCl (pH 7.5), 
50mM NaCl, 1mM DTT, 2mM PMSF, 0.25µg 
poly dI-dC, 7% (v/v) Ficoll/glycerol, 0.25 pmol 
HIV-LTR oligonucleotide containing 2 κB 
binding sites labeled 5’ with ATPγ32P and 7 µg 
of nuclear extract. The reaction was incubated 
for 20 minutes on ice and then resolved using a 
5% polyacrylamide gel in 0.5x TBE. The gel 
was run at 150V for 3 hours, dried and subjected 
to autoradiography. When supershifts were 
performed the binding reaction was pre-
incubated with the indicated antibody for 20 min 
on ice before the labeled oligonucleotide was 
added. 
Immunohistochemistry - Cells were plated at the 
density of 45 000 cells per chamber on poly-L-
lysine (Sigma) coated chamber slides (LAB-
TEK) and incubated over night at 37°C and 5% 
CO2. Next day the cells were treated with 
30µg/ml of TNFα for the indicated time. The 
cells were fixed in 4% paraformaldehyde and 
then permeabilized with 0.2% Triton-X-
100/PBS. After blocking for 1 hr in 2% 
BSA/0.1% Triton-X-100/PBS slides were 
incubated with anti-RelA/p65 C-20 antibody 
(1:300 dilution) followed by anti-rabbit Cy3 
(Jackson Immunology) antibody (1:250 
dilution). The samples were washed and 
Vectashield mounting solution (Vector 
laboratories) was applied to prevent bleaching. 
Cells were visualized using an Olympus T50 
microscope. 
GST-pull down experiments - GST, GST-
RelA/p65wt and GST-RelA/p65KTR proteins 
were immobilized on glutathione beads 
(Amersham Pharmacia) and incubated with 
purified his-p300 in binding buffer (20mM 
Hepes pH7.5, 60mM NaCl, 10% glycerol, 
1.5mM MgCl2, 1mM DTT, 1mM PMSF and 
1µg/ml pepstatin, bestatin, leupeptin) for 2 hrs at 
4°C rolling. Glutathione beads were washed 
with binding buffer. Proteins were boiled, 
resolved on SDS-PAGE and subjected to 
Western blot analysis using anti-his antibody 
(Qiagen). 
Nuclear extract preparation and 
immunoprecipitation - Nuclear extracts were 
prepared as previously described in (35). 200 µg 
of TNFα (30ng/ml) and HDAC inhibitor (TSA 
(2µM), NAM (5mM)) treated nuclear extracts of 
the complemented cells were incubated with 2µg 
of anti-RelA/p65 C-20 antibody for 2.5 hrs at 
4°C rolling in binding buffer (20mM Hepes 
pH7.9, 80mM NaCl, 2.5mM MgCl2, 0.05% NP-
40, 1mM PMSF, 1µg/ml pepstatin, bestatin, 
leupeptin). After incubation with protein G-
sepharose beads (Amersham Pharmacia) for 
another hour, the immunocomplexes were 
extensively washed in washing buffer (20mM 
Hepes pH7.9, 100mM NaCl, 2.5mM MgCl2, 
0.05% NP-40, 1mM PMSF, 1µg/ml pepstatin, 
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bestatin, leupeptin). Proteins were boiled, 
resolved on SDS-PAGE and analyzed by 
western blot using the anti-RelA/p65ac310. 
Membranes were reprobed with anti-RelA/p65 
antibody. 
MS/MS - In vitro acetylated RelA/p65 was 
resolved on SDS-PAGE, fixed and stained with 
Coomassie brilliant blue. The corresponding 
protein band was then excised and washed twice 
with 50% acetonitrile. After tryptic digestion the 
protein sequence analysis was performed at the 
Harvard Microchemistry Facility by 
microcapillary reverse-phase HPLC nano-
electrospray tandem mass spectrometry 
(µLC/MS/MS) on a Finnigan LCQ DECA XP 
quadrupole ion trap mass spectrometer. 
Lentiviral complementation of RelA/p65-/- 
MEFs - Virus production and transduction of 
RelA/p65-/- MEFs were performed as described 
in (36). Briefly, 293T HEK cells were 
transfected with 3.5 µg of the envelope plasmid, 
6.5 µg of packaging plasmid, and 10 µg of pTV-
myc-RelA/p65 wild type, RelA/p65 K/R or the 
control pTV vector. After 24 hrs the viral 
supernatant was harvested and used to infect 
RelA/p65-/-MEFs. 36 hrs post infection cells 
were split into selective medium containing 2.5 
µg/ml Blasticidin (Sigma). Expression of 
recombinant proteins in the complemented cells 
was screened by western blot analysis. Pools of 
cells were used for further analysis. 
RNA preparation - Total RNA was isolated three 
times from TNFα treated lysates from 
complemented RelA/p65-/- MEFs with the ‘Total 
RNA isolation kit’ (Agilent Technologies). RNA 
quality was checked with the RNA 6000 Nano 
kit using the Bioanalyzer 2001 (Agilent 
Technologies). Purified RNAs were converted 
into double-stranded cDNA and transcribed into 
Cy3-/Cy5 (PerkinElmer/NEN Life Science) -
labeled cRNA using the ‘Low RNA Input Linear 
Amp Kit’ (Agilent Technologies). cRNA from 
wild type RelA/p65 cells was Cy5-labeld while 
the RelA/p65KTR cRNA was Cy3-labeled. The 
purification of the labeled cRNAs was done with 
the RNeasy kit (Qiagen). Dye incorporation was 
measured on the ND-1000 Spectrophotometer 
(NanoDrop Technologies) 
Gene expression profiling - Gene expression 
profiling was performed in the Functional 
Genomics Center Zurich using the Agilent 
Microarray system (Agilent Technologies). 1µg 
of fragmented Cy5-labeled wild type and 1 µg of 
Cy3-labeled mutant cRNA were co-hybridised 
on the Whole Mouse genome 60mer-oligo array 
(G4122A, Agilent Technologies) according to 
the manufacturers protocol. The microarray 
analysis was performed in triplicates. The slides 
were scanned using the Agilent DNA microarray 
scanner and the scans were quantified with the 
Agilent Feature Extraction software. 
Data analysis - Data analysis was done with the 
GeneSpring software (Silicon Genetics). A 
significance value of p≤0.01 was applied. Genes 
with a fold induction of more then 1.6 or less 
then 0.625 between mutant and wild type cell 
line were considered to be significantly up- or 
down regulated. Screening for the NF-κB 
consensus sequence GGGRNNYYCC in the 
upstream regions of the respective genes was 
also performed with the GeneSpring software.  
Quantitative real time RT-PCR - Total RNA 
from untreated or 45 min TNFα treated cell lines 
(RelA/p65wt and RelA/p65KTR) was reverse 
transcribed using the high capacity cDNA 
Archive kit according to manufacturers protocol 
(ABI). Real time PCR was performed using 
mouse specific TaqMan probes (Gene 
expression assays, ABI) for Ccl-7, Fhl-1 and 
Mip-2. The 18SrRNA probe was used to 
normalize for differences in RNA input. The 
Rotor-Gene3000A real time PCR machine 
(Corbett) was used and the included data 
analysis software Rotor-Gene6 was applied. The 
figures show the results of three independent 
experiments. 
 
RESULTS 
 
RelA/p65 is acetylated in vitro by p300 or CBP. 
Since RelA/p65 was reported to interact 
directly with several histone acetyltransferases 
(HAT), we investigated whether RelA/p65 could 
serve as a substrate in an in vitro acetylation 
assay. We compared the ability of different 
HATs to acetylate RelA/p65 in vitro. Full length 
RelA/p65 was incubated with recombinant p300, 
CBP, GCN5L, P/CAF or Tip60 (all proteins 
expressed and purified from insect cells, Fig. 
1A) in the presence of radioactively labeled 
acetyl-coenzyme A (acetyl-CoA) as a donor of 
the acetyl group (Fig. 1B). All tested HATs, 
except for Tip60, acetylated RelA/p65 in vitro 
(Fig. 1B). Calf thymus core histones were used 
as a positive control of acetylation (Fig. 1C). 
p300 and CBP were the most potent HATs for 
RelA/p65 in our system. This prompted us to 
focus on p300 in this study. 
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RelA/p65 is acetylated in vitro by p300 or CBP 
at lysine 310, 314 and 315. 
To identify the acetylation residues, in 
vitro acetylated RelA/p65 by p300 was digested 
with trypsin and the resulting peptides were 
analyzed by LC/MS/MS. 81.8% of the K310 
comprising peptides contained an acetylated 
K310. 61.9% of K314 and 56.52% of K315 
containing peptides showed acetylated K314 and 
acetylated K315, respectively. These data 
indicate that lysine 310, 314 and 315 were 
acetylated by p300. The identified lysine 
residues are located close to the C-terminus of 
the Rel homology domain (RHD) (Fig. 2A). To 
confirm these findings, the corresponding 
lysines were replaced with arginine residues by 
site directed mutagenesis. Substitution of lysine 
to arginine maintains the positive charge of the 
residue and may cause only minimal changes in 
the local environment of the protein. Wild type 
or mutated RelA/p65 harboring K310R, 
K314/315R or all three K310/314/315R (KTR) 
substitutions were expressed and purified from 
insect cells (Fig. 2B). Subsequently, all proteins 
were subjected to in vitro acetylation by p300 or 
CBP (Fig. 2C). Acetylation of RelA/p65 mutated 
at single K310 or K314/315 was only slightly 
reduced compared to wild type, while mutation 
of all three lysine residues abolished acetylation 
of RelA/p65 (Fig. 2C). When the purified 
protein substrates were tested only in the 
presence of acetyl-CoA, no acetylation was 
observed confirming that the acetylation was 
mediated by p300 or CBP and not by a co-
purified acetyltransferase. These results clearly 
indicate that K310, K314 and K315 of RelA/p65 
are the main acetylation sites of p300 and CBP 
in vitro. To confirm that the RelA/p65KTR 
mutant was still able to interact with p300, myc-
tagged RelA/p65 wild type and RelA/p65K/R 
mutant proteins were overexpressed in HEK 
293T cells that were treated with PMA to induce 
NF-κB. RelA/p65 was immunoprecipitated with 
an anti-myc antibody and the 
immunoprecipitated complexes were analyzed 
by western blot analysis using an anti-p300 
antibody. Interaction of p300 with the 
RelA/p65KTR mutant was similar to that 
observed for the RelA/p65 wild type (Fig. 2D). 
To further confirm these findings, GST-pull 
down experiments were performed using GST-
RelA/p65 wild type or GST-RelA/p65KTR as 
bait proteins in the presence of purified p300. 
Subsequent western blot analysis revealed that 
p300 was able to equally interact with both 
RelA/p65 wild type and the RelA/p65KTR 
mutant (Fig. 2E). These results indicate that 
abolished acetylation of the RelA/p65KTR 
mutant was due to the lack of specific sites but 
not due to the inability of this mutant to interact 
with p300. 
 
RelA/p65KTR is transcriptionally active in vitro. 
To investigate whether acetylation of 
RelA/p65 might influence its potential to 
activate gene expression, in vitro transcription 
assays on chromatinised templates were 
performed (Fig. 3A). In these experiments the 
RelA/p65 wild type and the RelA/p65KTR were 
added to template DNA (HIV-LTR-luc) after 
chromatin assembly (Fig. 3B). Low basal 
transcription was detected in the absence of the 
activator proteins. When we added recombinant 
RelA/p65 wild type or RelA/p65KTR to the 
reaction, transcription was activated to similar 
extent by both proteins. These results suggested 
that the triple mutation in RelA/p65KTR per se 
did not affect the overall structure of RelA/p65. 
p300 substantially stimulated the transcription 
from chromatinised templates in the presence of 
RelA/p65 wild type and RelA/p65KTR. Such 
stimulation was not evident when p300 was 
added alone to the reaction. The level of p300-
induced transcription was not significantly 
different between the RelA/p65wt and the 
RelA/p65KTR. These results indicate that 
acetylation of K310, K314 and K315 by p300 
did not affect RelA/p65-dependent transcription 
initiation from the synthetic HIV-LTR reporter. 
 
RelA/p65 is acetylated in vivo in TNFα 
stimulated cells. 
To investigate the role of RelA/p65 
acetylation of K310, K314 and K315 in vivo, 
RelA/p65-/- NIH 3T3 mouse embryonic 
fibroblasts (MEF) were genetically 
complemented using lentiviruses encoding myc-
RelA/p65 wild type, myc-RelA/p65K310R, 
myc-RelA/p65K314/315R or myc-
RelA/p65KTR. After appropriate selection cells 
were kept in pools and the expression of 
recombinant proteins was analyzed by western 
blotting using an anti-RelA/p65 antibody (Fig. 
4A). The cells transduced with control virus 
encoding the resistance gene (mock infected) 
and non-transduced wild type NIH 3T3 cells 
expressing endogenous RelA/p65 protein were 
included as controls. The expression levels of 
the recombinant wild type and mutated 
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RelA/p65 proteins were comparable to that 
observed for endogenous RelA/p65 in NIH 3T3 
cells. Furthermore, analysis of the cell growth 
revealed that the proliferation rate was 
comparable between the tested cell pools under 
normal growth conditions (data not shown). 
It was shown before that RelA/p65 was 
acetylated in a stimuli dependent manner (28). In 
order to investigate whether RelA/p65 is 
acetylated at the identified lysine residues in 
vivo, antibodies directed against p65 peptides 
acetylated at residues 310, 314 or 315 were 
generated. Nuclear extracts were prepared after 
treating the complemented cells with TNFα and 
HDAC inhibitors (TSA and NAM). RelA/p65 
nuclear import upon TNFα treatment was 
induced in RelA/p65wt and RelA/p65 mutant 
complemented cells (Fig. 4B). 
Immunoprecipitation with an anti-RelA/p65 
antibody and subsequent western blot analysis 
using the specific acetyl K310 antibody revealed 
that RelA/p65 was indeed acetylated at this site 
upon TNFα treatment (Fig. 4C). Antibodies 
raised against acetylated 314 and acetylated 315 
were found to be unspecific in this analysis (data 
not shown). 
 
Neither shuttling nor DNA binding of RelA/p65 
is affected by the K/R substitution mutation. 
The complemented cells were treated 
with TNFα and subcellular localization of the 
recombinant RelA/p65 proteins was analyzed by 
immunofluorescence analysis at different time 
points (Fig. 5A). Nuclear translocation of the 
recombinant RelA/p65 wild type was detected 
after 20 minutes of TNFα treatment and 
relocation to the cytoplasm after 60 minutes. A 
similar shuttling kinetics was observed for 
endogenous RelA/p65 protein in NIH 3T3 cells 
(data not shown). Analysis of the cells 
complemented either with K310R, K314/315R 
or KTR revealed no significant differences in the 
shuttling kinetics between the mutated RelA/p65 
and the RelA/p65 wild type proteins (Fig. 5A). 
This suggested that acetylation of RelA/p65 at 
the three tested lysine residues was not essential 
for the regulation of the RelA/p65 nuclear-
cytoplasmic redistribution. This observation is 
supported by our findings that IκBα was able to 
bind to acetylated and non-acetylated RelA/p65 
with similar affinity (data not shown).  
Next we investigated the influence of 
p300-mediated RelA/p65 acetylation on the 
ability of RelA/p65 to bind DNA. Nuclear 
extracts of the complemented cells treated with 
TNFα were tested in an electro mobility shift 
assay using an oligonucleotide containing two 
κB elements of the HIV-LTR promoter. The 
experiments revealed that mutations of K310, 
K314 and K315 did not significantly influence 
the TNFα induced DNA binding of RelA/p65 
(Fig. 5B). Binding was substantially reduced by 
competition with non-labeled oligonucleotides 
containing a wild type κB site, but not a mutated 
κB site, indicating that the binding was specific 
(data not shown). The presence of RelA/p65 and 
p50 in the complex was confirmed by supershift 
experiments using specific anti-RelA/p65 and 
anti-p50 antibodies, respectively (Fig. 5B).  
 
Determination of genes regulated by p300-
mediated acetylation of RelA/p65. 
The important question was to 
investigate whether the acetylation deficient 
mutants would affect endogenous gene 
expression in TNFα treated cells. To determine 
which, if any, RelA/p65-target genes depend on 
acetylation of K310, K314 and K315 we 
performed microarray analysis (Agilent) with 
oligonucleotides representing annotated genomic 
mouse sequences. RelA/p65-/- cells 
complemented either with wild type or KTR 
mutant were treated for 45 minutes with TNFα 
and total RNA was isolated in three replicates 
from these cells. RNA was then amplified and 
co-hybridized to the Agilent mouse whole 
genome array. Statistical analysis of the 
expression profiles of cells complemented with 
wild type or KTR RelA/p65 revealed 
differentially expressed genes. Among them 28 
genes were up regulated more than 1.6 (log) fold 
with a p value ≤0.01 (Table 1) and 32 genes 
down regulated more than 0.625 with a p value 
≤0.01 in cells expressing RelA/p65KTR when 
compared to RelA/p65 wild type cells (Table 2). 
Since most of the regulated genes were 
previously not identified as NF-κB target genes, 
the upstream genomic regions (9kb) were 
searched for the presence of a NF-κB consensus 
DNA binding site (5’-GGGRNNYYCC-3’) 
using the GeneSpring program (Fig. 6A). We 
found that 68% of the up regulated genes and 
72% of the down regulated genes contained a 
consensus NF-κB binding site. Statistical test 
revealed a significant overlap between the 
regulation of these genes and the presence of the 
κB site (Fig. 6A). 
To confirm the results derived from the 
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microarray studies, we further analyzed the 
expression of several genes with quantitative 
RT-PCR. To perform quantitative real-time RT-
PCR total RNA isolated from RelA/p65-/- cells 
complemented either with wild type or KTR 
mutant was reverse transcribed with random 
hexamer primers to obtain cDNA. In these 
experiments the cells were stimulated with 
TNFα for 45 minutes. As expected from the 
microarray analysis Mip-2 expression was 
induced to the same extent in RelA/p65 wild 
type and RelA/p65 KTR complemented cells 
(Fig. 6B, left). However, Ccl-7 expression was 
increased (2 fold, p value=0.0695) in cells 
expressing KTR mutant confirming that lack of 
acetylation at these sites has a positive effect on 
its regulation (Fig. 6B, middle). Finally, Fhl-1 
expression was highly dependent on the 
acetylation of RelA/p65 (p=0.0123), since 
expression of the Fhl-1 gene could not be 
detected in cells expressing the KTR mutant 
(Fig. 6B, right). Therefore, the results obtained 
in the microarray analysis could be confirmed by 
the more sensitive real time RT-PCR method for 
three selected genes. Together, this analysis 
provides strong evidence that acetylation of 
RelA/p65 at lysine 310, 314 and 315 is required 
for the transcriptional regulation of a specific 
subset of genes.  
 
DISCUSSION 
 
Increasing experimental evidence has indicated 
that NF-κB-dependent gene expression is 
regulated by different post-translational 
modifications including acetylation (37). The 
acetylation-dependent NF-κB regulation was 
shown to occur via many different mechanisms 
(38). For example acetylation of histones is 
known to regulate NF-κB-dependent gene 
accessibility for the transcriptional machinery 
(37). The direct acetylation of NF-κB was 
reported to regulate the transcriptional potential 
of NF-κB, the duration of the NF-κB response, 
its DNA binding activity as well as protein-
protein interactions with several transcription 
cofactors (31,39,40).  
In this study we have addressed the role 
of p300-mediated acetylation of RelA/p65 in the 
regulation of gene expression in vivo. We 
identified three lysines (K310, K314 and K315) 
in RelA/p65 as targets for the acetylation by 
p300 in vitro (Fig. 2A). Interestingly, K310 was 
previously shown to be acetylated by p300 (31). 
However, we additionally found two new lysine 
residues acetylated in RelA/p65 that were not 
reported before. It is important to mention that 
among the previously reported acetylation sites 
(29,31) we could only confirm the acetylation of 
K310 in our experimental system. This could be 
due to the different experimental procedures 
used in the studies. Therefore, we cannot 
exclude that additional p300 specific acetylation 
sites exist in RelA/p65. The relevance of the in 
vitro acetylation sites identified in our study was 
confirmed by the ability of RelA/p65 to be 
acetylated in vivo upon TNFα stimulation (Fig. 
4C). 
 We also demonstrated by an in vitro 
transcription assay on chromatinised templates 
that both RelA/p65 wild type and RelA/p65KTR 
(K310R, K314R, K315R) are transcriptionally 
active and can be stimulated by p300 (Fig. 3B). 
Since the p300-mediated increase in 
transcription initiation was dependent on the 
presence of RelA/p65 proteins, this may suggest 
that RelA/p65 facilitates the recruitment of p300 
to the template. RelA/p65 is known to interact 
with p300 through its Rel homology and 
transactivation domains (25). Because a similar 
increase in transcription was seen for both the 
wild type and the acetylation deficient RelA/p65 
mutant, we conclude that acetylation of 
RelA/p65 was not important for the stimulation. 
We could not exclude that acetylation of other 
proteins by p300 was responsible for the 
transcriptional up regulation in this system. p300 
was previously reported to acetylate 
nucleosomal histones on chromatin templates 
(41) and is known to acetylate other non-histone 
proteins (42) .  
To investigate the role of RelA/p65 
acetylation in endogenous gene expression in 
vivo we genetically complemented RelA/p65-/- 
fibroblasts with a control vector or cDNAs 
encoding for RelA/p65 wild type, K310R, 
K314/315R and KTR mutant (Fig. 4A). Analysis 
of the complemented cells revealed that the 
mutation of the acetylation sites did not affect 
the kinetics of the cytoplasmic-nuclear 
redistribution of RelA/p65 upon TNFα 
stimulation (Fig. 5A). This implied that the 
upstream signalling events are not regulated by 
the acetylation of RelA/p65 at the identified 
sites. 
To elucidate the influence of RelA/p65 
acetylation on gene expression in vivo we 
performed genome-wide microarrays using total 
RNA isolated from the complemented cells. We 
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identified subsets of genes which were 
specifically up or down regulated depending on 
the ability of RelA/p65 to be acetylated at the 
described sites (Table 1, 2). The majority of 
these genes were previously not described as 
NF-κB target genes. However, the presence of a 
NF-κB consensus site in their upstream regions 
indicated that they could be regulated by NF-κB. 
The results of the microarray analysis revealed 
that the acetylation of RelA/p65 does not always 
correlate with activation of gene expression as 
has been suggested before (31). Rather we 
provide evidence that the p300-mediated 
acetylation of RelA/p65 contributes to both gene 
specific activation and repression of 
transcription. It is unknown how RelA/p65 
acetylation signals to activate certain genes 
while simultaneously suppressing the expression 
of others. One hypothesis would be that the 
regulation of certain genes by p300-mediated 
acetylation of RelA/p65 promotes the 
recruitment of additional factors or stabilizes the 
formation of specific preinitiation complexes at 
promoter sites. Like this acetylated RelA/p65 
could serve as a factor that regulates the 
recruitment of these proteins. It has been 
previously reported that many proteins can 
specifically recognize and bind acetylated lysine 
residues in histones and transcription factors 
through their bromo domains (43-45). Among 
them are well characterized histone 
acetyltransferases (e.g., p300, P/CAF and 
GCN5) (46) and subunits of chromatin 
remodelling complexes (e.g., ATPases of 
SWI2/SNF2 and proteins of the WAL/BAZ 
family of ISWI-associated proteins) (47). The 
nature of the recruited co-activator/co-repressor 
would determine the response of the specific 
genes. Another hypothesis would be that the 
presence of other cis-regulatory elements in a 
targeted gene and regulatory proteins recruited 
to these elements might be critical for the 
modulation of the acetylation dependent NF-κB 
response. Acetylation is known to be a reversible 
protein modification. In this regard HDAC-1, 
HDAC-2 and HDAC-3 were reported to repress 
NF-κB-dependent transcription upon treatment 
with inflammatory stimuli (31,37,38). These 
histone deacetylases were also shown to directly 
interact with several proteins involved in the 
NF-κB signalling pathway, including NF-κB 
itself (28,37,48). Deacetylation of RelA/p65 by 
HDAC-3 may provide a counterpart mechanism 
for p300 function. The exact molecular 
mechanism by which acetylation/deacetylation 
of RelA/p65 regulates the transcription activity 
of RelA/p65 in the context of chromatin remains 
to be investigated. 
Together, acetylation of RelA/p65 
presents an attractive regulatory mechanism for 
the control of NF-κB dependent gene 
expression. The combination of acetylation with 
other post-translational modifications will even 
more broaden the potential of this regulation. 
Combinations of different modifications have 
already been proposed to serve as a ‘code’ for 
the interacting domains of different proteins 
(49,50). Furthermore, acetylation can be 
regulated by other post-translational 
modifications. For example phosphorylation of 
RelA/p65 at serine 276 and 536 was shown to 
enhance the acetylation of lysine 310 (51). It 
cannot be excluded that other post-translational 
modifications of RelA/p65 can also regulate the 
acetylation of this transcription factor. Our 
findings could help to explain the diversity of 
NF-κB-dependent gene expression upon 
different stimuli. We hypothesize that unique 
combinations of post-translational markers and 
the presence of cell type specific cofactors 
determine the specific NF-κB-mediated 
response. 
In conclusion, our results support the 
hypothesis that p300-mediated acetylation of 
RelA/p65 is important to modulate the 
expression of defined genes, thereby 
contributing to the specificity of the NF-κB 
response.  
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FIGURE LEGENDS 
 
Fig. 1. RelA/p65 is acetylated by p300 and CBP in vitro. A, Recombinant histone acetyltransferases 
(HATs) expressed and purified from insect cells were analyzed by SDS-PAGE and Coomassie 
staining. Molecular weight markers are shown on the left. B, In vitro acetylation assay using full-
length RelA/p65 and the indicated HATs. RelA/p65 was incubated in the presence of radioactively 
labeled [14C]-acetyl-CoA with 500ng of p300 or CBP or the equimolar amount of GCN5L, P/CAF or 
Tip60. Proteins were resolved on SDS-PAGE, stained with SyproRuby (left) and exposed to X-ray 
films (right). RelA/p65 acetylation signals are indicated with an arrow. HATs or HAT autoacetylation 
signals are indicated with an asterisk (*). C, In vitro acetylation of histones. In vitro acetylation assay 
was performed as described in B. 
 
Fig. 2. RelA/p65 is acetylated by p300 at lysine 310, 314 and 315 in vitro. A, Protein domain diagram 
of RelA/p65 depicts the location of the acetylated lysine residues in the ‘linker’ region of RelA/p65 
(NLS, nuclear localization signal; RHD, Rel homology domain; TAD, transactivation domain). B, 
Coomassie staining of recombinant arginine to lysine substitution mutants of RelA/p65 expressed and 
purified from insect cells: wt, RelA/p65 wild type; K310R, RelA/p65K310R; K314/315R, 
RelA/p65K314/315R and KTR, RelA/p65K310/314/315R. C, In vitro acetylation of RelA/p65K/R 
mutants by p300 or CBP. Proteins were analyzed as in Fig. 1B. The autoacetylation signals of p300 or 
CBP are indicated with an asterisk (*). D, Analysis of interaction of recombinant RelA/p65 proteins 
with p300 in PMA treated HEK293T cells. Wild type myc-RelA/p65 and myc-RelA/p65 K/R mutants 
were immunoprecipitated from whole cell extract of PMA treated HEK 293T cells using anti-myc 
antibody. Immunocomplexes were resolved on SDS-PAGE and subsequently analyzed by western 
blot with anti-p300 and anti-myc antibodies. E, GST-pull down experiments using GST, GST-
RelA/p65wt and GST-RelA/p65KTR as bait proteins were performed in the presence of purified his-
p300. Co-precipitated proteins were analyzed by western blot using anti-his antibody. Coomassie 
staining of the bait proteins for equal loading is shown on the right.  
 
Fig. 3. RelA/p65KTR is transcriptionally active in vitro. A, Schematic representation for chromatin 
assembly and transcription. Chromatin was assembled with template DNA, S190 extract and core 
histones (CH). Transcription pre-initiation complex (PIC) formation was performed with HeLa 
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nuclear extract (NE) and transcription was initiated by adding rNTPs. RelA/p65 and p300 were added 
after chromatin assembly but before PIC formation. B, Transcriptional activation by RelA/p65wt or 
RelA/p65KTR on chromatin templates using in vitro transcription assays with the HIV-LTR DNA 
template. p300 was added at the indicated time point. The transcripts were detected with primer 
extension. The average mean with standard deviations of three independent experiments is shown 
below. 
 
Fig. 4. RelA/RelA/p65 is acetylated at lysine 310 in vivo in response to TNFα. A, Western blot 
analysis with anti-RelA/p65 antibody of whole cell extracts from RelA/p65-/- MEFs complemented 
with RelA/p65 wild type (wt) and the different substitution mutants of RelA/p65 (K310R, K314/315R 
and KTR). Mock transduced and NIH 3T3 cells were used as controls. The membrane was reprobed 
with anti-tubulin antibody as loading control. B, Nuclear extracts of the complemented cell lines 
untreated or treated with TNFα (30ng/ml) for 30 minutes were subjected to western blot analysis 
using anti-RelA/p65 antibody. The anti-PARP western blot was performed to check the extract 
fractionation. C, Nuclear extracts of the complemented cell lines treated with TNFα and HDACi 
(TSA/NAM) were subjected to immunoprecipitation analysis using anti-RelA/p65 antibodies. 
Western blot analysis with the anti-RelA/p65ac310 antibody was performed. The membranes were 
reprobed with anti-RelA/p65 antibody. 
 
Fig.5. Mutation of the acetylation sites in RelA/p65 does not affect its nuclear translocation and DNA 
binding. A, The complemented cells were treated with TNFα and fixed with paraformaldehyde 
followed by immunostaining using anti-RelA/p65 antibodies. Subcellular localization of RelA/p65 
protein was analyzed by immunofluorescence microscopy. B, Electro mobility shift assays were 
performed with nuclear extracts from the untreated or TNFα treated cells using 32P-labeled 
oligonucleotide DNA containing 2κB sites. The bound complexes were characterised by anti-
RelA/p65 or anti-p50 supershift assays. Specific NF-κB complexes are indicated with an arrow, 
unspecific bands are marked with an asterisk (*). 
 
Fig.6. Acetylation of RelA/p65 at lysine 310, 314 and 315 influences gene specific transcription. 
A, Venn diagram showing the overlap between the regulated genes found in the microarray analysis 
and the presence of a consensus NF-κB site in their 9 kb upstream region. The overlap is non-random 
(p (up-regulated)=0.0228 and p (down-regulated)=0.00283). B, Quantitative real time RT-PCR using 
TaqMan probes for three selected genes (Mip-2, Ccl-7 and Fhl-1). The 18SrRNA was used to correct 
for differences in cDNA inputs. The results of three independent experiments with standard deviations 
are shown. 
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Table 1. Upregulated genes, KTR(45’)/ wild type (45’), fold change>1.6, p≤0.01 
 
Gene name 
 
Description 
 
Genbank ID 
Fold 
change 
 
p value 
NF-κB site 
(+1 - -9000) 
 
Col4a6 
 
Collagen type IV 
 
BC057648 
 
11.74 
 
0.00177 
 
Y 
Peg12 Paternally expressed 12 NM_013788 6.696 0.000929 N 
Dlk1 (SCP1) Delta-like homolog 1 D16847 5.408 0.000811 N 
Riken cDNA A830059I20 NM_021427 4.859 0.00104 Y 
Dlk1 Delta-like homolog 1 NM_010052 4.703 0.000313 N 
Frat1 Frequently rearranged in advanced T-cell 
lymphomas 
NM_008043 4.577 0.00166 N 
Ptpns1 Tyrosine-protein phosphatase non-receptor 
substrate type 1 
D87968 2.871 0.00613 Y 
Kiaa1914 Riken cDNA AK087449 NM_146102 2.855 0.0088 Y 
Plf Proliferin, short variant X75557 2.797 0.00553 N 
Mrpplf4 Mitogen related protein, proliferin 4 NM_181852 2.598 0.00387 Y 
Plf2 Proliferin 2 NM_011118 2.571 0.00507 N 
Vegfc Vascular endothelial growth factor C NM_009506 2.286 0.002 N 
Serpinb6b Serine proteinase inhibitor, clade B, 
member 6B 
NM_011454 2.277 0.00769 Y 
Gcnt1 Glucosaminyl (N-acetyl)transferase 1,core 
2 
NM_173442 2.207 0.000969 Y 
Uchl1 Ubiquitin carboxyterminal hydrolase L1 NM_011670 2.167 0.000528 N 
Riken cDNA Similar to ARGBP2A (human) A530071H08 2.116 0.00439 N 
Lama5 Laminin alpha 5 chain U37501 2.111 0.00413 Y 
Msrb2 Methionine sulfoxide reductase B NM_029619 2.097 0.00328 Y 
Cdyl2 Chromodomain protein, Y chromosome–
like 2 
NM_029441 2.003 0.00526 Y 
Prkg2 Protein kinase, cGMP-dependent type II NM_008926 1.994 0.00293 N 
Riken cDNA Clone 3110013H01 AK01040460 1.939 0.0072 N 
Uchl1 Ubiquitin carboxyterminal hydrolase L1 NM_011670 1.862 0.00566 N 
Lrrc5 Leucine-rich repeat containing protein 5 NM_178701 1.859 0.00804 Y 
Riken cDNA Ionized calcium binding adapter molecule 2 
(Iba2) 
BC024599 1.796 0.00666 Y 
Mgst1 Microsomal glutathione S-transferase 1 AK002800 1.789 0.00754 Y 
Dusp9 Dual specificity phosphatase 9 NM_029352 1.779 0.0092 Y 
Gcnt1 Glucosaminyl(N-acetyl)transferase 1,core 2 NM_010265 1.76 0.0028 Y 
Ccl-7 Chemokine (C-C motif) ligand 7 NM_013654 1.717 0.00792 Y 
Bcl6b B-cell CLL/lymphoma 6, member B NM_007528 1.66 0.0032 Y 
Ssbp4 Single stranded DNA binding protein 3-
homolog 
NM_13372 1.643 0.00493 Y 
Baz1b Bromodomain adjacent to zinc finger 
domain, 1B 
NM_011714 1.634 0.00456 Y 
Npepl1 Aminopeptidase-like 1 NM_213733 1.629 0.00661 Y 
Mgst1 Microsomal glutathione S-transferase 1 NM_019946 1.614 0.00802 Y 
Gcnt1 Glucosaminyl (N-acetyl) transferase 1, core 
2 
NM_010265 1.613 0.00435 Y 
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Table 2. Downregulated genes: KTR (45’)/ wild type (45’), fold change <0.625, p≤0.01 
  
Gene name 
 
Description 
 
Genbank ID 
Fold 
change 
 
p value 
NF-κB 
(+1- -9000) 
 
Cnn1 
 
Calponin 1 
 
NM_009922 
 
0.0978 
 
0.00066 
 
Y 
Myl9 Myosin regulatory light chain 2, smooth 
muscle isoform 
AK007972 0.112 0.00195 N 
Fhl1 Four and a half LIM domains 1  NM_010211 0.23 0.00085 Y 
Acta2 Actin, alpha 2, smooth muscle, aorta  A530078I09 0.284 0.00688 Y 
Thy1 Thymus cell antigen 1, theta  NM_009382 0.285 0.00291 Y 
Tagln Transgelin NM_011526 0.296 0.00666 Y 
Rtp4 Receptor transporting protein 4 NM_023386 0.305 0.000914 Y 
Tagln Transgelin NM_011526 0.34 0.0087 Y 
Itgbl1 Ten integrin EGF-like repeat domains protein 
precursor homolog 
NM_145467 0.35 0.0021 N 
Bst2 DAMP-1 protein, Bone marrow stromal cell 
antigen 2 
NM_198095 0.382 0.00964 Y 
Gbp3 Guanylate nucleotide binding protein 3 NM_018734 0.404 0.00364 Y 
LOC56628 MHC (A.CA/J(H-2K-f) class I antigen NM_019909 0.454 0.00207 Y 
Kcnab1 Potassium voltage-gated channel, shaker-
related subfamily, beta member 1  
NM_010597 0.474 0.00664 Y 
Riken 
cDNA 
Unknown EST  1700006C13 0.485 0.00224 N 
H2-K1 MHC class I heavy chain precursor (H-
2K(b)) 
U47328 0.494 0.00338 Y 
Zfp286 Zink finger protein  NM_138949 0.498 0.00599 Y 
Agrn Agrin  NM_021604 0.52 0.00902 N 
Hmmr Hyaluronan mediated motility receptor NM_013552 0.521 0.00559 N 
Ak5 Adenylate kinase 5  AK053807 0.541 0.00501 N 
Akap12 A kinase (PRKA) anchor protein (gravin) 12  NM_031185 0.552 0.00565 Y 
Ccng1 Cyclin G1  NM_009831 0.558 1.20E-05 Y 
Gpr64 G protein-coupled receptor 64  NM_178712 0.559 0.00589 Y 
Hipk2 Homeodomain interacting protein kinase 2 AK003718 0.566 0.00268 N 
Pmaip1 Phorbol-12-myristate-13-acetate-induced 
protein 1  
NM_021451 0.567 0.000887 Y 
Dgat2 Diacylglycerol O-acyltransferase 2  NM_026384 0.57 0.00066 Y 
Cyba Cytochrome b-245, alpha polypeptide AK021200 0.573 0.00142 Y 
Sash1 SAM and Sh3 domain containing 1  NM_175155 0.576 0.00539 N 
Itpr1 Inositol 1,4,5-triphosphate receptor1 NM_010585 0.595 0.00803 Y 
Gng12 Guanine nucleotide binding protein (G 
protein), gamma 12  
NM_025278 0.601 0.00184 Y 
Nudcd2 NudC domain containing 2  NM_026023 0.603 0.00103 N 
Gbp2 Guanylate nucleotide binding protein 2  NM_010260 0.603 0.0086 Y 
Prkcm Protein kinase C, mu NM_008858 0.618 0.00447 Y 
Ghr High molecular weight growth hormone 
receptor/binding protein 
M33324 0.624 0.00245 Y 
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Acetylation of Poly(ADP-ribose) Polymerase-1 by
p300/CREB-binding Protein Regulates Coactivation
of NF-B-dependent Transcription*□S
Received for publication, July 12, 2005, and in revised form, September 28, 2005 Published, JBC Papers in Press,October 4, 2005, DOI 10.1074/jbc.M507553200
Paul O. Hassa‡, Sandra S. Haenni‡, Christine Buerki‡, Nadja I. Meier‡, William S. Lane§, Heather Owen‡,
Monika Gersbach‡, Ralph Imhof‡, and Michael O. Hottiger‡1
From the ‡Institute of Veterinary Biochemistry andMolecular Biology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich,
Switzerland and §HarvardMicrochemistry and Proteomics Analysis Facility, Department of Molecular and Cellular Biology,
Harvard University, Cambridge, Massachusetts 02138
Poly(ADP-ribose) polymerase-1 (PARP-1) and nuclear factor B
(NF-B) have both been demonstrated to play a pathophysiological
role in a number of inflammatory disorders.We recently presented
evidence that PARP-1 can act as a promoter-specific coactivator of
NF-B in vivo independent of its enzymatic activity. PARP-1
directly interacts with p300 and both subunits of NF-B (p65 and
p50) and synergistically coactivates NF-B-dependent transcrip-
tion. Here we show that PARP-1 is acetylated in vivo at specific
lysine residues by p300/CREB-binding protein upon stimulation.
Furthermore, acetylationofPARP-1 at these residues is required for
the interaction of PARP-1 with p50 and synergistic coactivation of
NF-Bby p300 and theMediator complex in response to inflamma-
tory stimuli. PARP-1 physically interacts with the Mediator. Inter-
estingly, PARP-1 interacts in vivo with histone deacetylases
(HDACs) 1–3 but not with HDACs 4–6 and might be deacety-
lated in vivo by HDACs 1–3. Thus, acetylation of PARP-1 by
p300/CREB-binding protein plays an important regulatory role
in NF-B-dependent gene activation by enhancing its functional
interaction with p300 and the Mediator complex.
Nuclear factor B (NF-B) is a widely expressed transcription factor
of particular importance to the regulation of cells of the immune system
(1). NF-B encompasses a family of inducible transcription factors
including RelA/p65, RelB, c-Rel, p50, and p52 (1). These proteins share
a conserved 300-amino acid region within their amino termini, desig-
nated Rel-homology domain (RHD). This domain is responsible for
dimerization, nuclear translocation, DNA binding, and interaction with
heterologous transcription factors (1). NF-B is composed of homo- or
heterodimers with a range of DNA binding and activation potentials.
The most abundant and best-studied form of NF-B in cells is a het-
erodimer consisting of the two subunits, p50 (NF-B1) and p65 (RelA).
NF-B plays a key role in the regulation of many genes involved in
mammalian immune and inflammatory responses, apoptosis, cell pro-
liferation, and differentiation (1, 2). NF-B has additionally been asso-
ciated with neurodegenerative processes and cancer (3, 4). In unstimu-
lated cells, NF-B is sequestered in the cytoplasm as an inactive
transcription factor complex by its physical association with one of sev-
eral inhibitors ofNF-B (IBs)2 (5). Treatment of cells with extracellular
stimuli including cytokines, bacterial lipopolysaccharides (LPS), phor-
bol esters, or potent oxidants leads to rapid phosphorylation of IB,
which results in ubiquitination of IB and subsequent degradation by
the 26 S proteasome (4, 5). Dissociation of NF-B unmasks the nuclear
localization sequences of p65 and p50 subunits, which leads to nuclear
translocation and binding of NF-B to specific B consensus sequences
in the chromatin and activation of specific subsets of genes (3).
NF-B-dependent gene expression requires growing families of tran-
scriptional coactivators (6, 7). The two key coactivators of NF-B, his-
tone acetyltransferases p300 and its homolog, the cAMP-response ele-
ment-binding protein (CREB)-binding protein (CBP), directly associate
with the NF-B subunits p50 and p65 (8–10). These coactivators are
thought to promote the rapid formation of the pre-initiation and re-ini-
tiation complexes by bridging the sequence-specific activators (like
NF-B) to the basal transcription machinery, thereby facilitating mul-
tiple rounds of transcription (11). Additionally, the histone acetyltrans-
ferases p300 and CBP can modify the amino-terminal tails of nucleoso-
mal histones, thereby altering the local chromatin structure (12–14).
Although the recruitment of p300 or CBP to NF-B-dependent enhan-
ceosomes is required for synergistic activation, tethering p300/CBP
alone to the promoter through NF-B is not sufficient for full activity of
NF-B in the context of chromatin. Several reports indicated that the
combined actions and interactions of distinct transcriptional coactiva-
tor complexes and cofactors seem to be attributable to the strong tran-
scriptional activity of NF-B, depending on the stimuli and the cell type
(6, 8, 15, 16).
Poly(ADP-ribose) poly-merase-1 (PARP-1) is a nuclear chromatin-
associated protein and belongs to a large family of enzymes that can
synthesize polymers of ADP-ribose units by using -nicotinamide ade-
nine dinucleotide (NAD) as substrate (17). PARP-1 and NF-B have
both been suggested to play a pathophysiological role in a number of
inflammatory disorders (17). Several studies showed that PARP-1(/)
mice were protected against myocardial infarction, streptozotocin-in-
duced diabetes, LPS-induced septic shock, zymosan-induced vascular
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failure, a non-septic model of multiple organ dysfunction as well as
collagen-induced arthritis. This indicates that PARP-1 has a vital role in
inflammatory disorders (17). PARP-1 has been suggested to act as a
promoter-specific coactivator of NF-B in these inflammatory disor-
ders (18). Indeed, up-regulation of subsets of inflammatory mediators
such as TNF, IFN, and iNOS was shown to be impaired in PARP-
1(/) mice upon treatment with LPS, zymosan, or streptozotocin (17,
19). We recently presented evidence that PARP-1 can act as a coactiva-
tor of NF-B in vivo (18). Neither the nuclear translocation nor the
DNA binding ability of NF-B was affected in PARP-1(/) cells (18).
However, PARP-1 directly interacted with both subunits of NF-B (p65
and p50) in vitro and in vivo (18, 20). Remarkably, the enzymatic activity
of PARP-1 was not required for full activation of NF-B in response to
various stimuli in vivo (20). In addition, PARP-1 directly interacted with
p300 and synergistically coactivated NF-B-dependent transcription
(8). Tulin and Spradling (21) recently found that Drosophila mutants
lacking normal PARP-1 levels display immune defects similar to mice
lacking the NF-B subunit p50. Their results imply that the role of
PARP-1 in NF-B-dependent gene expression during immune
responses has been conserved during evolution.
Because NF-B-dependent gene expression requires post-transla-
tional modifications (22), we decided to test whether the coactivator
activity of PARP-1 might also be regulated by post-translational modi-
fications. We show here that PARP-1-dependent gene expression not
only requires the enzymatic activity of p300/CBP but also that PARP-1
itself is acetylated in vivo in response to inflammatory stimuli. Acetyla-
tion sites weremapped in vitro and in vivo to Lys-498, Lys-505, Lys-508,
Lys-521, and Lys-524. Furthermore, acetylation of PARP-1 at these
lysines is required for the interaction with p50 and the transcriptional
activation of NF-B in response to inflammatory stimuli. Interestingly,
the synergistic coactivation of PARP-1, p300, and also the Mediator
complex was dependent on acetylation of PARP-1. Moreover, PARP-1
interacted with and is potentially deacetylated in vivo by class I HDACs.
PARP-1-dependent transcriptional activation of NF-B was negatively
regulated by HDACs 1–3 in vivo. Together, these results support the
hypothesis that acetylation of PARP-1 is important for its role as tran-
scriptional coactivator and that the different physiological functions of
PARP-1 might be in general regulated by post-translational modifica-
tions in a stimulus-dependent manner.
MATERIALS ANDMETHODS
Reagents—Recombinant TNF was obtained from R&D Systems.
Phorbol esters andmouse interferon-was purchased from Sigma. LPS
(Escherichia coli, O26:B6) prepared by phenol extractionwas purchased
from Sigma and prepared as dispersed sonicate in endotoxin-free water
before diluting to a final concentration in supplemented media. Nonfat
dry milk was obtained fromMigros (Switzerland). Nitrocellulose mem-
branes were purchased fromOsmonics Inc. Tosyl-activated Dynabeads
were purchased from Dynal Biotech GmbH.
Plasmids—GST-PARP-1 and GST-p50 full-length expression vec-
tors, CMV-PARP-1, and CMV-p300 expression vectors were described
in Hassa et al. (8) and Covic et al. (16). The CMV expression vectors for
the different Mediator subunits were generated by PCR or were a gen-
erous gift from Dr. L. Freedman (Merck Research Laboratories, West
Point, NY). The CMV expression vectors for Myc-tagged HDACs 1–3
were created by PCR. The CMV expression vectors for FLAG or hem-
agglutinin-tagged HDAC 4–6 were kind gifts from Dr. S. L. Schreiber
(Harvard University, Cambridge, MA). The expression vectors for
CDK8/cyclin C and subunits of TFIID and TFIIF were kind gifts from
Dr. M. Otsuka (University of Tokyo, Japan), Dr. Z. F. Burton (Michigan
StateUniversity, East Lansing,MI), andDr.G.Napolitano (University of
Naples “Frederico II,” Naples, Italy). NF-B-dependent luciferase
reporter constructs for MIP-2 (MIP-2 (531/wt and MIP-2 (-531/
mutB)-Luc) and iNOS (iNOS (1485/31wt)-Luc and iNOS(1485/
31-mutB)-Luc) were generous gifts from Dr. H.-J. Kwon, (Yonsei
University, Seoul, Korea) and Dr. M. A. Perrella (Harvard School of
Public Health, Boston, MA) and are described in Perrella et al. (23) and
Kim et al. (24). pphRSV-nt--galactosidase is described in Hassa et al.
(20). The baculovirus for CDK8 and cyclin C was a generous gift from
Dr. R. Pinhero (University of Guelph, Ontario, Canada) (25). The bacu-
lovirus for human p300 and mouse CBP was a generous gift from Dr.
W. L. Kraus (Cornell University, New York) and Dr. D. Thanos (Insti-
tute of Molecular Biology and Genetics, Alexander Fleming Biomedical
Sciences Research Center, Athens, Greece). The baculovirus for
PARP-1 full-length and different domains were created by PCR using
the PAK-8/9 system (BD Biosciences). GST-fusion expression vectors
for different domains of PARP-1 were created by PCR. The PARP-1
mutant constructs were obtained by site-directedmutagenesis and con-
firmed by sequencing.
Mice Breeding Conditions, Cell Culture, and Transient Trans-
fections—129S/EV-PARP-1(/) and 129S/EV-PARP-1(/) mice
were bred under specified pathogen-free conditions. The initial 129S/
EV-PARP-1(/) and 129S/EV-PARP-1(/) mice breeding pairs
were a kind gift from Dr. Z. Q. Wang (26) (International Agency for
Research on Cancer, Lyon, France). Primary macrophage cells were
isolated from fresh littermates of 129S/EV-PARP-1(/) and 129S/
EV-PARP-1(/) mice (20, 26) according to an isolation procedure
described in Petrilli et al. (19), and human monocyte/macrophage-like
THP-1 cells and Jurkat-T cells were grown in Hepes-buffered RPMI-
Glutamax-I (Invitrogen) containing 10% fetal calf serum U. S.-certified
(Invitrogen) and supplemented with 50 units/ml penicillin, 50 g/ml
streptomycin (Invitrogen), 1 mM sodium pyruvate, 0.05 mM -mercap-
toethanol, and minimum Eagle’s medium-nonessential amino acids.
Primary mouse fibroblast cells were grown in Hepes-buffered Dulbec-
co’s modified Eagle’s medium-Glutamax-I (Invitrogen) containing 4.5
g/liter glucose, 10% fetal calf serumU. S.-certified (Invitrogen) and sup-
plemented with 50 units/ml penicillin, 50 g/ml streptomycin (Invitro-
gen), 1 mM sodium pyruvate, 0.05 mM -mercaptoethanol, and mini-
mum Eagle’s medium-nonessential amino acids. HEK293 cells were
grown in Hepes-buffered Dulbecco’s modified Eagle’s medium-Glu-
tamax-I (Invitrogen) containing 4.5 g/liter glucose and 10% fetal calf
serum U. S.-certified (Invitrogen) and supplemented with 50 units/ml
penicillin, 50 g/ml streptomycin (Invitrogen), and minimum Eagle’s
medium-nonessential amino acids. For luciferase reporter assays, cells
were grown in 24- or 48-well dishes. Cells were transfected using cal-
cium phosphate or polyethyleneimine procedures (as described in Refs.
27–30) except that primary cells were grown for 12 h in RPMI medium
containing 2% fetal calf serum before stimulation with TNF or LPS/
IFN. The amount of DNA indicated in the figure legends was calcu-
lated for 10 ml of medium. Total amounts of DNA and equal molar
ratios of promoters were kept constant in all set-ups by using empty
vectors. For primary cells only cell passages 1–4 were used for transfec-
tion experiments. Because of differences in transfection efficiencies, an
expression plasmid of -galactosidase (pph-RSV-nt--Gal) was
co-transfected as a transfection efficiency control, and luciferase activ-
ities were normalized based on -galactosidase activity. Luciferase
activity wasmeasured as previously described in Hottiger et al. (27). For
further experimental procedures see the supplemental material.
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FIGURE 1. PARP-1 is acetylated upon stimulation in vivo and requires the enzymatic activity of p300 for full NF-B-dependent transcriptional activity. A, primary PARP-
1(/) or PARP-1(/) macrophages were treated with LPS (0.1 g/ml) as indicated, and the expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT), glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), andNF-B-dependent genes KC,MIP-2, iNOS, IB and interleukin-6 (IL-6) was assessed by reverse transcription-PCR. B, equal amounts
of total cell extracts fromprimary PARP-1(/) and PARP-1(/) lung fibroblasts or primary PARP-1(/) and PARP-1(/) macrophageswere resolved by SDS-PAGE followed by
immunoblot analysis using anti-p300, anti-PARP-1, anti-PCAF, or anti--tubulin antibodies. C andD, primary PARP-1(/) macrophages were cotransfectedwith RSV-nt--Gal (300
ng), expression vectors for PARP-1 (2g), andwild type (WT) or an enzymaticmutant (Mut) of p300 (2g) alongwith a luciferase reporter under the control of the endogenousMIP-2
(1g)or iNOS (3g)promoters; cellswere subsequently treated for 4hwithTNF (10ng/ml) or LPS/IFN (0.05g/ml/100units) in the simultaneouspresenceor absenceof lowdoses
of deacetylase inhibitors (10 nM TSA/200MNAM). Cellswere harvested 24h after transfection, andNF-B-dependent gene expressionwas determined. The indicated activationwas
determined by the ratio of the relative luciferase activitymeasured for the promoters containingwild type B sites (black bars) or mutB sites (white bars) after stimulation. The ratio
PARP-1 Is Acetylated by p300/CBP
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RESULTS
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-B-
dependent Transcriptional Activity and Is Acetylated in Vivo by p300/
CBP upon Stimulation—Because the coactivator activity of PARP-1 for
NF-B-dependent gene expression is dependent on the stimuli and cell
type (17), we first tested which NF-B-dependent genes are impaired in
freshly isolated primary PARP-1(/) macrophages. Primary PARP-
1(/) or PARP-1(/) macrophages were treated with LPS as indi-
cated, and the expression of NF-B-dependent genes was assessed by
reverse transcription-PCR (Fig. 1A). The experiments revealed that
LPS-induced levels of KC, MIP-2, and iNOS were impaired in PARP-
1(/) cells (Fig. 1A). The expression of IB and interleukin-6 (IL-6)
was not reduced (Fig. 1A), indicating that only a subset of NF-B-de-
pendent genes requires PARP-1 for gene induction in these cells. Similar
results were obtained when cells were stimulated with TNF (data not
shown). To confirm that the expression levels of histone acetyltrans-
ferases are not reduced in primary PARP-1 (/) cells, we tested the
protein levels of p300 and PCAF by immunoblot analysis using anti-
PARP-1, anti-p300, or anti-PCAF antibodies. The endogenous protein
levels of p300 and PCAF were not impaired in freshly isolated primary
PARP-1(/) lung fibroblast or macrophage cells (Fig. 1B).
PARP-1 and p300/CBP were shown to form a complex and function
synergistically to enhance NF-B-mediated gene expression (8). To test
whether the synergistic coactivation of NF-B-mediated transactiva-
tion by PARP-1 and p300/CBP might require the enzymatic activity of
p300/CBP, we transfected PARP-1(/) cells with expression vectors
for PARP-1 and wild type or an enzymatic mutant of p300 along with a
luciferase reporter under the control of the endogenousMIP-2 or iNOS
promoters, shown to be PARP-1-dependent. Cells were subsequently
treated with TNF or LPS/IFN in the simultaneous presence or
absence of low doses of deacetylase inhibitors (TSA and nicotinamide
(NAM)) (Fig. 1, C andD). Coexpression of wild type p300 with PARP-1
in PARP-1(/) cells resulted in a highly synergistic enhancement of
transcription regulated from both MIP-2 and iNOS promoters upon
stimulation (Fig. 1, C andD). However, the cooperativity between p300
and PARP-1 was severely impaired when an enzymatic mutant of p300
FIGURE 1—continued
obtained for untreated cells was arbitrarily set to 1. Error bars indicate S.E. of three independent experiments. E and F, primary PARP-1(/) and PARP-1(/) macrophages were
repeatedly transfected with scrambled- or p300-siRNA targeting vector DNA (30 g) as indicated and then transfected and treated as indicated and described in D. The indicated
activation was determined as described in D. G, equal amounts of total cell extracts from primary macrophages repeatedly transfected with scrambled- or p300-siRNA targeting
vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti- -tubulin antibodies. H, THP-1 or Jurkat-T cells were treated
as indicated with LPS (0.2g/ml) or phorbol ester (10 nM) and simultaneously with or without deacetylase inhibitors (100 nM TSA/400M NAM) for 30 min. PARP-1 was immunopre-
cipitated (IP) under high salt conditions from nuclear extracts, and the presence of acetylated forms of PARP-1 was subsequently tested by immunoblot analysis using anti-AcK or
anti-PARP-1 antibodies. PMA, phorbol 12-myristate 13-acetate. I, left panel, 293 cells were repeatedly transfectedwith scrambled-, p300-, or CBP-siRNA targeting vector DNA (30g)
and treated as indicated. PARP-1was immunoprecipitated under high salt conditions fromnuclear extracts, and the presence of acetylated forms of PARP-1was subsequently tested
by immunoblot analysis using anti-AcK or anti-PARP-1 antibodies. Right panel, equal amounts of total cell extracts from 293 cells repeatedly transfected with scrambled- or
p300-siRNA targeting vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti- -tubulin antibodies.
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was coexpressed. The most striking differences between wild type and
the enzymatic mutant of p300 were observed in the presence of low
doses of deacetylase inhibitors (Fig. 1, C and D). The same transfection
experiments with a reporter gene under the control of mutated B sites
revealed that the observed cooperative effect of p300 and PARP-1 was
mainly NF-B-specific (Fig. 1, C and D). To further confirm these
FIGURE 2.PARP-1 is acetylated in vitroand in vivoat Lys-498, Lys-505, Lys-508, Lys-521, andLys-524byp300/CBPuponstimulation.A, recombinantpurified full-lengthPARP-1was
incubatedwith recombinant purified full-length p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. B, baculo-purified
PARP-1 fragments corresponding to aminoacids (aa) 1–214, 215–372, 373–525, 525–656, or 657–1014were incubatedwith recombinant purified full-lengthp300orCBP in thepresenceof
radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. C, recombinant purified full-length PARP-1 wild type and two mutant forms of PARP-1; mutKTR
(K498R/K521R/K524R)andmutKQR(K498R/K505R/K508R/K521R/K524R)were incubatedwith recombinantpurified full-lengthp300orCBP in thepresenceof radioactive labeledacetyl-CoA
and resolved by SDS-PAGE followed by autoradiography.D, Myc-tagged PARP-1wild type (WT) ormutantmutKQRwere overexpressed in 293 cells and treated as indicatedwith TNF (10
ng/ml) and/or deacetylase inhibitors (100 nM TSA/400M NAM) for 30min. Myc-tagged PARP-1 wild type ormutantmutKQRwas then immunoprecipitated (IP) under high salt conditions
fromnuclear extracts of 293 cells, and thepresenceof acetylated formsof PARP-1was subsequently testedby immunoblot analysis (IB) usinganti-AcKor anti-PARP-1 antibodies. E, the same
experimentswere repeated in the presence of increasing amounts of overexpressed p300. Immunoblot of p300 input is shown in the upper panels
PARP-1 Is Acetylated by p300/CBP
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results, the same experiments were repeated in the presence of different
p300-siRNA targeting vectors (Fig. 1, E and F). These experiments
revealed that the presence of endogenous p300 is required for PARP-1-
dependent coactivation of NF-B-dependent gene expression (Fig. 1, E
and F). Together these results indicate that the enzymatic activity of
p300/CBP is required for NF-B-dependent transactivation of extra-
chromosomal templates upon treatment with inflammatory stimuli.
p300 and CBP are known to modify a variety of proteins, such as
histones and transcription factors (31). To investigate whether endog-
enous PARP-1 itselfmight be acetylated by p300/CBP in vivo, we immu-
noprecipitated endogenous PARP-1 under high salt conditions from
nuclear extracts of THP-1 or Jurkat-T cells upon treatment with the
indicated stimuli (LPS or TNF) in the simultaneous presence or
absence of deacetylase inhibitors (Fig. 1H, left and right panels). Possible
acetylation of PARP-1 was analyzed by immunoblot analysis using an
anti-AcK antibody. Endogenous PARP-1 was acetylated in vivo only in
the presence of deacetylase inhibitors upon stimulation of these cells
(Fig. 1H, left and right panels). Next we tested whether the observed
acetylation of PARP-1 is dependent on p300/CBP. 293 cells were
cotransfected with a control-siRNA vector and/or different siRNA tar-
geting vectors for p300 or CBP. Endogenous PARP-1 was immunopre-
cipitated under high salt conditions from nuclear extracts of 293 cells
upon treatment with TNF in the presence of deacetylase inhibitors
(Fig. 1H, left and right panels). These results revealed that endogenous
PARP-1 was only acetylated in vivo upon stimulation in presence of
endogenous p300 or CBP (Fig. 1I).
PARP-1 Is Acetylated by p300/CBP in Vitro and in Vivo at Lys-498,
Lys-505, Lys-508, Lys-521, and Lys-524—Next, we tested whether
PARP-1 can be acetylated by p300 or CBP in vitro. Recombinant-puri-
fied full-length PARP-1 was incubated with recombinant-purified full-
length p300 or CBP in the presence of radioactive labeled acetyl-CoA
and resolved by SDS-PAGE followed by autoradiography analysis (Fig.
2A). PARP-1 was strongly acetylated in vitro by p300 or CBP (Fig. 2A).
To map the domains within PARP-1 subjected to acetylation by p300
and CBP, the same in vitro acetylation assay was repeated with different
PARP-1 fragments corresponding to amino acids 1–214, 215–372, 373–
525, 525–656, or 657–1014. These experiments revealed that p300 and
CBP strongly acetylated the PARP-1 domain corresponding to amino
acids 373–525 (Fig. 2B, left and right panels). Interestingly, a longer
autoradiography exposure revealed that the domain corresponding to
amino acids 1–214 of PARP-1 and to the small product of caspase
cleaved PARP-1, was weakly acetylated by p300 or CBP (supplemental
information and data not shown). The physiological relevance of this
finding is currently under investigation. To identify the lysines acety-
lated by p300/CBP within PARP-1, recombinant purified full-length
PARP-1 was acetylated in vitro by p300 full-length and analyzed by
microcapillary reverse-phase high performance liquid chromatography
nanoelectrospray tandem mass spectrometry. Lys-498, Lys-505, Lys-
508, Lys-521, andLys-524were identified as strong candidates for acety-
lation. To confirm that these lysines are the main acceptor sites, full-
length PARP-1 wild type or two PARP-1 mutant forms, mutKTR
(K498R/K521R/K524R) and mutKQR (K498R/K505R/K508R/K521R/
K524R) were incubated with p300 or CBP in the presence of radioactive
labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiog-
raphy analysis (Fig. 2C). These experiments confirmed that only the
PARP-1 mutant harboring all five mutated lysines was no longer acety-
lated in vitro by p300 and CBP (Fig. 2C). To investigate whether these
lysines are also themain acceptor sites for acetylation in vivo by p300,we
immunoprecipitated Myc-tagged PARP-1 wild type or mutant mut-
KQR under high salt conditions from nuclear extracts of 293 cells upon
treatment with the indicated stimuli in the presence or absence of
deacetylase inhibitors (Fig. 2D). The presence of acetylated forms of
PARP-1was tested by immunoblot analysis using an anti-AcK antibody.
PARP-1 was acetylated in vivo at Lys-498, Lys-505, Lys-508, Lys-521,
and Lys-524 in the presence of deacetylase inhibitors upon stimulation
(Fig. 2D, also see the supplemental information). The same experiments
performed in the presence of increasing amounts of overexpressed p300
suggested that these lysines are acetylated in vivo by p300 (Fig. 2E).
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Is Required in Vivo for Full NF-B-dependent Transcriptional
Activity—To directly test whether acetylation of PARP-1 is required for
NF-B-dependent transcriptional activity in vivo, we transfected PARP-
1(/) cells with expression vectors for p300 and PARP-1 wild type or
mutant mutKQR along with a luciferase reporter under the control of
the endogenous MIP-2 or iNOS promoters. Cells were subsequently
treated with the indicated stimuli (TNF or LPS/IFN) in the simulta-
neous presence or absence of low doses of deacetylase inhibitors (Fig. 3,
A and B). Coexpression of wild type p300 and wild type PARP-1 in
PARP-1(/) cells caused a highly synergistic enhancement of tran-
scription regulated from both MIP-2 and iNOS promoters upon stim-
ulation (Fig. 3, A and B). However, the cooperativity between p300 and
PARP-1 was severely impaired when the PARP-1 mutant mutKQR was
coexpressed. The most striking differences between PARP-1 wild type
and the mutant mutKQR were observed in the presence of low doses of
deacetylase inhibitors. The same transfection experiments with a
reporter gene under the control of mutated B sites revealed that the
observed induction was mainly NF-B-specific (Fig. 3, A and B; and
supplemental information).
Pavri et al. (32) have very recently shown that PARP-1 can associate in
vivo with the Mediator. Therefore, we repeated the same transfection
experiments in the presence of overexpressed subunits of the Mediator
complex. Coexpression of PARP-1 wild type, p300, and Mediator sub-
units inPARP-1(/) cells causedasynergisticenhancementofNF-B-
dependent transcription, whereas no synergistic enhancement was
observed when the mutant form of PARP-1, mutKQR, was coexpressed
(Fig. 3, C and D), indicating that acetylation of PARP-1 is also required
for the transcriptional cooperativity between p300/CBP, Mediator, and
PARP-1 on these promoters.
PARP-1 Interacts in Vivo with the Mediator Complex and in Vitro
Directly with the Mediator Subunits CDK8 and DRIP150—To further
confirm these data and to investigate whether CDK8 or other subunits
of the Mediator complex might directly interact with PARP-1, we first
coexpressed tagged forms of different Mediator subunits in 293 cells
(Fig. 4A). Immunoprecipitation experiments using an anti-PARP-1
antibody revealed that PARP-1 interacted with the whole Mediator
complex (Fig. 4A). Next, we repeated these experiments with primary
macrophages (Fig. 4B). These experiments revealed that endogenous
PARP-1 could indeed interact with the endogenous Mediator complex
under physiological conditions (Fig. 4B). DNAdid notmediate the asso-
ciation of PARP-1 with the Mediator in the nucleus since the presence
of ethidium bromide or DNase I did not affect PARP-1/Mediator inter-
action (data not shown). Surprisingly, whereas the interaction of
PARP-1 with the core Mediator module was increased upon stimula-
tion, the interaction of PARP-1 with CDK8 was decreased (Fig. 4,A and
B). CDK8 is thought to act mainly as a repressor sub-module of the
Mediator complex (32).
Because these results strongly suggested that PARP-1 would directly
interact with at least one of theseMediator subunits, recombinant puri-
fied GST-PARP-1 full-length was bound to glutathione beads followed
by incubation with in vitro translated and radioactive-labeled Mediator
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subunits as indicated in Fig. 4C. After extensive washes, bound proteins
were resolved by SDS-PAGE followed by autoradiography analysis for
Mediator subunits. PARP-1 directly bound to CDK8 and MED14,
although to a low extent, but not to the other tested subunits (Fig. 4C).
We next tested whether PARP-1 might also directly interact with other
components of the RNA polymerase II machinery. Recombinant puri-
fied HMG(YI), CDK8, cyclin C, TFIIF/RAP74, TFIIF/RAP30, TATA
box-binding protein (TBP), and TBP-associated factors fused to GST
were bound to glutathione beads followed by incubation with recombi-
nant baculo-purified PARP-1 (Fig. 4D, left and right panels). After
extensivewashes, bound proteins were resolved by SDS-PAGE followed
by immunoblot analysis for PARP-1. PARP-1was able to bind directly to
HMG(YI), CDK8, and TFIIF/RAP74 but not to the other factors tested
(Fig. 4D, left and right panels).
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Stabilizes the Interaction of PARP-1 with p50—To investigate
whether acetylation of PARP-1 mechanistically influences protein-pro-
tein interactions, we first tested which of the interaction partners asso-
ciates with the acetylated domain of PARP-1. Different domains of
PARP-1 fused to GST were bound to glutathione beads and incubated
with purified p300, PARP-1, CDK8/cyclin C, p65, p50, TFIIF/RAP74 or
in vitro transcribed/translated and radioactive-labeledMED14 (Fig. 5,A
and B). After extensive washes, bound proteins were resolved by SDS-
PAGE followed by immunoblot analysis with the indicated antibodies
(Fig. 5A) or autoradiography (Fig. 5B). p300, PARP-1, CDK8, p65, p50,
TFIIF/RAP74, and MED14 bound to different domains of PARP-1 as
schematically drawn in Fig. 5C. PARP-1 interacted with a region
between amino acids 1 and 214 as well as between amino acids 465 and
FIGURE3.AcetylationofPARP-1 is required forNF-B-dependent transcriptionand for the transcriptional cooperativitybetweenPARP-1, p300/CBP, andMediator in vivo.
A and B, primary PARP-1(/) macrophageswere cotransfectedwith RSV-nt--Gal (300 ng), expression vectors for p300 (2g), and PARP-1wild type (WT) ormutantmutKQR (2g)
along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (A) or iNOS (3 g) (B) promoters; cells were subsequently treated for 4 h with TNF (10 ng/ml) or
LPS/IFN (0.05g/ml/100units) in the simultaneouspresenceor absenceof lowdoses of deacetylase inhibitors (10nMTSA/200MNAM). Cellswereharvested24hafter transfection,
and NF-B-dependent gene expression determined as described in Fig. 1C. C andD, primary PARP-1(/) macrophages were cotransfected with RSV-nt--Gal (300 ng), expression
vectors for p300 (2 g), MED-1 (2.5 g), MED-7 (0.4 g), MED-14 (2 g), MED-15 (1.1 g), MED-17 (0.75 g), MED-23 (1.5 g), MED-24 (1 g), and PARP-1 wild type or mutant
K498R/K505R/K508R/K521R/K524R ((mutKQR) (2 g) along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (C) or iNOS (3 g) (D) promoters; cells were
subsequently treated for 4 h with TNF (10 ng/ml) or LPS/IFN (0.05 g/ml/100 units) in the simultaneous presence of low doses of deacetylase inhibitors (HDi; 10 nM TSA/200 M
NAM). Cells were harvested 24 h after transfection and NF-B-dependent gene expression was determined as described in Fig. 1C.
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FIGURE 4. PARP-1 interacts with theMediator complex in vivo and directly with theMediator subunits MED14 and CDK8 in vitro. A, Myc- or FLAG-tagged Mediator subunits
MED-1, MED-7, MED-14, MED-17, MED-23, and MED-24 were overexpressed in 293 cells and treated as indicated, and PARP-1 complexes were immunoprecipitated (IP) under
physiological salt conditions fromnuclear extracts usingananti-PARP-1 antibodyand tested for PARP-1 andMyc- or FLAG-taggedMediator subunits, p300, andCDK8by immunoblot
analysis using anti-PARP-1, anti-p300, anti-CDK8, anti-Myc, or anti-FLAG antibodies. C, control IgG; P1, anti-PARP-1. B, primary macrophages were treated as indicated with LPS (0.2
g/ml) for 1 h. PARP-1 was immunoprecipitated under physiological salt conditions from nuclear extracts, and the presence of Mediator subunits was subsequently tested by
immunoblot analysis using anti-MED1, anti-MED6 anti-TRAP150, anti-CDK8, or anti-PARP-1 antibodies. C, GST pull down assays under physiological salt conditions with PARP-1
full-length fused to GST (3 g GST fusion protein) and the indicated in vitro transcribed/translated Mediator subunits. Bound proteins were resolved by SDS-PAGE followed by
autoradiography. TheCoomassie control gel is shown in the left panel.D, GSTpull downassaysunderphysiological salt conditionswith the indicatedgeneral transcription factors and
CDK8/cyclin C fused to GST (1–4g of GST fusion protein) and baculo-purified PARP-1 (0.5g input). Bound proteins were resolved by SDS-PAGE followed by immunoblot analysis
using anti-PARP-1 antibodies (upper panel). The corresponding Coomassie control gel is shown in the lower panel. TBP, TATA box-binding protein.
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FIGURE5.AcetylationofPARP-1 stabilizes the interactionofPARP-1withp50butnotp65orPARP-1.A andB,mappingof the interactiondomains inPARP-1. ShownareGSTpull
down assays under high salt conditions with PARP-1 fragments fused to GST (1–3 g of protein) as indicated and recombinant purified p300 (2 g), PARP-1 (0.3 g), RAP74 (1 g),
CDK8 (1 g), cyclin C (0.5 g), p65 (0.5 g), and p50 (0.5 g) (A) or in vitro transcribed/translated MED14 (B). Bound proteins were resolved by SDS-PAGE followed by immunoblot
analysis with the corresponding antibodies (A) or autoradiography (B). The corresponding Coomassie control gel is shown in the lower panels. aa, amino acids. C, schematic picture
of the PARP-1 interactionmap: ZF I and ZFII, zinc finger 1 and 2;NLS, nuclear localization signal;HTH, helix turn helix domain, BRCT, C-terminal domain of a breast cancer susceptibility
protein (BRCA); WGR, central WGR motif-containing domain;PADR1, PARP regulatory domain; CC, catalytic center. D and E, acetylation-dependent interaction of PARP-1 and p50.
PARP-1 (D) or p50 (E) fused to GST (3 g/2 g) were incubated with in vitro acetylated or non-acetylated baculo-purified PARP-1 wild type (WT) or mutant form mutKQR (500 ng) in
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524 (Fig. 5C). MED14 was the only tested protein that bound to the
BRCT (carboxyl-terminal domain of a breast cancer susceptibility pro-
tein (BRCA)) domain of PARP-1. We have previously shown that p50
and p65 interact with a region between amino acids 341 and 531 of
PARP-1 (20). In addition, p50 interacted also with a region between
amino acids 1 and 140 containing the zinc finger I. Our more detailed
interaction analysis suggests that p65 would interact with a region
between amino acids 341 and 383 of PARP-1. p50 would interact with
zinc finger I or zinc finger II and with a region between amino acids 477
and 524 (Fig. 5C). Together, these experiments revealed that only the
interaction of PARP-1 with PARP-1 itself or p50might be influenced by
acetylation of PARP-1.
To test this hypothesis, recombinant purified PARP-1 or p50 fused to
GST were bound to glutathione beads and incubated with non-acety-
lated or in vitro acetylated purified PARP-1 wild type and the mutant
form mutKQR in the presence of increasing concentrations of NaCl as
indicated (Fig. 5,D and E). After extensive washes, bound proteins were
resolved by SDS-PAGE followed by immunoblot analysis for PARP-1
(Fig. 5, D and E). No significant differences between the acetylated or
non-acetylated form of PARP-1 were observed for the dimerization or
potential tetramerization of PARP-1 (Fig. 5D). Surprisingly, in vitro
acetylated PARP-1 bound significantly better to p50 than did the non-
acetylated PARP-1 (Fig. 5E). These results suggest that PARP-1 would
dimerize or potentially tetramerize through the regions between amino
acid 1 and 214 as well as between amino acid 465 and 497, whereas the
region between amino acid 477 and 524 is required for acetylation-de-
pendent interaction with p50 (Fig. 5C).
To confirm these in vitro data and to investigate whether acetylation
would influence the stimuli-dependent complex formation between
subunits of NF-B and PARP-1 in vivo, we coimmunoprecipitated the
NF-B subunits p65 and p50 from nuclear extracts upon treatment of
THP-1 with LPS in the presence or absence of deacetylase or phospha-
tase inhibitors (Fig. 5F, left and right panels) and tested the presence of
PARP-1 by immunoblot analysis using anti-PARP-1 antibodies.
Remarkably, PARP-1 bound significantly better to p65 when cells were
simultaneously treatedwith LPS and phosphatase inhibitors (Fig. 5F, left
panel), whereas p50 bound significantly better to PARP-1 upon simul-
taneous treatment with LPS and deacetylase inhibitors (Fig. 5F, right
panel). No significant differences between deacetylase or phosphatase
inhibitors were observed for the interaction between p50 and p65 (Fig.
5F, left and right panels). Taken together, these results suggest that
phosphorylation might mainly enhance the interaction between p65
and PARP-1, whereas acetylation mainly enhances the interaction
between p50 and PARP-1.
PARP-1 Interacts with Members of HDAC Class I and Is Potentially
Deacetylated by HDACs 1–3 in Vivo—Because acetylation of proteins is
known to be a reversible modification in vivo, we next tested whether
PARP-1 might physically interact with HDACs in vivo. Because of the
low quality of commercially available anti-HDAC antibodies, we
decided to perform these experiments with overexpressed Myc- or
FLAG-tagged HDACs. We coimmunoprecipitated PARP-1 complexes
from nuclear extracts of untreated 293 cells overexpressingMyc-tagged
versions of HDAC-1, HDAC-2, or HDAC-3 (Fig. 6A) and FLAG-tagged
versions of HDAC-4, HDAC-5 or HDAC-6 (Fig. 6B) and tested the
FIGURE 5—continued
presence of increasing concentrations of NaCl (125 mM NaCl, 25 mM potassium acetate to 225 mM NaCl, 25 mM potassium acetate) as indicated. Bound proteins were resolved by
SDS-PAGE followed by immunoblot analysis using a anti-PARP-1 antibody. F, acetylation and stimuli-dependent complex formation of PARP-1 and subunits of NF-B in vivo. NF-B
subunits p65 and p50were coimmunoprecipitated (IP) from nuclear extracts upon treatment of THP-1 with LPS in the presence or absence of deacetylase or phosphatase inhibitors
(left and right panels) and tested for the presence of p50, p65, and PARP-1 by immunoblot analysis using anti-p50, anti-p65, and anti-PARP-1 antibodies. C, control.
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FIGURE 6. PARP-1 interacts with members of HDAC class I and is potentially deacetylated by HDAC-1, HDAC-2, or HDAC-3 in vivo. A and B, FLAG-tagged HDACs were
overexpressed in 293 cells. PARP-1 complexes were co-immunoprecipitated (IP) from nuclear extracts of untreated 293 cells using an anti-PARP-1 (P1) antibody and subsequently
tested for PARP-1 and Myc-tagged HDAC-1, HDAC-2, or HDAC-3 and FLAG-tagged HDAC-4, HDAC-5, or HDAC-6 by immunoblot (WB) analysis using anti-PARP-1, anti-Myc or
anti-FLAGantibodies. c, control IgG.C, GSTpull downassaysunderphysiological salt conditionswithPARP-1 fused toGST (4gofprotein) and in vitro transcribed/translatedHDAC-1,
-2, -3, or -8. Bound proteins were resolved by SDS-PAGE followed by autoradiography (left panel). The corresponding Coomassie control gel is shown in the right panel. D and E,
FLAG-tagged PARP-1 wild type was coexpressed with increasing amounts of Myc-tagged HDAC-1, HDAC-2, or HDAC-3 and hemagglutinin (HA)-tagged HDAC-4 or HDAC-5 in 293
cells. 24 h later cells were simultaneously treated with TNF (10 ng/ml) and NAM (1 mM) for 30 min. FLAG-tagged PARP-1 was subsequently immunoprecipitated under high salt
conditions from nuclear extracts of 293 cells, and the presence of acetylated forms of PARP-1 was tested by immunoblot analysis using anti-AcK or anti-FLAG antibodies.
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FIGURE 7. The coactivator activity of PARP-1 is negatively regulated in vivo byHDAC-1 HDAC-2, or HDAC-3. A–F, primary PARP-1(/) macrophages were cotransfectedwith
expression vectors for RSV-nt--Gal (300 ng), PARP-1wild type (WT) ormutantmutKQR (2g), p300 (2g), HDAC-1, HDAC-2, or HDAC-3 (2.5g each) alongwith a luciferase reporter
under the control of the endogenous MIP-2 (1 g) (A–C) or iNOS promoters (3 g) (D–F); cells were subsequently treated for 4 h with TNF (10 ng/ml) or LPS/IFN (0.05 g/ml/100
units) in the simultaneous presence of low doses of deacetylase inhibitor (500 M NAM). Cells were harvested 24 h after transfection, and NF-B-dependent gene expression was
determined as described in Fig. 1C.
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presence of these HDACs by immunoblot analysis using anti-PARP-1,
anti-Myc, or anti-FLAG antibodies. Interestingly, PARP-1 interacted
with HDAC-1, HDAC-2, and HDAC-3 but not with HDAC-4,
HDAC-5, or HDAC-6 (Fig. 6, A and B). DNA did not mediate the asso-
ciation of PARP-1 withHDACs since the presence of ethidium bromide
orDNase I did not affect the interaction (data not shown). Because these
results suggested that PARP-1 would directly interact with at least one
of these HDACs, GST-PARP-1 full-length was bound to glutathione
beads and incubated with in vitro translated and radioactive-labeled
HDAC class ImembersHDAC-1, HDAC-2, HDAC-3, orHDAC-8 (Fig.
6C). After extensive washes, bound proteins were resolved by SDS-
PAGE followed by autoradiography analysis forHDACs. PARP-1 bound
directly to HDAC-1, HDAC-2, and HDAC-3 but not to HDAC-8
(Fig. 6C).
To investigate whether PARP-1 might be deacetylated by HDAC-1,
HDAC-2, or HDAC-3 in vivo, FLAG-tagged PARP-1 wild type was
coexpressed with increasing amounts of Myc-tagged HDAC-1,
HDAC-2, or HDAC-3 (Fig. 6D) and hemagglutinin-tagged HDAC-4 or
HDAC-5 in 293 cells (Fig. 6E). FLAG-tagged PARP-1 was immunopre-
cipitated from nuclear extracts under high salt conditions upon treat-
ment of cells with TNF andNAM. The presence of acetylated forms of
PARP-1 was tested by immunoblot analysis using anti-AcK or anti-
FLAG antibodies. These experiments revealed that PARP-1 might be
deacetylated in vivo byHDAC-1,HDAC-2, orHDAC-3 (Fig. 6,D andE).
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be
Negatively Regulated by HDACs 1–3 in Vivo—Next, we tested which
HDAChas the strongest influence on the transcriptional coactivator activ-
ity of PARP-1 andmight therefore also act functionally as a deacetylase for
PARP-1 in vivo. PARP-1(/) cells were cotransfected with expression
vectors for PARP-1 wild type or PARP-1 mutant form; that is, mutKQR,
p300, HDAC-1, HDAC-2, or HDAC-3 along with a luciferase reporter
under the control of the endogenousMIP-2 (Fig. 7,A–C) or iNOSpromot-
ers (Fig. 7,D–F). Cellswere simultaneously treatedwith the indicated stim-
uli (TNF or LPS/IFN) and low doses of deacetylase inhibitors (Fig. 7,
A–F). Coexpression of p300 with HDAC-1, HDAC-2, or HDAC-3 in the
absence of PARP-1 resulted in a reduced activation of NF-B-dependent
transcriptional activation (Fig. 7, A–F). No significant differences between
HDAC-1, HDAC-2, or HDAC-3 were observed in the absence of PARP-1
for eitherMIP-2 or iNOSpromoters (Fig. 7,A–F), indicating that the resid-
ual activation of NF-B in PARP-1(/) cells in the absence of PARP-1 is
equally repressed byHDAC-1, HDAC-2, or HDAC-3. Similar results were
obtained in presence of PARP-1 wild type, although the repression by
HDAC-2was weaker when comparedwithHDAC-1 andHDAC-3 (Fig. 7,
A–F). Remarkably, the repression by HDAC-1, HDAC-2, or HDAC-3 was
strongly reduced when HDAC-1 HDAC-2, or HDAC-3 was coexpressed
withPARP-1mutantmutKQR (Fig. 7,A–F). Together these results suggest
that HDAC-1, HDAC-2, and HDAC-3 might repress NF-B-dependent
transcription in part through deacetylation of PARP-1.
DISCUSSION
Growing experimental evidence suggests that PARP-1 can function
as a promoter-specific coactivator (17). PARP-1was also identified as an
interaction partner not only of NF-B but also of several sequence-
specific transcription factors and cofactors including E2F1, Oct-1, and
PC3/topoisomerase-I (17, 33) and has been shown to increase the tran-
scriptional activity of these transcription factors (17). In 1997 Meister-
ernst et al. (34) identified human PARP-1 as one active component of
the upstream stimulatory activity (USA)-derived positive cofactor com-
plex PC-1 (34). The crude precursor human USA fraction consists of
PC1/PARP-1, PC2/Mediator-like complex, PC3/topoisomerase-I, PC4/
single-stranded DNA-binding protein, PC52, PC6, and HMG2 (34, 35).
Earlier studies showed that full activation of transcription by NF-B,
Sp1, and Oct-1 in cell-free systems required a crude precursor USA
coactivator fraction in addition to general transcription factors (36).
Because PC1/PARP-1, PC3, and PC4 are all sequence-unspecific DNA-
binding proteins, it was suggested that PC1/PARP-1 provide together
with the other USA-derived positive cofactors PC3, PC4, PC52, and
HMG2 a mainly structural/architectural role in assembling and stabi-
lizing the pre-initiation complex by affecting the accessibility of RNA
polymerase II to chromatin (17, 34, 35, 37).
The aim of this study was to investigate whether the coactivator activity
of PARP-1 might be regulated by post-translational modifications such as
acetylation. We provide both biochemical and functional evidence that
acetylation of PARP-1 is required for its NF-B coactivator activity.
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-B-
dependent Transcriptional Activity—Several reports demonstrated that
coactivator activity of PARP-1 for NF-B-dependent gene expression
seems to be dependent on the stimuli and cell type (17).We observed an
impaired expression in primary PARP-1(/) macrophages of iNOS,
KC, and MIP-2 genes but not of IB and IL-6 upon stimulation with
TNF or LPS/IFN, indicating that PARP-1 acts in a promoter-specific
manner, similar to other coactivators of NF-B such as CARM1 (16).
PARP-1 and p300/CBP were shown to form a complex and function
synergistically to enhance NF-B-mediated gene expression (8). More-
over, we recently provided evidence that the enzymatic activities of
p300/CBP and protein argininemethyltransferase CARM1 are required
for NF-B-dependent gene expression in vivo (16). NF-B-dependent
reporter gene analysis using the PARP-1-dependent MIP-2 and iNOS
promoters revealed that the cooperativity between p300 and PARP-1
was severely impaired when an enzymatic mutant of p300 was coex-
pressed, indicating that the enzymatic activity of p300/CBP is required
for NF-B-dependent transactivation of PARP-1-dependent promoters
upon treatment with inflammatory stimuli.
PARP-1 Is Acetylated in Vivo at Lys-498, Lys-505, Lys-508, Lys-521,
and Lys-524 by p300/CBP upon Stimulation—Growing experimental
evidence has accumulated that NF-B-dependent gene expression is
also regulated by post-translational modifications such acetylation (22).
This acetylation-dependent regulation was shown to occur at multiple
levels (38). Acetylation of histones regulates theNF-B-dependent gene
accessibility (22). Moreover, direct acetylation of the NF-B subunits
p65 and p50 was shown to regulate transcriptional activation of NF-B
(39–41). Finally, other acetylation eventswere suggested to temporarily
modulate the duration of NF-B presence in the nucleus and DNA
binding activity as well as protein-protein interactions with several
cofactors involved in the transcriptional activity of NF-B (22, 38). It
was recently reported that the USA-derived positive cofactor PC4 is
specifically acetylated by p300, thereby stimulating its double-stranded
DNA binding activity which correlates with its coactivation activity (42,
43). Here we show that PARP-1 is acetylated in vitro and in vivo by p300
and CBP. Combined analysis by microcapillary reverse-phase high per-
formance liquid chromatography nanoelectrospray tandemmass spec-
trometry and coexpression of p300/CBP and PARP-1 wild type or
mutant revealed that PARP-1 is acetylated in vivo at Lys-498, Lys-505,
Lys-508, Lys-521, and Lys-524 by p300/CBP upon stimulation. In vitro
acetylation experiments using purified recombinant PARP-1 wild type
or mutant forms supported these in vivo observations.
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Is Required for NF-B-dependent Transcriptional Activity in
Vivo—The importance of PARP-1 acetylation for NF-B-dependent tran-
scription is supported by complementation experiments in primary PARP-
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1(/)macrophages using the PARP-1mutantmutKQR (K498R/K505R/
K508R/K521R/K524R). Full synergistic enhancement of transcription
regulated from the MIP-2 and iNOS promoters was obtained only when
PARP-1 wild type was coexpressed with p300 in PARP-1(/) macro-
phages. The observed residual cooperative effects in the presence of
mutatedBsites on thepromotermost likely reflect the coactivator activity
of PARP-1 on other sequence-specific transcription factors such as activa-
tor protein-1, Sp-1,Oct-1, interferon regulatory factors, or signal transduc-
ers and activators of transcription (STATs), which are also important for
full activity of NF-B on these promoters (24, 44–46). Several recent
reports provided evidence that PARP-1 might also act as a coactivator of
AP-1 and STATs (47–49). Interestingly, the observed differences between
PARP-1 wild type and mutant mutKQR regarding the co-operativity of
p300 and PARP-1 were less significant in experiments using reporter plas-
midswithmutatedBsites, suggesting that acetylationofPARP-1mightbe
mainly required for the NF-B-dependent promoter activity. However, it
remains to be further investigated whether acetylation of PARP-1 could
also strongly influence other sequence-specific transcription factors or
cofactors under certain conditions. Remarkably, coexpression of PARP-1
wild type or mutant mutKQR with p300 andMediator subunits in PARP-
1(/) macrophages demonstrated that acetylation of PARP-1 is also
required for the transcriptional cooperativity between p300/CBP, Media-
tor, and PARP-1 on these promoters. Recent reports showed that ARC/
Mediator interacts with the transactivation domain of p65 and enhances
chromatin-dependent transcriptional activation by p65 in vitro (50). The
Mediator complex is thought to provide the penultimate step in the activa-
tion process by bridging a given activator to RNA polymerase II and form-
ing a scaffold onto which RNA polymerase II and general transcription
factors can assemble and initiate transcription (51). Based on themultistep
interaction model of transcriptional activation proposed by Roeder and
co-workers (51), it was suggested that PC1/PARP-1 might facilitate
togetherwith other structural/architectural positive cofactors the co-oper-
ative interactions between sequence-specific activators and different coac-
tivator complexes such as p300/CBP and Mediator, thereby providing an
architectural function in stabilizing the pre-initiation complex (17). In our
current studiesweprovidedevidence thatPARP-1 interacts in vivowith the
Mediator complex under physiological conditions. Furthermore, PARP-1
directly interacted in vitrowith the Mediator subunits MED14 and CDK8
aswell as theTFIIF subunit RAP74but notwithTFIIB,TATAbox-binding
protein (TBP) and the testedTBP-associated factors. These results are con-
sistent with the observation ofMeisterernst et al. (34) that in “in vitro tran-
scription” assays, PARP-1 is only required during assembly of RNApolym-
erase II andgeneral transcription factorsonpreformedTFIID-TFIIA-DNA
complexes (34). In these studies PARP-1 was unable to stimulate the for-
mation of a TFIID-promoter complex. In addition, PARP-1 stimulated
transcription only when added before the complete pre-initiation complex
was formed,which implies that PARP-1might only functionduring assem-
bly of the pre-initiation complex (34).
Whether acetylation of PARP-1 might regulate the PARP-1 activity at
this level in the context of chromatin remains to be investigated. However,
it seems unlikely since theMediator subunits DRIP150 and CDK8 did not
bind to the acetylated domain in PARP-1. Surprisingly, acetylation of
PARP-1 regulates the stimuli-dependent interaction of PARP-1 with
NF-B1 subunit p50 but not p65. Because the acetylationmutantmutKQR
of PARP-1 could still partially coactivate NF-B, acetylation of PARP-1
might be mechanistically required for the stabilization of preformed
PARP-1 containing transcriptional coactivator-cofactor complexes.
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be
Negatively Regulated in Vivo by HDACs 1–3—Overexpression of
HDAC-1, HDAC-2, and HDAC-3 was shown to repress NF-B-de-
pendent transcription upon treatment with inflammatory stimuli (22,
38, 41). HDAC-3 was shown to be required for the deacetylation of p65
(52). HDAC-1, HDAC-2, and HDAC-3 interact directly with several
proteins involved in the NF-B signaling pathway, including NF-B
itself (22, 52, 53). Interestingly, PARP-1 formed a complex with
HDAC-1, HDAC-2, or HDAC-3 in the nucleus but not with HDAC-4,
HDAC-5, or HDAC-6. The direct interaction in vitro between PARP-1
and HDACs 1–3 was weak and might be very transient or regulated in
vivo by other unidentified post-translational modifications. Subsequent
in vivo deacetylation experiments with increasing amounts of overex-
pressed HDACs suggested that deacetylation of PARP-1 in vivo might
be mediated by HDAC-1, HDAC-2, or HDAC-3. Transient reporter
assays revealed that the PARP-1-dependent transcriptional activity of
NF-B is negatively regulated in vivo by HDAC-1, HDAC-2, or
HDAC-3. Because transiently transfected plasmids seemnot to be prop-
erly chromatinized, nucleosomal histones are unlikely to represent the
only relevant substrates whose lysine acetylation is required for NF-B-
dependent transcription. Remarkably, when HDAC-1, HDAC-2, or
HDAC-3 was co-expressed with PARP-1 mutant mutKQR, no signifi-
cant additional promoter-specific decrease in NF-B-dependent tran-
scription was obtained. These results suggest that HDAC-1, HDAC-2,
and HDAC-3might deacetylate promoter-bound PARP-1 or other uni-
dentified cofactors or coactivators dependent on acetylation of PARP-1.
Interestingly, several recent reports demonstrated that inhibition of
HDACs could selectively suppress transcription in a gene-specific manner
by inducing an elongational arrest and/or premature termination between
exons 1 and 2 (54–57). Thus, in the context of chromatin, it might be that
for at least a subset of NF-B-dependent genes, deacetylation of NF-B
itself or of coactivators involved in the nuclear activity of NF-B, such as
PARP-1, could be required for transcriptional elongation or re-initiation.
For at least a subset of PARP-1-dependent NF-B target genes, both the
enzymatic activities of p300 and acetylation of PARP-1 are required for
transcriptional activity. However, the exact molecular mechanism by
which acetylationofPARP-1 regulates the coactivator activity of PARP-1 in
the context of chromatin remains to be investigated. In addition,we cannot
exclude the possibility that other histone acetyltransferasesmight acetylate
PARP-1 on other lysine residues and thereby influence its activities.
Whether p65 or other sequence-specific transcription factors known to
cooperate with NF-B in gene induction could regulate the acetylation of
PARP-1 is currently under investigation.
Taken together, these results support the hypothesis that the differ-
ent physiological functions of PARP-1 are regulated by post-transla-
tional modifications such as acetylation in a stimuli-specific manner.
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Results 
 
6 Unpublished results 
6.1  MYBBP1a cellular localisation 
6.1.1 Introduction and Aim 
Section  5.2 shows that MYB binding protein 1a (MYBBP1a) represses NF-κB 
dependent transcription despite the fact that myc-MYBBP1a localises mainly to the 
nucleoli in non-stimulated Jurkat cells. The nucleolar localisation of MYBBP1a raises 
the question as to how MYBBP1a can repress nucleoplasmic RelA(p65) dependent 
transcription. It is possible that the small amount of MYBBP1a seen diffusely in the 
nucleus is the pool of MYBBP1a responsible for the observed repression. It is also 
possible that MYBBP1a could function by sequestration of RelA(p65) in the 
nucleolus. Repression of RelA(p65) by nucleolar sequestration has been shown 
previously [234]. Therefore, the localisation of MYBBP1a in the nucleolus may be 
important for its function. In 293T cells, flag tagged MYBBP1a was shown to be able 
to shuttle from the nuclear/nucleolus to the cytoplasm [235]. The aim of this work 
was to determine whether NF-κB activating signals could regulate the localisation of 
MYBBP1a in Jurkat cells.  
6.1.2 Result 
In order to investigate whether NF-κB activating signals could regulate the 
localisation of MYBBP1a immunoflorescence was performed in Jurkat T cells. Due 
to the lack of MYBBP1a specific antibodies appropriate for detection of endogenous 
MYBBP1a by immunoflourescence, myc tagged MYBBP1a was overexpressed in 
cells and detected with an anti-myc antibody as described in Section  5.2. In non-
treated cells, MYBBP1a was detected in the nucleolus (Figure 10). In cells treated 
with 17.5 nM PMA (the same concentration that was used in the transient transfection 
reporter experiments in Section  5.2) myc-MYBBP1a was localised in most 
transfected cells (85 %) in the nucleoli, with just a few cells showing myc-MYBBP1a 
cytoplasmic staining.  
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Figure 10. Detection of myc-MYBBP1a in Jurkat T cells by immunoflourescence. Myc tagged 
MYBBP1a was over-expressed in Jurkat T cells. The cells were stimulated for 1 hour with 17.5 nM 
PMA, 175 nM PMA or 30 ng/ml TNFα as indicated. Over 100 transfected cells were scored for 
nucleolar localisation, and the results are given as the % of transfected cells showing nucleolar 
staining. Bright green signals are from transfected cells, whilst the faint green signal is background. 
The experiment was repeated twice for non-stimulated and 175 nM PMA stimulated samples with 
similar results.   
 
When the cells were stimulated with 175 nM PMA, approximately 70 % of 
transfected cells showed myc-MYBBP1a localisation mainly in the nucleolus. The 
rest of the transfected cells showed myc-MYBBP1a mainly in the cytoplasm and 
some in the nucleus. The effect of another NF-κB stimuli, TNFα, on the sub-cellular 
localisation of myc-MYBBP1a was also tested. Upon 1 hour TNFα treatment, 90 % 
of the transfected Jurkat cells showed mainly nucleolar staining for myc-MYBBP1a. 
These results indicate that MYBBP1a is found mainly in the nucleolus of Jurkat cells, 
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but can also be found in other sub-cellular compartments, upon cellular stimulation.  
Stimulation of Jurkat cells with PMA, a protein kinase C activator, resulted in a small 
pool of MYBBP1a being relocated to the cytoplasm.  
6.2 PIKK family involvement in NF-κB dependent 
transcription 
6.2.1 Introduction and Aim  
We found that among other proteins, TRRAP (transactivating/transformation domain 
associated protein), ATR (ATM and rad3 related) and DNA-PKcs (DNA dependent 
protein kinase-catalytic subunit) could bind to the TAD of RelA(p65) (Section  5.1). 
These are homologous proteins of the phosphoinositide-3-kinase-related kinases 
(PIKK) superfamily. Another member of this family is ATM (Ataxia Telangiectasia). 
ATM, ATR and DNA-PKcs are serine/threonine kinases that are activated upon DNA 
damage to phosphorylate proteins involved in cell cycle progression, DNA 
replication, DNA repair and cell death (reviewed in [236], [237]). ATM and ATR can 
bind DNA directly and DNA-PKcs associates with DNA via ku80 and ku70. Upon 
DNA damage, they form foci in the nucleus together with other DNA damage 
response and effector proteins. One of these foci proteins is BRCA1, an NF-κB 
interacting protein.  
 ATM and ATR have distinct but overlapping roles. ATM is activated upon 
DNA damage caused by irradiation and other factors and is autophosphorylated 
within minutes (reviewed in [236], [237]). It is thought that it senses damaged DNA 
through recognition of aberrant chromatin structure. ATR is typically activated upon 
DNA damage caused by UV and stalled replication forks. DNA-PK is activated by 
DNA damage and is also involved in non-homologous end joining. Since DNA 
damage signalling pathways often lead to a change in gene expression, it is not 
surprising that these proteins have also been shown to have a role in transcription 
regulation. ATM binds to HDAC1 and ATR to HDAC2 and the DNA damage 
induced foci contain TFs like E2F1. All three kinases, especially DNA-PK, have been 
shown to phosphorylate p53, and activate p53 dependent apoptosis genes (reviewed in 
[238]).  
 The first indication that these proteins may be involved in the NF-κB response 
came from the observation that ionizing γ-irradiation (IR) led to activation of DNA 
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binding by NF-κB [239]. ATM was shown to be important for this pathway as cells 
lacking active ATM (AT5BIVA) showed no IR induced IκBα degradation, NF-κB 
DNA binding or activation of HIV reporter expression. Overexpression of ATM in 
these cells could rescue IκBα degradation, and IκBα was shown to be phosphorylated 
by ATM in vitro [240]. Also, protein extracts from ATM-/- mice were deficient in IR 
induced IKK activity and NF-κB DNA binding activity [241]. In the same study, 
protein extracts from DNA-PK -/- mice were not deficient in IR induced NF-κB 
binding activity. However in a different cellular system, DNA-PK was found to be 
involved in activation of NF-κB. In cells lacking active DNA-PK (M059J) IR 
irradiation did not lead to NF-κB DNA binding activity, and DNA-PK could 
phosphorylate IκBα and IκBβ in vitro [242]. The discrepancies may be due to the use 
of different cellular systems, since it is known that deficiencies in one PIKK family 
member can also affect other family members, and that the cells are chromosomally 
unstable and accumulate many mutations upon passaging. 
 The function of TRRAP is slightly different since it does not contain kinase 
activity. Instead it is a member of many HAT complexes, including SAGA, GCN5, 
P/CAF, Tip60, TFTC and STAGA complexes (reviewed in [243]).  TRRAP and its 
yeast homologue (Tra1) interact with many TFs, bridging DNA binding proteins to 
HAT complexes at various promoters. TRRAP disruption in mice leads to embryonic 
lethality [244] and many genes were found to be down-regulated in conditional knock 
out cells [245].  
 The aim of this work was to perform preliminary experiments to investigate the 
hypothesis that the direct interaction of a PIKK family member with the RelA(p65) 
TAD could lead to regulation of the transcriptional potential of NF-κB, through 
phosphorylation of RelA(p65). 
6.2.2 TRRAP may activate NF-κB dependent transcription 
Transient transfection reporter assays were carried out with reporter constructs in 
293T cells. The reporter constructs were based on the pGL2 vector with the luciferase 
under the control of the minimal fos promoter (pf) or the same construct with two 
consensus NF-κB sites inserted (pBII). As expected PMA stimulation led to an 
increase in luciferase reporter gene expression of pBII (Figure 11A).  
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Figure 11. Functional assay showing the effect of TRRAP over-expression on transcription. A. 
TRRAP activates transcription of the NF-κB reporter, pBII. The numbers are relative luciferase levels 
*103. B. TRRAP also slightly activates transcription from another NF-κB independent promoter (RSV-
βgal). Each condition was in duplicate, the bars indicate the mean and the error bars indicate the 
standard deviation. The experiment was performed twice, with TRRAP activating pBII driven reporter 
expression both times, but to very different extents. The experiments need to be repeated, confirmed 
and extended to be confident that TRRAP is acting as a cofactor of NF-κB regulated transcription. 
 
TRRAP activated reporter gene expression to the same extent as PMA treatment. 
However, TRRAP also slightly increased the levels of the pf reporter and the β-
galactose expression controlled by the constitutive RSV promoter (internal control). 
This indicates that TRRAP might increase general transcription in this cellular 
system. PMA treatment and TRRAP over-expression further increased pBII reporter 
expression. Again, these conditions also activated pf driven luciferase and RSV 
driven β-galactose expression, although to a lesser extent than the pBII driven 
luciferase expression.  
 135
Results 
 
6.2.3 ATM may be to be required for UV activation of NF-κB 
To test if ATM could influence the transcriptional potential of NF-κB transient 
transfection reporter assays were carried out in ATM mutant cells (AT) and the same 
cells complemented with flag tagged ATM (Z5). Cells were stimulated with ionizing 
radiation (IR) at levels that have been shown to activate NF-κB or with other NF-κB 
activating signals (TNFα, etoposide, camptothecin (CPT) or UV). IR had no effect on 
reporter expression at 10 Gy (gray) or 20 Gy in AT (no functional ATM) or Z5 (ATM 
functional) cells (Figure 12A). This is unexpected since IR was shown to activate NF-
κB DNA binding activity as well as HIV reporter expression in ATM functional cells 
[239, 240]. TNFα stimulated pBII reporter gene expression in Z5 (ATM functional) 
and AT (no functional ATM) cells, however the activation was higher in AT cells 
(Figure 12B). UV did not stimulate reporter expression in AT (no functional ATM) 
cells, but did stimulate NF-κB dependent reporter expression in Z5 (ATM functional) 
cells (Figure 12B). This indicates that functional ATM was required for UV 
stimulation of NF-κB dependent transcription in this experiment. 
 
 
 
 
 
 
 
 
 
 
 
A. 
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Figure 12. Functional assay to show the role of ATM in NF-κB dependent reporter expression. A. 
Cells containing functional ATM (Z5) or cells deficient for ATM (AT) were transfected with the NF-
κB reporter gene pBII and stimulated with IR as indicated. B. AT or Z5 cells were transfected with 
pBII (contains NF-κB sites) or pf (no NF-κB sites) and stimulated with Etoposide (Et), camptothecin 
(CPT), TNFα or UV as indicated. Each condition was in duplicate, fold activation is the mean of the 
luciferase level/β-galactose level, where the filler sample (-) is set as 1. The error bars indicate the 
standard deviation. The experiment was performed only once, and needs to be confirmed. 
 
6.2.4 RelA(p65) is phosphorylated by a DNA associated kinase 
To test if a DNA associated kinase could phosphorylate RelA(p65) in vitro kinase 
reactions were performed. DNA associating kinases from HeLa extracts were 
immobilised on DNA cellulose and used to phosphorylate RelA(p65) or GST-p53 as a 
positive control or GST as a negative control (Figure 13).  
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Figure 13. In vitro kinase assay. DNA associated kinases from HeLa cell extract were used to 
phosphorylate myc tagged RelA(p65), GST-p53 or GST in the presence of 32P-γATP. The 
phosphorylated proteins were separated by SDS-PAGE and exposed to film. The experiment was 
repeated many times, with similar results. Arrow heads indicate the position of phosphorylated myc-
RelA(p65) or GST-p53. Asterix indicates non specific phosphorylation of nuclear extract proteins. 
 
 As expected GST-p53 was phosphorylated while GST was not. His-myc-
RelA(p65) was found to be phosphorylated by a DNA associated kinase. The DNA 
associated kinase could be a DNA binding kinase or a kinase associated with a DNA 
binding complex.  
6.3 Materials and Methods 
6.3.1 Functional assays 
For the ATM transient transfection reporter assays the AT cells used are AT22IJE-T 
fibroblasts which are SV40 transformed cells from a skin biopsy of a female A-T 
patient  [246]. Z5 cells are these cells stably transfected with flag-ATM protein. AT 
or Z5 cells were transfected with 2 µg pBII-luc or pf-luc reporters plus 2µg RSV-β 
galactose internal control using the calcium phosphate method. 6 h after transfection 
the medium was changed. Cells were stimulated with 10 or 20 Gy of gamma 
irradiation, 5 or 20 µM etoposide (inhibits topoisomerase II), 5 or 20 µM 
camptothecin (inhibits topoisomerase I), 10 ng/ml TNFα, or 100 J/m2 UV and 
harvested approximately 6 h later.  
 For the TRRAP transient transfections, experiments were performed as above, 
but 293T cells were transfected with 0.5 µg pBII or pf reporter, 0.2 µg RSV-β 
galactose, and 5 µg TRRAP expression vector (flag tagged TRRAP in bluescript 
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based vector under the control of a CMV promoter provided by Prof. Michael Cole) 
or 2.5 µg of empty vector filler. The cells were treated with 175 µM PMA for 4 h. All 
conditions were performed in duplicate.  
6.3.2 HeLa extract preparation 
Approximately 100 million HeLa cells were harvested and washed in PBS + 0.2 mM 
PMSF. Cell pellets were resuspended in LBS (10 mM HEPES, 25 mM KCl, 10 mM 
NaCl, 1 mM MgCl2, 0.1 mM EDTA, pH 7.2 + 0.1 mM DTT + 0.2 mM PMSF), 
washed in LBS, centrifuged and then resuspended in 2.5 cell volumes of LBS. The 
cell suspension was incubated on ice for 10 min and then flash frozen. The cell 
suspension was thawed quickly, protease inhibitors were added and the salt was 
adjusted to 0.5 M NaCl, 10 mM MgCl2, 5 mM DTT. The cell suspension was 
incubated on ice for 3 min and centrifuged at 10 krpm, 3 min at 4 °C. The supernatant 
was saved and the pellet re-extracted. The supernatent was flash frozen and 
centrifuged at 14 krpm, 10 min at 4 °C before use.  
6.3.3 GST and GST-p53 purification 
GST and GST-p53 expression plasmids were transformed into E. coli strain BL21. 
Expression was induced for 4 h with 0.5 mM IPTG when bacteria were at O.D. 0.6.  
Bacteria were harvested and lysed by french press in 50 mM tris pH 7.5, 120 mM 
NaCl, 5 mM DTT, 0.5 % NP40, 1 mM PMSF. Lysates were incubated with 
Glutathione sepharose beads (Amersham) (500 µl beads for 1L culture in 15 ml lysis 
buffer) at 4 °C for 1 h. Bound material was washed 3 X PBS, 1 X lysis buffer + 200 
mM NaCl, 1 X PBS. Protein was eluted 2 X elution buffer (50 mM tris pH 8, 10 mM 
reduced glutathione, 50 mM NaCl, 50 mM NaF, 2 mM NaVO4, 50 mM β-
glycerophosphate, 0.5 mM PMSF).  
6.3.4 His-myc-p65 purification 
His-myc-p65 was expressed in insect Sf21 cells using a baculovirus expression 
system. Three days after infection, the insect cells were harvested, washed in PBS, 
and lysed by homogenising in 10 mM tris pH 7.5, 500 mM NaCl, 10 % glycerol, 0.1 
% NP40, 15 mM imidazole, 2 mM β-mercaptoethanol. The protein was purified in 
batch using nickel sepharose (Amersham), with elutions in 10 mM tris pH 7.5, 200 
mM NaCl, 10% glycerol, 0.2 % NP40, 250 mM imidazole, 2 mM β-mercaptoethanol, 
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0.2 mM PMSF. 
6.3.5 Kinase reaction 
DNA cellulose (Sigma) was washed, then incubated 5-10 min with 1V HeLa extracts 
to 4V dilution buffer (50 mM HEPES, pH 7.5, 0.5 mM DTT, 10 mM MgCl2 + 
protease inhibitors). Bound material was centrifuged at 1000 rpm for 10 seconds. The 
pellet was washed three times with wash buffer (25 mM HEPES pH 7.5, 50 mM KCl, 
10 mM MgCl2, 0.1 mM EDTA, 0.2 mM EGTA, 0.5 mM DTT, 0.5 mM PMSF, 10 % 
glycerol) and one time with kinase buffer (wash buffer + 10 mM β-glycerophosphate, 
10 mM NaF, 2 mM NaVO4). The substrates were aliquoted into fresh tubes, 20 µl of 
DNA cellulose/kinase was added to each tube, followed by 1 µl 2.5 mM ATP and 1 
µl 10 µCi/ul 32P-γATP. The reaction was performed at 30°C for 10 minutes. To stop 
the reaction SDS containing loading buffer was added, and the reactions were 
analysed by SDS-PAGE and autoradiography. 
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Discussion 
7 Summary of Results 
The aim of this work was to identify cell type specific cofactors of RelA(p65) 
dependent transcription. The first step was to isolate proteins that could interact with 
the TAD of RelA(p65) from different cell types. This was achieved by performing 
GST pull down experiments using GST-RelA(p65)-TAD as bait and nuclear extracts 
from three different cell types as prey. Liquid chromatography-mass spectrometry 
was used to identify the proteins that bound to the GST-RelA(p65)-TAD. Many novel 
TAD interaction proteins were found, and some were found at higher levels when 
isolated from the nuclear extracts of certain cell types. For example, MYB binding 
protein 1a (MYBBP1a) was found to bind RelA(p65)-TAD at higher levels from 
Jurkat T cell nuclear extracts,  than from HeLa or THP1 nuclear extracts. The 
function of MYBBP1a was investigated further, since it was previously shown to 
regulate the activity of other TFs. The interaction between MYBBP1a and RelA(p65) 
was confirmed with purified proteins and MYBBP1a was found to repress NF-κB 
dependent transcription. MYBBP1a could compete with the NF-κB co-activator p300 
for TAD binding. It inhibited transcription activation at a step before pre-initiation 
complex formation. These results indicate that MYBBP1a is a co-repressor of NF-κB 
dependent transcription and is enriched in Jurkat T cells compared to HeLa epithelial 
cells or THP1 monocytes. 
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8 Interaction partners of RelA(p65)-TAD 
8.1 Interaction Proteomics 
In order to identify cofactors of RelA(p65) dependent transcription, the proteomic 
approach used was to isolate RelA(p65)-TAD binding proteins from nuclear extracts 
of different cell types. A high amount of GST-RelA(p65)-TAD (bait) and nuclear 
extract (prey) was used with stringent binding and wash buffer conditions. An 
alternative procedure would have been to isolate proteins that bind to full length 
RelA(p65). This was not attempted since it is known that most cofactors of 
transcription interact with the TAD of RelA(p65), as this is the domain responsible 
for most of the transactivating potential of RelA(p65) [110]. Also, there is evidence 
that full length RelA(p65) forms a closed structure when not phosphorylated at serine 
276 and this closed structure is incompatible with interaction with the cofactor p300 
[99]. Another alternative would have been to perform immunoprecipitation of tagged 
RelA(p65) and analyse the co-immunoprecipitated proteins. The advantage of this 
would be that the lower amount of bait used would isolate less false positive 
interactions. However, a previous report using TAP-tagged RelA(p65) failed to 
identify any known cofactors of transcription [247]. By using a relatively high amount 
of the specific functional domain, we were able to isolate known protein interaction 
partners of RelA(p65)-TAD. 
Nuclear extract was used as the prey since most cofactors of transcription are 
present in the nucleus. Any cofactors present in the cytoplasm of unstimulated cells 
would not be identified with this approach. Whole cell extracts were not used as 
nuclear proteins would be diluted with cytoplasmic proteins in the whole cell extract 
leading to a reduced probability of forming a favourable cofactor interaction with the 
prey. The nuclear extracts were made from large cultures (2L) of Jurkat T, THP1 
monocyte, or HeLa suspension cells. All the cells types were chosen as they contain 
inducible NF-κB activity and they are easy to culture. It is very time consuming and 
expensive to culture the required amount of cells from tissues or primary cell, so 
transformed cell lines were used. However, the protein constituents and metabolism 
of these cell lines may not be representative of their primary cell counterpart.  
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As shown in Table 2, Section  2.5.1, there are many different signalling events 
leading to the phosphorylation of specific sites in the TAD of RelA(p65). However, 
non-modified TAD was used in the proteomic approach, therefore proteins with the 
ability to interact only with specifically phosphorylated TAD could not be isolated. It 
would be very informative to repeat the GST-pull down experiments using mutant 
versions of TAD. A glutamic acid residue partially resembles the structure of a 
phosphorylated serine, and can be used to mimic a specific phosphorylatable serine. A 
mutant form of RelA(p65)-TAD could be used to isolate interaction proteins that have 
a high affinity for the specifically phosphorylated TAD.   
Whilst interpreting the results, it is important to realise that all interaction 
partners that were isolated are proteins that have the ability to interact directly or 
indirectly with TAD in this system, but may not interact physically or functionally 
with RelA(p65) in vivo. For example, many chaperones were found to interact from 
all cell types with GST-RelA(p65)-TAD, but are unlikely to do so in the cell to 
regulate NF-κB transcriptional function. However, many of the novel TAD 
interaction proteins found may have a role in RelA(p65) dependent transcription. To 
investigate this further it would be necessary to confirm the specificity of the 
interactions and to perform functional assays. 
8.2 Protein Separation and Identification 
The protein interactors of RelA(p65)-TAD were separated by gel 
electrophoresis and the high molecular weight proteins (above 100 kDa) were 
identified by mass spectrometry. Two approaches were used to separate the 
RelA(p65)-TAD interacting proteins. The first approach was separation of individual 
proteins by gradient 1D SDS-PAGE. This approach allowed separation of the 
dominant GST-RelA(p65)-TAD band from the proteins of interest. Another approach 
would have been to use 2D gel electrophoresis. This is normally the separation of 
proteins according to isoelectric point (the pH at which a protein has no charge), and 
then according to mass. The advantage of 2D gel electrophoresis is that it separates 
the proteins more thoroughly into individual spots. This would have helped to 
separate band 3 and 4 containing p300, CBP and Down Regulated in Metastasis 
(DRIM) in the Figure 1 of Section  5.1, which would have enabled comparisons of 
these proteins between the cell types. The disadvantage of 2D gel electrophoresis is 
that specialised equipment is required and the procedure is longer. We used Sypro 
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Ruby (Molecular Probes) to visualise protein bands on the 1D SDS-PAGE. Sypro 
Ruby is thought to be as sensitive as the conventional method of silver staining [248]. 
Advantages of using this staining technique is that it interacts with proteins non-
covalently and relatively independently of the amino acid sequence. Therefore, Sypro 
Ruby staining does not interfere with mass spectrometry analysis and can be used to 
quantify stained proteins. Silver staining involves silver covalently interacting with 
cysteine residues which can interfere with mass spectrometry analysis. The strength 
of the silver staining of each protein is dependent on the number of cysteines within 
the protein, so silver staining is less quantitive.  
The second approach we used to separate the proteins was a “shot gun” 
approach. A short (2 cm) minigel was used to separate the GST-RelA(p65)-TAD from 
the proteins of interest. The gel piece containing a large mixture of proteins of interest 
was then cut into smaller pieces before trypsin digestion. The advantage of this 
approach is that all proteins were present in the gel, so no faint bands could be 
missed. With this approach, many Mediator subunits were identified that were not 
detected in the first approach.  
After tryptic digestion, liquid chromatography-tandem electrospray mass 
spectrometry was used to identify the proteins isolated by both separation approaches 
(reviewed in [249]). The instrument used was adapted for high throughput accurate 
analysis of complex protein/peptide mixtures. High performance liquid 
chromatography separates peptides according to how hydrophobic they are by use of 
a reverse phase (hydrophobic) column. The mass/charge ratio of all the peptides was 
then determined by mass spectrometry, which consists of ionisation, mass analysis 
and detection. Ionisation of the sample was performed by electrospray ionisation. In 
this method of ionisation, the peptide mixtures dissolved in a solvent are forced 
through a charged metal capillary. Droplets are then formed, normally containing 
positively charged peptide ions. The repulsion of the positive charges forces the 
droplets into the gas phase, and evaporation and collision between droplets separates 
each charged peptide.  The major advantage of using of electrospray ionisation rather 
than the other common method of ionisation, matrix-assisted laser 
desorption/ionization, is that electrospray is easily coupled to liquid chromatography. 
After ionisation, the peptides are directed to the mass analyser, in our case a 
quadrupole-time of flight. The mass analyser guides the charged peptides to the 
detector, based on their mass/charge ratio. We used tandem mass spectrometry, a 
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method to perform multiple rounds of mass spectrometry. Each round involved 
separation of peptides and dissociation of each peptide into smaller pieces by collision 
induced dissociation. The data collected was analysed with the program MASCOT, 
and peptide sequences could be calculated from the mass/charge ratio of the many 
peptide fragments formed. Overall, the “shot gun” approach allowed identification of 
proteins below the detection limit of Sypro Ruby staining (about 1 ng/band), from a 
large protein mixture.  
Using both approaches many different proteins were identified as RelA(p65)-
TAD interacting partners [250]. The known RelA(p65)-TAD interacting co-
activators, p300 and CBP were identified, indicating that the approach used was 
suitable for the identification of  high molecular weight novel transcription cofactors 
of RelA(p65). Many hypothetical proteins were also found to interact with the TAD 
of RelA(p65), indicating that they may be involved in transcriptional regulation by 
RelA(p65). Other proteins with known cellular functions were identified and are 
discussed in the next sections. Some proteins were found at higher levels to bind the 
RelA(p65)-TAD from specific cell types. The cell type enriched binding could be due 
to higher expression levels of the protein in particular cell types, or due to cell type 
specific PTM of proteins regulating the interaction with RelA(p65)-TAD. 
8.3 New RelA(p65)-TAD interaction partners 
8.3.1 TRRAP 
Many proteins were discovered to interact with the TAD of RelA(p65) that were 
previously not known to do so, including the transcription regulator TRRAP 
(transactivation/transformation-domain associated protein) (Section  5.1). Preliminary 
experiments indicate that TRRAP may be a co-activator of NF-κB dependent 
transcription (Section  6.2.2). TRRAP is a member of many HAT complexes known to 
be involved in transcription activation (reviewed in [243]). Yeast have a homolog of 
TRRAP called Tra1. The CT of Tra1 was shown to bind to other acidic transcription 
activation domains (VP16 and GCN4), and Tra1 recruited HAT activity to promoter 
regions [251]. TRRAP has also been shown to be recruited to promoters by 
mammalian TFs, like Myc [252]. It has been shown that TAFs [117] and P/CAF [173] 
activate NF-κB dependent transcription, and these proteins are often present in 
TRRAP containing complexes. Therefore, the mechanism of NF-κB activation by 
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TRRAP could also be through the recruitment of HAT complexes to the RelA(p65)-
TAD. Recruitment of TRRAP containing HAT complexes to RelA(p65)-TAD could 
result in the acetylation of the surroundings, including histones and non-histone 
proteins at promoters. In this hypothesis, TRRAP would directly interact with the 
TAD of RelA(p65), which has yet to be investigated. 
Many TRRAP complexes also contain TAFs. TAFs that are known to interact 
with RelA(p65)-TAD are TAF1 (TAFII250), TAF6 (TAFII80) and TAF11 (TAFII28) 
[117]. Both TRRAP and TAF6 are present in SAGA [253] and TFTC [254] and it is 
likely that other complexes also contain TRRAP and RelA(p65)-TAD interacting 
TAF subunits. Unexpectedly, the high molecular weight TAF1 was not found in our 
search for RelA(p65)-TAD interacting proteins. This could be due to its presence at 
concentrations too low for detection, or because it does not interact at the stringent 
conditions that we tested.  
There is also a possibility that TRRAP containing P/CAF complexes could 
acetylate RelA(p65) since recombinant P/CAF was shown to acetylate lysine 122 and 
123 in the RHD of RelA(p65) [169]. Acetylation at these sites led to termination of 
NF-κB dependent transcription, implying that if TRRAP containing P/CAF 
complexes acetylate these sites in vivo, TRRAP would be functioning as a terminator 
of NF-κB dependent transcription. On a simple level, this would not be in agreement 
with the hypothesis that TRRAP is a co-activator of transcription. However, 
transcriptional regulation is complex and it is possible that a transcriptional activator 
can also be a transcriptional terminator. This is the case with p300, which is recruited 
to estrogen receptor response genes within 1 hour of estrogen stimulation to activate 
transcription [255], however, upon continued stimulation, p300 mediated the 
acetylation of the transcription co-activator SRC-3 (ACTR). This acetylation event 
reduced the interaction between SRC-3 and the estrogen receptor, and led to 
attenuation of transcription. 
The importance of TRRAP in normal cellular activity is apparent from the 
lethal phenotype of TRRAP-/- cells [244]. TRRAP was found to be essential for cell 
proliferation and mitotic exit. In a conditional knock out cell line, TRRAP was found 
to regulate transcription of a wide variety of genes [245]. Loss of TRRAP led to down 
regulation of approximately 70% of the TRRAP regulated genes, indicating that 
TRRAP acts mainly positively on transcription (but also negatively). The failure of 
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TRRAP deficient cells to proliferate was found to be due to defective transcription of 
the mitotic checkpoint proteins, Mad1 and Mad2 [256]. It would be useful to know 
which NF-κB dependent genes are regulated by TRRAP, and whether they are also 
genes important for controlled proliferation. 
8.3.2 DNA-PK, ATR and ATM 
Ionising radiation has been shown to activate NF-κB, and this has been suggested to 
be dependent on DNA-PK or ATM mediated phosphorylation of IκB [241, 242]. 
Here, ATR and DNA-PKcs were found to interact with RelA(p65)-TAD (Section 
 5.1), and a DNA associated kinase could also phosphorylate RelA(p65) (Section 
 6.2.4). Also, preliminary experiments indicated that ATM might be important for a 
UV mediated NF-κB response (Section  6.2.3). These results support a hypothesis that 
genotoxic stress could activate NF-κB through the IκB degradation pathway, as well 
as interacting with the TAD to regulate NF-κB transcriptional potential, possibly by 
phosphorylation of specific residues. This would be similar to the mechanism of p53 
activation in response to genotoxic stress. Upon ionising radiation and activation of 
ATM, the inhibitors of p53 (MDM and MDMX) are phosphorylated and inactivated 
[257, 258]. p53 is also directly phosphorylated by ATM, at residues that enhance its 
transcriptional activity [259]. Experiments to further investigate the hypothesis that 
genotoxic stress could trigger ATM, ATR or DNA-PK mediated phosphorylation of 
RelA(p65) to enhance transcription of specific genes are required.  Phosphorylation 
experiments using recombinant proteins could be used to identify which of the 
kinases (if any) have the ability to phosphorylate specific threonines or serines within 
RelA(p65). These experiments could be followed by in vivo phosphorylation 
experiments and functional assays. The use of siRNA knock down cells would be 
beneficial, as the genetic instability seen in ATM-/-, and DNA-PK-/- mouse cells 
would be largely avoided due to the shorter duration of the experiments. 
DNA-PKcs has a role in non-homologous end joining (NHEJ) in the repair of 
DNA damage and also in V(D)J recombination [237]. It is possible that the 
interaction seen between DNA-PK and RelA(p65) is due to involvement of DNA-PK 
in NF-κB dependent transcription, or involvement of NF-κB in DNA-PK mediated 
NHEJ. Interestingly, there is a link between the two processes, since NF-κB is 
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involved in germline transcription of light chain genes, which is necessary for 
recombination [260]. 
8.3.3 Mediator Subunits 
In the “shotgun” proteomic approach many Mediator subunits from nuclear extracts 
were found to interact with the TAD of RelA(p65) and in vitro translated Med14, 
Med24 and Med17 subunits bound weakly to RelA(p65)-TAD (Section  5.1). This 
confirms a previous study from Näär et al. [120] where the whole Mediator complex 
was found to interact from nuclear extracts with RelA(p65)-TAD. However, we could 
not detect Mediator subunits when analysing each band indicating that in our study 
the proteins were present at levels below the detection limit of Sypro Ruby staining. 
This is interesting since in the previous study, Mediator subunits were the main 
interaction partners of RelA(p65)-TAD as shown by silver staining [120]. It is likely 
that in our experiment Mediator interacts with a lower affinity than in the experiments 
performed by Näär et al. Both experiments were GST pull down experiments with 
HeLa nuclear extracts prepared in similar ways. The main difference in experimental 
conditions are that Näär et al used a wash buffer containing 250 mM KCl, whereas 
we used a similar buffer, but containing 400 mM KCl. Other small differences in 
procedures are that they used amino acids 434-551 of RelA(p65) (instead of 428-551), 
and approximately twice the amount of HeLa nuclear extracts. Therefore, it is likely 
that the Mediator/RelA(p65) interaction is sensitive to salt concentrations, due to a 
low affinity interaction or an indirect interaction (bridged by another protein). 
The in vitro translated Mediator subunits Med14, Med24 and Med17 
interacted very weakly with RelA(p65)-TAD (Section  5.1), indicating that either i) 
another Mediator subunit that we did not test or another protein forms the direct 
interaction with RelA(p65)-TAD, or ii) multiple Mediator subunits interact weakly 
with RelA(p65), to stabilise a higher order complex. Many RelA(p65) containing NF-
κB dimers often bind to many κB sites within the same enhancer, and each TAD 
could interact with a subunit of the Mediator complex. Together with other TFs, 
which also interact with Mediator subunits, Mediator could be effectively recruited to 
the enhanceosome through multiple weak interactions. 
Med14 and Med 17, two of the Mediator subunits that we found to interact 
with RelA(p65)-TAD also interact with other TFs (reviewed in [149]). Med14 (also 
called TRAP170/DRIP150) interacts ligand independently with the nuclear hormone 
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receptors glucocorticoid receptor ([261]) and hepatocyte nuclear factor 4 [262] as well 
as with signal transducer and activator of transcription 2 (STAT2) [263] and sterol 
regulatory element binding protein 1a (SREBP1a) [264] to activate transcription. 
Med17 (also called TRAP80/DRIP77) interacts with Dif (a Drosophila melanogaster 
RHD containing protein) [265], VP16 [266], p53 [266], heat shock factor [267] and 
STAT2 [263]. These observations indicate that STAT2 interacts with at least two of 
the same Med subunits as RelA(p65)-TAD. The transcription activation domain of 
STAT2 contains acidic residues (like RelA(p65)-TAD) [268]. However, alignment of 
STAT2 and RelA transcription activation domains shows no similarity between them.  
Mediator has been shown to have different structural conformations depending 
on whether it is free, bound to RNAPII, or to different transcription factors [147, 
269]. The conformation of the Mediator complex was similar when bound by TFs that 
interact with the same subunit of Mediator [270]. This indicates that each TF may 
interact with particular Mediator subunit(s) to form a specific conformation of 
Mediator. Each conformation of Mediator may have a distinct function. How 
conformation affects Mediator function remains to be determined. Conformations 
more or less able to form interactions with other TFs would result in the coordination 
and integration of different signals. Conformations more or less able to interact with 
GTFs and RNAPII would regulate the transcriptional outcome. This would lead to the 
precise regulation of transcription at specific enhanceosomes. If the conformation of 
Mediator were dependent on the Med subunit contacted by the TF, it would be 
expected that the Mediator bound to RelA(p65) would have a different conformation 
depending on which Med subunit was bound by the TAD. If RelA(p65)-TAD 
interacted with Med17 (as VP16) it may have a structure similar to the one seen when 
Mediator was bound to VP16 (Figure 14). If RelA(p65) bound to Med14 (as 
SREBP1a) it may have a structure similar to the Mediator bound to SREBP1a (Figure 
14). The fact that RelA(p65) (and other TFs) can interact with more than one 
Mediator subunit indicates that the accumulation of TF/Mediator interactions might 
lead to a specific Mediator conformation and function. 
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Figure 14. Electron micrograph of different conformations of the Mediator complex. Mediator 
forms several different conformations upon interaction with SREBP, RNAPII CTD, VP16, VDR or 
TR, or when alone (unliganded). A RelA(p65) bound Mediator complex might form a similar 
conformation, depending on whether it binds through the Med14 or Med17 subunit. The bar indicates 
7.5 nM. Picture adapted from [270].  
 
8.3.4 IQGAP1/3 
IQGAP1 and IQGAP3 are homologous proteins that were also detected to be novel 
interacting partners of RelA(p65)-TAD. IQGAP1 promotes cell/cell adhesion and 
mobility by activation of GTPases [271], indicating RelA may have a function in 
these processes. It is also possible that these IQGAP proteins have a role in 
transcription.  
 151
Discussion 
 
 
9 MYBBP1a  
9.1 MYBBP1a in RNAPII dependent transcription 
9.1.1 Interaction with transcription factors 
MYBBP1a was found to interact with RelA(p65)-TAD from all three cell lines, 
although the levels of MYBBP1a isolated from Jurkat nuclear extracts were much 
higher than from THP1 or HeLa nuclear extracts. MYBBP1a (originally called p160), 
and its proteolytically NT cleavage product (p67) were first identified as factors that 
could bind to the leucine zipper negative regulatory region of the transcription factor 
Myb [272]. The interaction between p67 and Myb seemed stronger than the 
interaction between MYBBP1a and Myb. Since its identification, MYBBP1a has also 
been shown to interact with other TFs. MYBBP1a, but not p67, was found to interact 
with the leucine zipper of c-Jun [272] and MYBBP1a could also interact with the 
acidic activation domain of the aromatic hydrocarbon receptor (AhR) [273]. 
However, it is not known whether these interactions between MYBBP1a and Myb, 
AhR or c-Jun are direct or via a bridging factor. MYBBP1a was found to interact with 
the negative regulatory domain of the peroxisome proliferator activated receptor γ 
(PPARγ) co-activator 1α (PGC-1α), probably through two leucine rich domains in 
PGC-1α [274]. PGC-1α could interact with the in vitro translated NT of MYBBP1a 
(p67) as well as the CT of MYBBP1a, indicating a probable direct interaction with at 
least two parts of MYBBP1a. In this thesis, an interaction between the acidic 
activation domain of RelA(p65) and MYBBP1a is shown, and is likely to be a direct 
interaction since there are only a few contaminants present (Section  5.2). It may be 
that MYBBP1a contains multiple protein interaction domains, for binding particular 
types of domain (Figure 15). The sequence of MYBBP1a contains two putative 
leucine zipper motifs, indicating that it may be able to dimerise with other leucine 
zippers. Also, many LXXLL (L = leucine X = any amino acid) motifs are present, 
which often form interaction surfaces with nuclear hormone transcription factors and 
other transcriptional regulators (reviewed in [275]). It would be interesting to map 
which region of MYBBP1a interacts with the acidic TAD of RelA(p65). 
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Figure 15. Features of MYBBP1a. Potential LXXLL motifs are indicated by black lines. The two 
possible leucine zipper domains are shown as shaded bars with a light L inside. The acidic domain is 
shown as a shaded bar with A inside. The CT was found to contain 7 nuclear localisation signal (NLS) 
motifs indicated with a *. Regions found to interact with Myb, c-Jun or PGC-1α are indicated. 
Sequence similarity with POL5 and H1.4 is indicated, as determined by BLAST [276]. K, lysine; X, 
any amino acid; L, leucine; I, isoleucine; M, methionine; Q, glutamine. Picture adapted from [235]. 
 
p67 is the CT proteolytical cleavage product of MYBBP1a approximately 
corresponding to residues 1-580. It was detected in mouse bone marrow lymphoblast 
(FDC-P1) cell extracts, but not in mouse embryonic fibroblasts (NIH3T3) cell 
extracts [277]. Neither p67 nor the yeast homolog POL5 contain the nuclear 
localisation signals mapped to be in the CT of MYBBP1a. However, endogenous p67 
was found by western blot in nuclear extracts not cytoplasmic extracts [277] and 
POL5 has been detected by immunoflourescence in the nucleolus. A CT deletion 
construct of MYBBP1a was cloned and called p67* since the precise cleavage site for 
p67 is not known. Interestingly, flag-p67* was found by western blot to be 
cytoplasmic in HEK 293 cells [235]. However, the presence of p67 has also been 
suggested to be due to extract handling, since Tavner et al. claim that little p67 
protein was seen when the cells were lysed directly in SDS-LB [277]. The putative 
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p67 protein was not investigated in this thesis, however it may be that it also has a 
role in NF-κB regulated transcription.   
9.1.2 MYBBP1a as a transcriptional repressor 
Previous work indicated that MYBBP1a could repress the transcription factors 
Myb and PGC-1α [274, 277]. Although full length MYBBP1a had little effect on 
Myb reporter gene expression, the N terminal of MYBBP1a (p67*) repressed 
transactivation in CV-1 (kidney fibroblast) cells in a concentration dependent manner, 
largely dependent on the leucine zipper of Myb [277]. Transfection of both 
MYBBP1a and p67* repressed Gal4-DBD-PGC-1α reporter expression in HIB1B 
brown fat cells, and this was dependent on the negative regulatory region of PGC-1α. 
MYBBP1a and p67* also repressed transcription of PPARγ and PGC-1α dependent 
reporter transcription. Adenoviral expression of MYBBP1a (but not p67*) in C2C12 
myoblasts resulted in the repression of PGC-1α activation of mitochondrial 
respiration and cytochrome c and β-ATP synthase mRNA production. Gal4-DBD-
MYBBP1a or Gal4-DBD-p67* could repress reporter transcription indicating 
MYBBP1a and p67* have intrinsic transcriptional repressive abilities. MYBBP1a 
also repressed NF-κB dependent reporter expression in vivo and in vitro (Section  5.2). 
However MYBBP1a does not generally repress all transcription factors, since 
expression of MYBBP1a increased AhR dependent reporter expression in mouse 
hepatoma cells [273] and had little effect on p53 dependent reporter gene expression 
(Section  5.2). This indicates that MYBBP1a might be a specific repressor of 
transcription for a select group of transcription factors.  
9.1.3 Mechanism of MYBBP1a repression 
There are multiple lines of evidence that MYBBP1a represses transcription as a 
classical transcriptional co-repressor. First, MYBBP1a was found to have intrinsic 
repressive ability since it repressed transcription when fused to the DBD of GAL4 in 
GAL4 dependent reporter assays [274]. Second, MYBBP1a repressed transcription 
without disturbance of PGC-1α binding to the promoter region of a PGC-1α activated 
endogenous gene (myoglobin) in C2C12 myotubes. Lastly, in this thesis I show that 
MYBBP1a could also repress transcription in vitro, on chromatin templates with 
RelA(p65) pre-bound (Section  5.2). 
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MYBBP1a may function as a co-repressor through multiple mechanisms, 
depending on the enhanceosome context. In vitro, MYBBP1a was found to repress 
NF-κB activated transcription at a step after TF binding to the chromatinised 
template, but before addition of GTF containing HeLa nuclear extracts (Section  5.2). 
This indicates that it represses transcription at a stage before PIC formation, which is 
the stage at which many transcriptional cofactors modify the nucleosomes in the 
promoter region. MYBBP1a was shown to compete with p300 for TAD binding, 
indicating that the repressive affect of MYBBP1a could be by displacement of the co-
activator p300 (Section  5.2). This would lead to less acetylation of histones, or other 
non-histone proteins including RelA(p65) itself, which are thought to activate 
transcription. There is also some evidence that MYBBP1a mediated repression could 
be through recruitment of a HDAC containing co-repressor complex. GAL4-DBD-
MYBBP1a repressed transcription was partially alleviated by treatment with the 
HDAC inhibitor TSA [274]. The HDAC proteins present in this possible 
HDAC/MYBBP1a complex remain to be identified. There is also evidence that 
protein stability of PGC-1α may be affected by MYBBP1a expression levels in some 
cell types [274]. MYBBP1a expression in brown fat HIB1B cells caused a decrease in 
the protein levels of expressed full length PGC-1α and 1-400 (containing the negative 
regulatory region that binds to MYBBP1a). However, MYBBP1a did not cause a 
decrease in the protein levels of a phosphorylation mimic of PGC-1α, which no 
longer has the ability to interact with MYBBP1a [274].  
9.2 Cell type expression pattern of MYBBP1a 
MYBBP1a mRNA is transcribed as a single 4.5 kb mRNA transcript to varying levels 
in all cell lines tested, including NIH 3T3 (embryonic fibroblast), J774 (macrophage), 
FDC-P1 (bone marrow lymphoblast), WEHI-3B (leukaemia) mouse cell lines [277] 
and HEK 293T (embryonic kidney epithelial cells), TF-1 (erythroleukemia), HeLa 
(cervical carcinoma epithelial), HFF2 (foreskin fibroblast) human cell lines [278] and 
in all mouse tissues tested [277]. Data from the publicly available Symatlas database 
[279] (http://symatlas.gnf.org/SymAtlas/) indicate that the amygdala (emotion 
processing part of brain), whole brain tissue, bone marrow CD105+ endothelial cells 
(similar to mesenchymal cells that differentiate into osteoblasts, chondrocytes, 
myocytes, adipocytes and neuronal cells), bone marrow CD34+ stem cells, 721 B 
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lymphoblasts (immature B lymphocyte), CD4+ (helper T cells) and CD8+  (cytotoxic 
T cells) have consistently high levels of MYBBP1a between different data sets and 
micro-array platforms. However, high levels of MYBBP1a protein cannot 
automatically be assumed to occur in these tissues, since proteolytical cleavage to p67 
(if found not to be a handling phenomena) seems only to occur in some cell types. 
MYBBP1a protein was found in higher levels in Jurkat T cells, than in THP1 
monocytes or HeLa epithelial cells, indicating that cell type specific differences in 
MYBBP1a protein levels do occur (Section  5.2). It is necessary to determine the 
MYBBP1a protein levels in many other cell types. 
The expression pattern of MYBBP1a mRNA does not to completely overlap 
with the expression pattern of the transcription factors that are known to be regulated 
by MYBBP1a. RelA(p65) is constitutively expressed, and is found especially high in 
the cells of the immune system, including lymphoblasts and T cells [200]. PGC-1α is 
expressed in cells with high oxidative metabolism such as heart, skeletal muscle, 
kidney, brown fat, liver, and the brain (reviewed in [280]). Myb is expressed mainly 
in immature haematopoietic cells [281]. AhR expression is induced and is particularly 
high in the lung, liver, brain, heart, and spleen [282] while c-Jun expression is 
ubiquitous [283]. 
Control of transcription through cell type specific expression of cofactors has 
been suggested to be important for regulation of gene expression. Tissue restricted 
expression of a cofactor of transcription will regulate transcription of genes in those 
cells only. For example, the B cell specific BOB1/OCA-B co-activator is required for 
transcription of immunoglobulin genes in B cells by the ubiquitously expressed OCT1 
(reviewed in [280]). Even greater selectivity can be achieved since cofactors are likely 
only to regulate selected promoters or enhancers. A cell type restricted cofactor could 
coordinate transcription of specific genes by various TFs. If the regulated genes are 
involved in the same cellular process, then coordinated regulation of their expression 
would lead to an extremely fast response during the regulation of the particular 
cellular process (reviewed in [280]). The cellular processes regulated by MYBBP1a 
are not known, but are likely to be important in the cell types where MYBBP1a levels 
are highest, possibly T, B and neuronal cells.   
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9.3 Function of MYBBP1a in the nucleolus 
MYBBP1a is found mainly in the nucleoli of cells, the sub-nuclear organelles where 
rDNA transcription and ribosome synthesis occurs (reviewed in [284]). Within the 
nucleus there are 1-5 nucleoli, and together they contain a total of 250 copies of three 
of the four rDNA genes on 5 different chromosomes. MYBBP1a has a single 
homologue in animals, yeast and fungi [285]. The S. cerevisiae homologue, POL5, is 
also a nucleolar protein, with an essential function in the regulation of rRNA 
transcription [286]. It was found to bind near the enhancer region of rDNA repeats 
indicating it could be acting as a transcription cofactor for RNAPI. POL5 was first 
thought to be a new member of the B type polymerases by sequence homology of the 
conserved Pol domains, and recombinant POL5 was found to have polymerase 
activity in vitro [286]. However, POL5 purified from yeast had no detectable 
polymerase activity, and POL5 temperature sensitive mutants had no defect in DNA 
replication or DNA repair at the restrictive temperature. Therefore, POL5 does not 
have an essential function in DNA synthesis. Closer inspection of the POL5 amino 
acid sequence, showed that POL5, and therefore also MYBBP1a, is very unlikely to 
be a polymerase [285]. POL5 and MYBBP1a are predicted to be entirely α-helical, 
unlike polymerases, which are α-β fold proteins, where the catalytic site is within a β 
sheet. The Pol motifs are not present in MYBBP1a and only one full consensus Pol 
sequence was found to be conserved in POL5 [285]. Since POL5 is essential for 
viability, and rRNA synthesis, it is also possible that MYBBP1a has an important role 
in rDNA transcription regulation [286].   
 The nucleoli are also involved in other functions, such as cell cycle control, 
apoptosis, virus infection and cellular stress (reviewed in [287-289]). The nucleoli can 
regulate RNAPII transcription by sequestration of RNAPII transcription machinery 
[234, 290, 291]. Therefore the nucleolar MYBBP1a may have a function in these 
processes. RelA(p65) was found to be sequestered to the nucleolus upon cell 
treatment with the pro-apoptotic stimuli, aspirin, serum deprivation or UV-C [234]. 
Aspirin treatment led to IκBα degradation (after 2 hours), nuclear localisation of 
RelA(p65) and nucleolar accumulation (at 5-8 hours). Nucleolar sequestration of 
RelA(p65) coincided with a decrease in NF-κB reporter expression, and led to 
apoptosis after 16 hours of aspirin treatment [234]. Protein synthesis was required for 
the nucleolar localisation of RelA(p65). The nucleolar sequestration was dependent 
 157
Discussion 
 
on nucleolar localisation sequence in the NT of RelA(p65) . Transfection of a 
nucleolar localisation signal mutant of RelA(p65) led to a dominant effect, and no 
sequestration of endogenous wild type or transfected mutant RelA(p65) was observed 
[234]. There was also no transcription inhibition or apoptosis in these cells. An 
interesting possibility is that MYBBP1a could have a role in the nucleolar 
sequestration of RelA(p65) and other proteins. Further experiments to investigate this 
hypothesis would be to co-express RelA(p65) and MYBBP1a in cells, and determine 
the localisation of the proteins after treatments with various stimuli, such as aspirin.  
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10  RelA(p65)-TAD cofactors of transcription 
10.1  TAD complex formation 
In this work many proteins were identified to interact with the TAD of RelA(p65). 
These proteins, together with previously characterised TAD interacting proteins form 
a large number of potential transcriptional cofactor complexes capable of interacting 
with the TAD of RelA(p65) (Figure 16). 
 
Figure 16. Protein complexes with the ability to interact with RelA(p65)-TAD. Proteins known to 
interact with RelA(p65)-TAD are TRRAP (present in TFTC, SAGA, STAGA, tip60, P/CAF and 
others HAT complexes), p300 (present in SRC, PRMT, TBP, TFIIB, P/CAF HAT complexes), 
MYBBP1a (possibly in HDAC containing complexes), TAFs and TFIIB (present in TFIID, plus some 
other HAT complexes), SMRT (present in HDAC complexes) and the  Mediator. ? indicates that the 
components of the complex are unknown. Other complexes involved in RelA(p65) transcription are 
NCoR, HDAC 1/2/3 containing complexes, hSWI/SNF complexes and PARP complexes. These 
complexes have not been identified to interact with RelA(p65)-TAD, and are labelled with ??. 
Complexes are shown as ovals and are not to scale. Members of the complex known to interact with 
RelA(p65)-TAD and catalytic subunits are named.  
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Since many proteins were found to bind to the TAD of RelA(p65), an 
important aspect to consider is whether only one protein can interact with the TAD at 
once, or whether many proteins can interact with the TAD. In a model where only one 
protein can interact with the TAD at once, many indirect interactions could result in 
the formation of a higher order complex. Many RelA(p65) proteins and other TFs are 
present in a single enhanceosome, which means even with only one protein binding at 
a time to the TAD, effective complex recruitment could occur. This is modelled for 
multiple Mediator subunit/TF interactions in Figure 17A. However it is unlikely that 
only one protein can bind the TAD at once. There are 3.6 residues per turn of a α-
helix, each residue exposing its side group to the solvent. Each side chain has the 
possibility to form bonds with side chains from other proteins, and there is enough 
surface space for more than one protein to interact. Also, the TAD has two potential 
α-helices (one in TA1 and one in TA2) separated by 50 amino acids of presumably 
random coil [111, 112]. Therefore, it is likely that the TAD can interact with more 
than one protein at once, and this is shown in the model in Figure 17B.  
Weak interactions of different subunits in the same complex with RelA(p65)-
TAD would lead to a strong interaction with the whole complex. This could explain 
the weak interaction detected between RelA(p65)-TAD and Med14, Med17 and 
Med24 of the Mediator complex (Section  5.1), and also RelA(p65)-TAD interaction 
with multiple components of the TFIID complex (TBP, TAF6, TAF1, TAF11). It 
would be possible that building up of a transcription complex at an enhanceosome 
could involve the shift from a basally active complex to an induced transcriptionally 
active one, depending on the type and number of transcriptional co-activator 
complexes present.  
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Figure 17. Model of enhanceosome function when each TAD can interact only with one protein at 
a time (A) or with more than one protein at a time (B). In (A) one TAD contacts Med17 and another 
TAD contacts Med24. Another transcription activation domain from a different TF (diamond) also 
contacts Mediator. In (B) one TAD can interact with Med24 and Med17, while another TAD can 
interact with TAF6 and TAF11. Another TF can interact with a p300 complex.  
 
Different transcriptional cofactor complexes are used in the same 
enhanceosome, normally by a series of ordered recruitment events. It has been 
proposed that the order of cofactor recruitment to NHRs may be hSWI/SNF, followed 
by HATs, and then GTFs [72]. The evidence for this comes from multiple in vitro 
transcription experiments. For example, RAR/RXR dependent transcription from 
purified chromatin templates was synergistically activated by p300 and hSWI/SNF 
[292]. Order of addition experiments revealed that transcription was optimal when 
RXR/RAR, then hSWI/SNF, then p300 and SRC2 and finally nuclear extracts 
(containing GTFs) were added in order [292]. In a different system, transcription of 
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chromatinised reporter genes activated by the thyroid receptor- βA in Xenopus 
oocytes required first nucleosome remodelling, then p300 action [293]. Also ACF 
(ATP-utilizing chromatin assembly and remodeling factor) remodelling preceded 
p300 mediated acetylation during transcription activated by the acidic transcriptional 
activator Gal4-VP16 [294]. For NF-κB and Sp1 dependent transcription in vitro of the 
interferon regulatory factor 1 promoter, p300 HAT activity and acetyl CoA were 
found to be required for transcription initiation indicating p300 must be recruited to 
the promoter before active PIC formation [165, 295].  
In vivo, ChIP experiments are used to determine the order of cofactor 
recruitment to specific promoter and enhancer regions, along with the pattern of 
histone modifications. For NF-κB regulated genes the order of cofactor recruitment to 
different endogenous gene control regions is not always the same, and does not 
strictly follow the TF, hSWI/SNF, HAT, GTF order. For example, upon virus 
infection NF-κB and other TFs were found to bind the INF-β enhancer after 2 hours, 
recruit hGCN5 HAT complexes, then CBP/RNAPII complexes, then hSWI/SNF 
complexes and finally GTFs to initiate transcription after 6 hours [296]. In contrast, 
hSWI/SNF was already present before TNFα stimulation at the E-selectin promoter 
[210]. After 30 min, hSWI/SNF levels decreased whilst NF-κB, IKKα and HDAC2 
levels were increased. TBP was present at the transcriptional start site whilst p300 and 
SRC1 were present downstream of the start site. At 1 hour after treatment, most 
proteins were not detected apart from P/CAF and RNAPII [210]. These studies 
support the model that cofactor requirement and the order of complex recruitment to 
NF-κB regulated genes may be dependent on the promoter context. 
The ChIP studies of NF-κB regulated genes often compare cofactor presence 
at time points varying by around 30 minutes. This could result in a simplified view of 
cofactor recruitment, as studies with other TFs have shown a more complex cycle of 
cofactor recruitment events.  A ChIP study in five minute intervals of cofactor 
recruitment to the estrogen receptor (ER) responsive pS2 promoter showed that there 
were three cycles of events, leading to effective transcription [80]. The first cycle was 
found to be unproductive and involved recruitment of ligand bound ER, followed by 
hSWI/SNF, PRMT, HATs and GTFs. This cycle ended in the degradation of ER, but 
upon re-binding of ER, the following cycles were found to be transcriptionally 
productive. After recruitment of GTFs, RNAPII closely followed by Mediator is 
 162
Discussion 
 
associated with the promoter region. There is evidence that transcription regulated by 
NF-κB also occurs in cycles on many different promoters [119, 181, 297]. When 
considering the mechanism of NF-κB cycles it should be kept in mind that most 
nuclear NF-κB binds to DNA dynamically, interacting with the DNA for just a few 
seconds as measured by fluorescence loss in photobleaching experiments [297]. This 
indicates that any enhanceosome structure component could be in constant flux with 
the surroundings, but that the equilibrium is towards the well characterised cofactor 
complexes detected when analysing a single time point by ChIP experiments.   
Together, these studies indicate that there are a vast number of transcriptional 
cofactor complexes for RelA(p65). The cofactor requirement and the cyclic order of 
recruitment of different RelA(p65) cofactor complexes to enhancers is likely to 
dependent on many factors. These factors could be the chromatin structure 
surrounding the gene and its regulatory elements, the other TFs present, the cell type, 
the stimuli and position in the cell cycle. 
10.2  TAD cofactor exchange by PTMs 
Exchange of co-repressor complexes for co-activators, or co-activators for other co-
activators occurs during transcription activation. Cofactor complex exchange could be 
through signal specific post translational modifications (PTMs) of TFs allowing 
regulated interactions with cofactors. For example, PKA mediated phosphorylation of 
RelA(p65) at serine 276 increased p300 interaction, but reduced HDAC1 interaction 
[298]. The TAD of RelA(p65) has many serines that have been shown to be 
phosphorylated upon cell stimulation, and result in the increase of the transactivation 
potential of RelA(p65) (Section  2.5.1). Calcium/Calmodulin-dependent protein kinase 
IV (CaMKIV) mediated phosphorylation of GST-RelA(p65)-TAD led to an increase 
in p300 binding and a decrease in co-repressor SMRT binding [131]. The 
phosphorylated serine was mapped to be serine 535 in vitro, and mutation of this 
residue to alanine prevented phosphorylation by CaMKIV, p300 binding and SMRT 
release [132]. In a different study CHIP experiments showed that laminin stimulation 
of cells led to IKKα dependent phosphorylation of SMRT and serine 536 of 
RelA(p65) at the cIAP-2 promoter [119]. The phosphorylation events correlated with 
a decrease in HDAC3 association with the promoter region, and increase in RNAPII 
association. Following RelA(p65) phosphorylation, and HDAC3 release, acetylation 
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of RelA(p65) at serine 310 occurred, which was shown to be mediated by p300. 
Therefore, the specific phosphorylation of RelA(p65) and SMRT co-repressor, led to 
HDAC release and HAT activity recruitment [119]. TNFα was also found to 
stimulate p300 interaction with wild-type RelA(p65), but not with non-
phosphorylatable mutants S276A and S536A, as detected by co-immunoprecipitation 
[299]. More experiments are required to determine whether other cofactor interactions 
with RelA(p65)-TAD are also affected by site specific, signal induced PTMs. 
Cofactor exchange may also require more than a change in PTMs of 
RelA(p65).  TBL1 and TBLR1 were found to be required for NF-κB dependent 
transcription [300]. These proteins were identified as co-repressor/co-activator 
exchange factors that are recruited to promoters upon transcription induction and 
cause the exchange of cofactors through ubiquitin mediated degradation of factors 
[300].  
10.3  Regulation of MYBBP1a interaction with RelA(p65) 
MYBBP1a interacts with RelA(p65) to repress NF-κB regulated transcription, while 
p300 interacts with RelA(p65) to activate transcription. Further experiments are 
required to determine whether the interaction between RelA(p65) and MYBBP1a or 
p300 is regulated to control the expression of specific genes. It would be expected that 
the levels of MYBBP1a available in the nucleus to interact with RelA(p65) could be 
one way to regulate the transcriptional outcome of RelA(p65). MYBBP1a is 
expressed differentially between cell types, and is higher in Jurkat T cells than in 
HeLa epithelial or THP1 monocyte cells, indicating that a larger pool of RelA(p65) 
may be associated with MYBBP1a in Jurkat T cells. This could lead to repression of 
certain NF-κB genes in these cells. The cellular localisation of MYBBP1a would also 
be expected to regulate the MYBBP1a/RelA(p65) interaction. MYBBP1a was shown 
to shuttle between the nuclear/nucleoli and cytoplasm [235]. Preliminary experiments 
showed that PMA stimulation of Jurkat cells led to a pool of MYBBP1a relocating 
from the nucleolus to the cytoplasm and nucleoplasm (Section  6.1). PMA activates 
members of the protein kinase C (PKC) family and other effectors. These effectors 
signal via many different kinases such as IKK and p38 MAPK (mitogen activated 
protein kinase) to cause a wide variety of cellular responses including cell death, 
differentiation, transformation, proliferation, inflammation, apoptosis, adhesion, 
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survival and motility depending on the cell type and context (reviewed [301, 302]). 
Extension of these preliminary MYBBP1a localisation experiments is required to 
investigate the mode of MYBBP1 mobilisation in the nucleus and its effect on NF-κB 
dependent transcription. 
Another level of regulation of the MYBBP1a/RelA(p65) interaction versus the 
p300/RelA(p65) interaction could be through regulation of PTMs of RelA(p65), 
MYBBP1a or p300. This would be similar to the regulation of the MYBBP1a 
interaction with PGC-1α, which affects the potential of PGC-1α to activate 
transcription. PGC-1α is phosphorylated by p38 MAPK at serine residues in its 
negative control region upon p38 MAPK induction by cytokines and β-adrenergic 
signals [303]. Phosphorylation of PGC-1α by p38 MAPK in vitro reduced MYBBP1a 
binding [274]. In vivo, TNFα, IL-1α and IL-1β stimulation reduced MYBBP1a co-
immunoprecipitating with PGC-1α and this coincided with p38 MAPK 
phosphorylation of the specific sites in PGC-1α. MAP kinase kinase 6, an upstream 
activator of p38 MAPK, relieved repression of MYBBP1a [274]. Also, the mutant of 
PGC-1α that mimics phosphorylated, activated PGC-1α was found to be resistant to 
MYBBP1a repression. Interestingly IL-1β stimulation leads to p38 MAPK activation 
and transcription activation by RelA(p65) dependent on the phosphorylatable serines 
529 and 536 of RelA(p65) [122]. p300 and Akt (the MAPK activator) synergistically 
enhance reporter transcription [122]. This leads to the model that some signals such as 
IL-1β could activate phosphorylation of RelA(p65) at serine 536, resulting in an 
increase of p300 interaction with TAD. This might also coincide with a decrease in 
MYBBP1a binding, since MYBBP1a was shown to compete with p300 for interaction 
with the TAD (Section  5.2). Alternatively other signal specific inducible PTMs of 
RelA(p65) could regulate the exchange of p300 and MYBBP1a.  
A model is proposed in Figure 18, suggesting a mechanism for cell type specific 
regulation of certain genes by MYBBP1a/p300 exchange. In cells with high levels of 
MYBBP1a (e.g. Jurkat T cells), activation of NF-κB nuclear import (by stimulus X in 
Figure 18), may lead to activation of some RelA(p65) regulated genes (such as IκBα) 
but not others that are repressed by MYBBP1a (gene A in Figure 18A). MYBBP1a 
may repress the specific genes by interacting with TAD only at the enhancers of 
specific genes. Alternatively MYBBP1a containing HDAC complexes may only be 
repressive in certain promoter environments. Stimulation of T cells by another signal, 
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such as IL-1β (stimuli Y in Figure 18), could lead to phosphorylation of the TAD at 
specific residues (probably serine 536 for IL-1β). This phosphorylation would 
increase the p300/TAD interaction, perhaps with a decrease in MYBBP1a/TAD 
interaction allowing transcription activation at these specific genes (Figure 18B). In 
another cell type, where low levels of MYBBP1a are expressed (e.g. epithelial cells 
such as HeLa), stimulation of NF-κB nuclear import with factor X could activate both 
types of gene, since MYBBP1a is not available to repress transcription (Figure 18C). 
Upon stimulation with the second signal Y (e.g. IL-1β) the gene could be fully 
activated by phosphorylation of the TAD enhancing p300 recruitment (Figure 18D). 
This model shows how specific RelA(p65) regulated genes could be differentially 
regulated according to cell type due to a transcriptional repressor whose expression is 
restricted to certain cell types. 
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Figure 18. Model to illustrate that MYBBP1a could repress subsets of genes in specific cell types. 
(A) In T cells, MYBBP1a expression is likely to be high. Upon T cell treatment with factor X (black 
flash) certain RelA(p65) genes could be activated such as IκBα. Others genes (shown as gene A) may 
be repressed by MYBBP1a interaction with the TAD (shown as a helix). MYBBP1a may be associated 
with HDAC complexes and can compete with p300 binding to the TAD. (B) In T cells, treatment with 
X and Y (e.g. IL-1β, red flash) may lead to phosphorylation of serine 536 and p300 interaction with the 
TAD of RelA(p65). It is possible that the MYBBP1a/TAD interaction could also be reduced, enabling 
transcription activation of gene A. (C) In cells with less MYBBP1a (possibly epithelial), MYBBP1a is 
not available to repress gene A, which could then be transcribed upon treatment of the cell with only 
factor X. (D) Treatment of cells with low MYBBP1a levels with factor Y (e.g. IL-1β) could lead to 
phosphorylation of TAD and p300 interaction, and further activation of gene A. 
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10.4  Perspectives 
The results presented in this thesis, together with previous studies identify 
MYBBP1a as a transcriptional repressor differentially expressed in certain cell types. 
In particular high levels of MYBBP1a were found in Jurkat T cells. Currently, it is not 
known under which conditions MYBBP1a represses endogenous gene expression, or 
whether MYBBP1a represses the majority or only a subset of RelA(p65) regulated 
genes. This could be investigated by micro-array analysis of mRNA expressed under 
different conditions in siRNA mediated MYBBP1a knock down cells. This 
knowledge, together with identification of the expression pattern of MYBBP1a 
normal tissues would help us to understand the contribution of MYBBP1a to NF-κB 
cell type specific transcription and which cellular processes are regulated by 
MYBBP1a. 
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